UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT PUBLIC ADVISORY COMMITTEE MEETING

QUARTERLY MEETING

Alexandria, Virginia Thursday, August 2, 2018

- 1 PARTICIPANTS:
- 2 PPAC Members:
- 3 MARYLEE JENKINS, Chair
- 4 JENNIFER CAMACHO
- 5 CATHERINE FAINT
- 6 MARK GOODSON
- 7 BERNIE KNIGHT
- 8 DAN LANG
- 9 JULIE MAR-SPINOLA
- 10 PAMELA SCHWARTZ
- 11 JEFFREY SEARS
- 12 PETER THURLOW
- 13 P. MICHAEL WALKER
- 14 USPTO:

17

- 15 THOMAS BEACH, PE2E & PTAB Portfolio Manager
- 16 SCOTT BOALICK, Deputy Chief Judge, Patent and Trial Appeal Board
- DANA COLARULLI, Director, Office of Governmental Affairs
- 19 JOHN COTTINGHAM, Director, Central Re-Exam Unit
- 20 ANDREW FAILE, Deputy Commissioner for Patent Operations
- ANDREI IANCU, Under Secretary of Commerce for 22 Intellectual Property and Director, USPTO

1	LARRY LIAN, Office of Policy and International Affairs
2	
3	CHARLES PEARSON, Director of International Patent Legal Administration
4	SHIRA PERLMUTTER, Chief Policy Officer and Director for International Affairs
5	
6	MARK POWELL, Deputy Commissioner for International Patent Cooperation
7	MARTIN RATER, Statistician, Office of Quality Management
8	DAVID RUSCHKE, Chief Judge, Patent Trial and
9	Appeal Board
10	ANTHONY SCARDINO, Chief Financial Officer
11	DEBBIE STEPHENS, Associate Commissioner for Patent Information Management
12	-
13	ANDY TOOLE, Acting Chief Economist, Office of the Chief Economist
14	VALENCIA MARTIN WALLACE, Deputy Commissioner for Patent Quality
15	
16	MINDY BICKEL, Associate Commissioner for Innovation Development
17	
18	* * * * *
19	
20	
21	
22	

PROCEEDINGS 1 2 (9:03 a.m.) 3 MS. JENKINS: Are we ready to start? Yes, yes, yes. I've got a nod, Mark we're going 4 5 to start. Mark told me we should start. Are we 6 qood? 7 So, welcome. Welcome to the August 2nd 8 PPAC Meeting. I looked at my notes from our main 9 meeting and I keep saying time passes so quickly 10 and it does. And here we are in August and very 11 excited about the many initiatives that the office 12 is doing, but I obviously will leave all the 13 exciting news the Director. We usually start 14 introducing the Director so I will do that. 15 Andrei Iancu, Under Secretary of Commerce to 16 Intellectual Property and Director of the U.S. 17 PTO. If you would share some comments and then at 18 the end we'll go around and introduce everyone at 19 the table. So, welcome. 20 MR. IANCU: Sure. Thank you Marylee. So good to see everybody here once again. It's a 21 22 pleasure to be with all of you and as I was

mentioning to Marylee before we got going, we're
 beginning to measure our lives by PPAC acts and
 PPAC increments. So this is my PPAC increment so
 to speak. But it's great to be together.

5 So let me talk a little bit about some of the events at the PTO in the past few months 6 since we have last met. Obviously, as you all 7 8 know one of the most exciting events that we've 9 had this year is the issuance of patent to number 10 10 million. It was a fantastic event and we have used it and continue to use it as an opportunity 11 12 to discuss the history of the patent system, the 13 great benefits the patent system and intellectual 14 property brings to the United States economy, culture, history, and the like. And we have 15 16 marked the day with events and we continue to be 17 celebrate it throughout the summer.

18 The patent was signed as usual by myself 19 as a director but more importantly in this case it 20 was signed by the President of the United States 21 and also the Secretary of Commerce. The signing 22 ceremony was at the White House in the Oval Office

1 and it was a remarkable event. First of all let 2 me just say that it was important for me and for 3 the office that the PPAC was represented at the 4 ceremony. Marylee was there for the ceremony and 5 I think she will agree that it was a very 6 meaningful event for the IP system.

Patents at the beginning of our history 7 8 were always signed by the President of the United 9 States. George Washington signed the first patent 10 obviously and all the presidents through John 11 Quincy Adams signed patents. But since John 12 Quincy Adams only two presidents signed patents; 13 Gerald Ford signed a patent in 1976 as a ceremony 14 for the bicentennial and now President Trump 15 signed a patent Number 10 million.

16 Obviously IP and the patent system are 17 critically important to this administration but 18 even more importantly they have become an 19 increasingly important part of the economy and our 20 growth. So patent 10 million is an opportunity 21 for us all to recognize the importance of our 22 system.

So other than the fun ceremonies we are 1 2 also engaged in a number of activities and policy 3 considerations. Let me talk about some of them, and in no particular order, but let me just start 4 5 with section 101. Since we last met we have issued a couple of memoranda to our examining core 6 about how to implement Section 101. 7 8 The first one we issued in the last few 9 months is what has been called for better or worse 10 the Berkheimer Memo. That memo deals with step 11 two of the Alice Mayo Framework and addresses how 12 examiners are to think about conventionality in 13 the 101 analysis and how to document it. We have also issued what's been called 14 the Vanda Memo in light of the Vanda case that 15 16 preceded it. And it deals with method of treatment claims and how to deal with those within 17 18 Section 101. 19 We are continuing to work on a more 20 comprehensive section 101 guidance and hopefully in the coming months we will have more to say on 21

that issue. We are working on various issues

22

1 coming out of the PTAB.

2 And some particular examples, we issued 3 a Notice of Proposed Rulemaking recently on the claim construction standards during post grant 4 5 proceedings. That's NPRM, as it is called, Notice of Proposed Rulemaking was out for public comment. 6 7 The public comment period closed on July 9th. We 8 received more than 350 comments and we are 9 currently reviewing them all and addressing the 10 various issues that have come up from the 11 comments.

We are working on the amendment process for four post grant proceedings and were looking towards issuing guidance on amendments and the process for amendments, again in the next few weeks or months.

17 A few guideposts, we believe that 18 amendments in post grant proceedings should be 19 done during the post grant proceedings themselves. 20 We think the statutes asks for us to allow for 21 that. We think they should be completed under 22 normal circumstances in the 12 months prescribed

1 by the by the statute. We think they should be 2 fully participatory because they are intraparty 3 processes, so that means that both the patent owner and the petitioners should have an 4 5 opportunity to participate in the amendments. There are other issues that we're 6 7 looking at but those are some of the main 8 parameters. And we're trying to figure out 9 exactly how to make the schedule work and all the 10 other requirements to meet the various parameters. 11 We're looking a variety of other issues with 12 respect to the PTAB such as the trial practice 13 guide and the like. 14 Last time I believe I mentioned that we're also looking at the initial search process. 15 16 The search that examiners conduct during the 17 initial examination; I believe that surfacing the 18 best prior art is critically important to 19 conducting a good examination and issuing good patents. So we're looking towards helping 20 examiners do that search, perhaps with enhanced 21 22 technology, perhaps with other tools such as

training or collaboration between examiners and 1 2 the like. And we have an internal task force 3 that's focused on those issues. Overall and those are just some of the 4 5 examples. Happy to answer questions if anybody has questions. We're working a lot of other 6 7 issues as well. Overall I personally believe that 8 it is important for the IP system and 9 practitioners in the IP system beginning with 10 folks at the PTO and all of you and everybody else 11 who participates to engage in, what I call, a new 12 dialogue about IP and patents and the like. 13 I think it is critically important for 14 our economy and for our country that as leaders in this field we communicate the importance of 15 16 innovation, the critical role played by inventors 17 and entrepreneurs in our innovation and 18 entrepreneurial ecosystems and the great benefits 19 all of this activity brings to the United States. 20 So I think all the policy considerations should keep that in mind and the discussions should have 21 22 that in mind and promote the great benefits of our

1 wonderful system.

2 So I will leave you with that and I hope 3 you have a great set of meetings today. I looked at the schedule and it really looks really, really 4 5 interesting. So thanks for having me here to 6 start the day. MS. JENKINS: Great. Thank you. Any 7 8 questions from committee members? With respect to 9 -- yeah, Mark --10 MR. GOODSON: This is two questions from Marla Grossman of the American Continental Group, 11 12 one what are your IT priorities during the coming 13 year and second is the USPTO accelerating or

14 slowing down the patent end to end program?

15 MR. IANCU: Thanks for the question. So 16 IT is obviously a very high priority for us. We 17 are looking at all aspects of our IT systems. The 18 IT systems are very important for our examiners to 19 conduct their work on a day-to-day basis. They're 20 obviously very important to our stakeholders because they interact with our office in large 21 22 part through electronic means.

1 So one of the main things that we are 2 looking at is trying to find ways to bring us to 3 the most up to date technologies. So instead of continuously and incrementally update the systems, 4 5 which we have to do. It would be great to find the very latest technologies and potentially 6 7 perhaps leapfrog our current state. This is a 8 long-term project, it's not something that can be 9 done overnight. But we are looking at that and 10 frankly a great place to start would be with a search activities and the state of the art 11 12 technologies that can be added to help examiners 13 with that process. So anyway that's just that's 14 just one example and we're working towards all 15 that. 16 With respect to your second question 17 about patents end to end, I will defer to Drew and 18 the patents group to address that.

MR. HIRSHFIELD: Sure. So there is no
plan to slow down patents end to end and rather we
have every plan to continue moving forward. I
don't know if accelerate is the right word, I

1 think right now we're still determining the best 2 path forward. I know that we've made some good 3 progress with some of the examiners tools, particularly the official correspondence tool has 4 5 been a success and I know we're making some steady 6 progress in our search tool. So a long way to say that the patents end to end is continuing, is a 7 8 big focus of ours, and will remain a focus.

9 MR. WALKER: Director Iancu, I just want 10 to make a comment and thank you for the leadership 11 on 101 because having been in this patent business for over 30 years, you know when I started the CFC 12 13 was just created and there was a lot of wind in 14 our sales to keep the peace system going and people were very enthused and now that wind has 15 16 died down, it's non- existent and blowing in her 17 face with a lot of this 101 jurisprudence.

And I think as part of your platform the business community has a sense now that patents are not as valuable as they were. And you have to Defend Trade Secrets Act so people are looking more at trade secret protection in lieu of patent

1 protection, which is not in my opinion a great 2 thing because you don't have the social contract 3 where you are trading publication of information, of innovation, in exchange for the limited rate. 4 5 So congratulations for that effort. Thank you. And I think you'll get a lot of support 6 from the business community but it's a big hill to 7 8 climb to get, not just the legal community, but 9 the business community mind around the fact that 10 there is still a lot of potential in the patent 11 system because reading the business papers, I 12 think do have a different sense. So thanks for 13 the leadership on that, it's a critically important issue. 14 MR. IANCU: Thank you, Mike. I very 15 16 much appreciate that. It is true, we do have a 17 fairly big hill to climb but I have no doubt -there's absolutely zero doubt in my mind that the 18 19 patent system is critically important and having a 20 robust patent system is critically important. All we have to do is look at our history 21 22 from the founding of the Republic until today, and

all the amazing technology and science and growth 1 2 that we have experienced in this country and 3 provided leadership to the world. And throughout all that time, all that work was backed by our 4 5 patent system and for the patent system to function as intended and as you're suggesting we 6 7 really need to have faith in the system. The 8 business community must have faith in the system. 9 And that's why it's critically important 10 to understand the needs of the business community. 11 Of course, the business community is not 12 monolithic. There are many, many different 13 interests and they cover a whole spectrum. There 14 are different technologies with different life spans, different needs, different points of view. 15 16 That's why I believe that in everything we do we 17 need to have a very careful balance; we need to 18 listen to everybody. Understand the various 19 pressure points in the system and provide the 20 appropriate balance. The last thing we need to do is to 21

22 ignore or downgrade the patent system that will

have a detrimental effect in my opinion across the 1 2 board. Instead we need to have a robust system, 3 strengthen the system in a balanced fashion. Thank you. 4 5 MS. COTTINGHAM: I'll follow with that with Mike. Thank you for taking the leadership on 6 7 101. I represent the Life Sciences and Pharma 8 industry and particularly the venture capital 9 investors in that industry as well as the startup 10 companies. 11 Trade secrets is interesting but patents

12 are critical; they're absolutely critical to the 13 funding, to the growth of companies and getting 14 them off of that off the ground. And I thank you 15 for that guidance on the particular cases and that 16 sort of thing.

I'm interested in hearing what else you see, what other opportunities you see as far as providing a little more predictability or certainty or simplicity in understanding the lol's. I'm constantly having to explain to investors for example 101 isn't an issue here or

why 101 is an issue. And also trying to 1 2 understand issue patents that that issued 10 years 3 ago that would never issue today and what risk that poses to our company for example. 4 5 MR. IANCU: Sure. Thanks, Jennifer. So, 101 is very important in providing additional 6 7 clarity to the to the 101 analysis is very 8 important. I have said before that I do believe 9 that there is a level of uncertainty in our patent 10 system as a result of the current state of Section 101 jurisprudence. I do think that there is more 11 12 that the Patent Office can do. 13 As you've comment and as I've mentioned 14 at the beginning, we have issued two guidance memoranda on two particular aspects of 101, but 15 16 I'm hoping we can do more. And some of the 17 overall parameters of where I think we can go 18 relate to understanding exactly what are the 19 areas, the so to say prohibited areas or the 20 problematic areas that the Supreme Court has identified. And I believe that if we look 21 22 carefully at the Supreme Court jurisprudence over

1 the arc of patents history.

2 I think we can identify the select 3 issues that the Supreme Court has found problematic. The statute itself has by and large 4 5 been the same since about 1793. There's been Supreme Court jurisprudence since basically that 6 7 time; it's been about 200 years of the Supreme 8 Court looking at Section 101 and its equivalence 9 over history. 10 During that time the Supreme Court has identified fairly narrow set of patent 11 12 applications that it thought have been 13 problematic. And I think that it would behoove the system for all of us to exercise judicial 14 15 restraint and stick closely to those Supreme Court cases. And they think if we do that I think it 16 17 will help clarify section 101 a little bit. So 18 that's one approach we're trying to follow and see 19 if we can issue some guidance that is based more 20 closely on our reading of those Supreme Court 21 cases. 22

MR. KNIGHT: Director, I think the

initiatives on 101 are great and I think it does 1 2 promote your initiative to enhance the certainty 3 of the patent right so the business community and the patent community can rely on that right. 4 5 I think another issue that we have to 6 face though is the difference between what happens 7 in examination and what happens before the Patent 8 Trial and Appeal Board. And I think the user 9 community is really concerned about the fact that 10 the PTO is issuing patents and those same claims 11 are being found to be unpatentable by the board. 12 And so along those lines what are the initiatives 13 that you have started to make certain or to 14 enhance the certainty of the patent right when it goes before the board? 15 16 MR. IANCU: Thanks Bernie. I definitely agree that it's critically important to have 17 certainty and predictability of issued patent 18 19 rights. And let me just touch upon some of the initiatives at the PTAB. 20 I did mention the NPRM regarding claim 21 22 construction. I think this is an important issue

when it comes to predictability. If you think about it, whether you're a patent owner who's trying to build a business around her patent or you are a member of the public, a competitor let's say, that is trying to assess somebody else's patent.

7 And you're trying to decide whether you 8 need to design around, whether you need to license 9 the patent, or do something else. When you make 10 those decisions, when the business community makes those decisions, it needs to be able to understand 11 12 what the scope of that patent is. And the scope 13 of the patent, the boundaries of a patent cannot 14 possibly depend on the happenstance of which 15 tribunal will review that patent years down the 16 line because you don't know whether it might be the PTO that takes it up first or district court 17 or the ITC that takes it up first. 18

19 The boundaries, at least from an 20 objective point of view, should be the same no 21 matter who reviews it. And that's why we proposed 22 -- that's one of the main reasons we propose that

the claim construction standards should be the
 same. As I said we are reviewing the comments
 from the public and will reach our final decisions
 fairly soon.

5 I also think that through the post grant process, the result of any post grant proceeding 6 7 should not be an all or nothing proposition. The 8 only options should not be either the patent is 9 completely valid or completely invalid. The 10 statute allows for amendments and I think it is 11 good for everybody; the patent owner, the public, 12 the patent system. If the claim is as issued 13 happened to be invalid or too broad, then if there 14 is patentable subject matter to allow the patent owner to hone in the patent in a more appropriate 15 16 way.

17 So that's why I think having a robust 18 amendment process is critically important and we 19 have been working very hard at that and I think we 20 will have something that will go a long way 21 towards honing in claims during the post grant 22 process.

1 There are a variety of other things 2 we're working on. Let me mention one more thing 3 that I did not mention in my opening comments, which is the question of the review panel itself. 4 5 There has been some criticism out there about the way we sometimes enhance or expand the panel. I 6 7 don't particularly subscribe to those criticisms 8 but I hear them. So we are working towards 9 clarifying that process, providing more 10 transparency, both to the parties in the process 11 as well as to the public. And again hopefully in 12 the next several weeks or so we'll have more to 13 say about that as well. So those are some 14 examples. MR. KNIGHT: If I may just one follow 15 up. One item that when I worked here that I was

16 up. One item that when I worked here that I was 17 always grappling with, that I always thought would 18 sort of enhance the certainty of the patent right 19 would be when you come out with guidelines for the 20 patent examiners, to coordinate with the board, to 21 make certain the board judges are on the same page 22 so that they are following the same guidelines.

1 Because when I worked here a lot you 2 know I would hear from the judges that they don't 3 have to follow those guidelines, but the judges do 4 report to you, you prepare their performance 5 plans. So I would think that one great initiative 6 would be to make certain that the board judges are 7 following the same guidelines that the examiners 8 are following. MR. IANCU: Yeah. 9 Thanks for the 10 suggestion. Let me just state the obvious; we are 11 one agency. 12 MS. JENKINS: Thank you for the 13 questions. Thank you for the answers and having 14 been at several of your speeches, when Bernie 15 asked that question I immediately thought of the 16 many times you've said this is one office. And so 17 as a PPAC we appreciate all the input, we've been 18 hearing many positive comments from the user 19 community about all the new initiatives. 20 One thing that I know I've always been 21 lucky because I've been on the committee for six 22 years and I know the office listens and I always

tell -- when I go out I always tell folks they are 1 2 listening to you and I do believe that the 3 initiatives that you're doing now help to show the user community that you truly are listening. And 4 5 trying to hear as many voices as possible to give 6 guidance and that helps the business, that helps 7 the practitioners, that it helps the courts. And 8 so all of these things and more that you're doing 9 are very exciting and you know we commend you for 10 doing this and in doing the initiatives on these different issues. 11

12 On the issue that Mark brought up 13 quickly about IT also too the PPAC during my 14 tenure here has always been supportive of funding for IT. It is vital, crucial not only for the 15 16 office, but also for the outside as we become more 17 and more dependent on a paperless environment. So anything that PAC can do to get more information 18 19 for the office of what the user community is 20 expressing in this area, we will certainly step up 21 and help in that area.

22 Personally it was an honor -- switching

1 to the 10 million patent ceremony at the White 2 House, when Andrei called me and asked me to represent the PAC. It is wonderful to see the 3 support from the White House for IP and for 4 5 patents and I think President Trump's signature got even bigger when he signed it on these 6 7 ceremonial patent, which was literally this large. 8 So it was wonderful to see and the other thing 9 too, which I want to share is that the inventor 10 and the CEO of Raytheon were so excited to be there they. They were so excited to have this 11 12 honor of being the 10 millionth patent. And it 13 was just an honor and a pleasure to be there with 14 you to see that enthusiasm. 15 MR. IANCU: Thanks for all those 16 comments. It really was a remarkable day between 17 the signing at the office and the various other 18 celebrations that we had it was a wonderful time 19 for the IP system, highlighting the best of what we do, I think. 20 MS. JENKINS: So with that we'd like to 21

move on here. So at this point, one thing I'd

22

like to do differently -- just a little 1 2 differently today is I've had a lot of comments 3 that we don't express where people are from, so if we could when you introduce yourself if you can 4 5 just express more than just being a PPAC member, obviously briefly. So Pam you want to start? 6 MS. SCHWARTZ: I'm Pam Schwartz. I am 7 8 the President of the Panthers Professional 9 Association and a member of the PPAC. So I work 10 for the U.S. PTO and I am a patent examiner. MR. GOODSON: I'm Mark Goodson and I'm 11 12 an independent inventor. I come from the Dallas 13 Texas area. MR. KNIGHT: My name is Bernie Knight. 14 I was Deputy General Counsel and General Counsel 15 at the PTO previously. I'm a partner at 16 17 McDermott. Will, and Emery and now I have my own 18 patent consulting firm. 19 MS. CAMACHO: I'm Jennifer Camacho, I'm from Boston Massachusetts where I am the Chief 20 Legal Officer and a Patent Attorney at Tort 21 22 Therapeutics, which is a cancer immune-

1 therapeutics company. 2 MR. LANG: I'm Dan Lang, I'm from San Jose California. I'm Vice President of 3 Intellectual Property and Deputy General Counsel 4 5 at Cisco Systems and a member of the PPAC. MR. WALKER: I'm Mike Walker from 6 7 Wilmington, Delaware. I was Vice President Chief 8 Intellectual Property Council at Dupont and 9 retired three years ago. Member of PPAC. 10 MS. JENKINS: I'm Marylee Jenkins, Chair of PPAC and partner at Arent Fox in New York. 11 12 MR. HIRSHFIELD: Drew Hirshfield, Commissioner for Patents, here at the USPTO. 13 MR. FAILE: Andrew Faile, Deputy 14 Commissioner for Patent Operations here at the 15 16 U.S. PTO. 17 MS. MARTIN-WALLACE: Valencia Martin-Wallace. I'MS. I'm Deputy Commissioner of 18 19 Patent Quality for U.S. PTO. 20 MR. SEIDEL: Hi, I'm Rick Seidel, Deputy Commissioner for Patent Administration USPTO. 21 22 MR. POWELL: I'm Mark Poweel, Deputy

1 Commissioner for International Patent Cooperation. 2 MS. JENKINS: Okay with that -- oh thank 3 you, Mike. We have several of our members unfortunately could not make it in person but they 4 5 are online, so I'm looking at the ceiling right now. So Julie, Jeff, and Catherine are you there? 6 7 MS. FAINT: Yes, this is Catherine 8 Faint, I'm Vice President of the Trade Market 9 Union and an Interlocutory Attorney for the 10 Trademark Trial and Appeal Board and a member of PPAC. 11 12 MR. SEARS: This is Jeff Sear's, I'm Associate General Counsel and Chief Patent Counsel 13 14 at the University in New York and also a member of 15 PPAC. 16 MS. JENKINS: Not hearing Julie, so we'll get Julie later. Just remind me. Okay, so 17 I would like to move forward. Can we do the next 18 19 presentation? And Director, thank you again. We 20 appreciate your comments, your leadership, and look forward to the November PPAC meeting. 21 22 MR. IANCU: Thanks for having me.

1 MR. FAILE: Okay. So in our combined 2 operations and quality update, we have a number of 3 different items to go today. I will start farming 4 trends. So is there a clicker? Thank you. Thank 5 you, Mark. I'm actually going to start with this 6 side.

So one of the things I thought I would 7 8 do today, we get a lot of questions about filings 9 and the basics of filings and how do we look at 10 filings here at the office. So I only have three sides, I thought I'd spend a couple minutes 11 12 walking through filings in general and then give 13 some data on where we are now, where we were last year, and hopefully what we're going to see for 14 15 the end of this year, as far as what we are 16 modeling.

17 So as everyone probably knows by now, we 18 run a patent model where we're basically looking 19 at the work that we need to do in trying to match 20 the appropriate staff. Obviously in patents, we 21 can't just take a patent examiners and have them 22 examine any technology. They're pretty much

1 rooted in a certain technology with a little 2 latitude on the left and right of that technology, 3 but you're not generally going to assign a biotech 4 examiners to a computer system case, et cetera. 5 So one of the things we really need to 6 do is very specifically match our incoming hires to the technology areas that we have, that they 7 8 have expertise in or that we will be training them 9 in, number one. 10 And number two, we want to very 11 carefully match the actual pendency's of all the 12 areas that we have with our incoming hires. So if

13 you can imagine we have hundreds and hundreds of 14 different dockets, when we hire they all have 15 different tendencies that turn into our aggregate 16 number that we're reporting on in our pendency, 17 such as 15.4 months average pendency.

18 Underneath that number is a lot of 19 different areas; hundreds and hundreds that have 20 different penances. So we're very careful to match 21 our hires to those areas. We can try to have as 22 equal a pendency as possible given the situation

1 that we're in.

2 A huge driver of that particular 3 placement, the number of hires we need, where we need to place them, is the incoming filing rates. 4 5 We look at the incoming filing rates from a workload perspective in two different ways. We 6 7 have a new filing, we call them serialized 8 filings; the reason you see serialized is they 9 actually getting new serial number; that's a 10 serialized new filing. And we also have requests for continued examination RCE work. 11 12 So we really need to be on top of how 13 the filings are coming in and even more 14 specifically where they're coming in in different areas. So we know we're matching hires and 15 16 workload to those particular areas so we don't 17 have dockets that are driven too deep and we don't 18 have dockets that are ballooning up on the other 19 end of the spectrum. 20 So one of the questions that we often get is about our filing rates and what have filing 21 22 been doing. There seems to be a narrative that

filings have been dropping off over the years. 1 So 2 what I have here in this graph is hopefully 3 attempt one to kind of dispel that particular myth. What you see here and you probably can't 4 5 see the numbers on the bottom, at the very bottom is on the far left is 1995 the year of filings and 6 7 on the far right is 2017. So you got a pretty 8 wide spectrum of years.

9 And then on the axis going up is the 10 number of filings per year. The numbers aren't 11 necessarily important for this but the graph kind 12 of tells the story that within the last 10, 13 probably 15 years we've had one dip in filing rates and that was in a 2009 time period and we 14 have been steadily moving up since about 1995 or 15 16 1996 actually.

For a couple data points on the very far right, in 2017 we had about 419,000 new cases come in last year. That was about a.3 percent increase over the prior year. So you can see on the last part of that blue line, a slow little tick upward that's a general filing rate increase that we've

1 been seeing.

2 This year we are actually seeing --3 you'll see that line go up a little bit more. We're currently at about a 1.7 percent increase 4 5 over last year. And we've modeled in our patent model about 1.5 percent, so we're kind of on that 6 7 target. We'll land somewhere in that end zone by 8 the end of the year. Again very important for us 9 to be predicting that for making sure we have our 10 workflows adequately staffed. Another a big part of our work is RCE's 11 12 and if you think about the ratio of work it's 13 roughly 70 percent of our workload comes in under serialized filings, 30 percent comes in over 14 15 RCE's. It's been a relative constant off throughout the years. So in our seas you see a 16 17 little bit more of a dramatic performance. You see an increase around the 2000 and 2006 18 19 timeframe. And as we move up lately we've been 20 seeing a lot of different performance in RCE's, they have roughly been coming down and they went 21

22 up a little bit and they're coming down.

Last year at the end of 2017 we had a 1 2 negative 6.7 percent growth so we were 6.7 percent 3 below what we had last year. And right now we're even a little bit lower that we're at 7.7 percent 4 5 down from last year's numbers. So the RCE part of the equation is coming down, we consider that 6 7 generally a good thing. We have a number of 8 initiatives that were designed at trying to reduce 9 the need for RCE's. At least in the aggregate, 10 the numbers seem to be reflecting on that trend; 11 that's an overall positive. 12 Go back to the very first slide and

13 here's just a snapshot of our monthly serialized 14 filings and there's a lot more unevenness as you move down to monthly or you can even do daily. 15 16 But again we are on pace for probably about a 17 percent and a half increase over last year. Right now we're running a little bit over that 1.7 18 19 percent. Again the big point I'd like to make 20 here is that on this particular graph, you do see serialized but for one exception you do see 21 22 serialized filings rise throughout the years

1 throughout the couple decades that this graph
2 shows.

3 So that's it for filings, they'll be a 4 little bit more in the afternoon presentation from 5 international folks about some international 6 filing. These are filings here domestically, of 7 course. So let me stop for any questions here 8 before we keep going on to the next point, 9 Jennifer.

10 MS. CAMACHO: I have a quick question on the serialized filings on the last -- the 11 12 composition of the serialized filings over the 13 last decade or so. Has the composition of brand new disclosures versus continuations and division 14 changed? And does that impact how you predict 15 your hiring's as much as it's continuations and 16 17 divisional's tend to go to the same examiners, someone who is familiar with the disclosure 18 19 already? 20 MR. FAILE: Yes, that's a good question. Those percentages are roughly the same. 21 The

continuation part of the filings is in the 20

22

percent to maybe 30 percent, off top of my head. 1 2 They don't necessarily -- the fact that is a con 3 doesn't necessarily affect staffing trends because we will match that to the technology and they'll 4 5 generally inherit their technology from the parent 6 case, to the extent the examiners not here, we 7 obviously would reassign it to the extent 8 examiners overburden, we possibly would reassign 9 it. But generally the cons counts are would be 10 matched up with the person that had the parent 11 case. 12 MR. KNIGHT: Just wondering, it looks --13 just looking at this graph it looks like the rate 14 of increase in filings has -- the rate of increase has really dropped from about 2013 to present. Is 15 16 that accurate, that from year to year the increase 17 has been less than less in the number of serialized filings? 18 19 MR. FAILE: That is accurate. 20 MR. KNIGHT: Okay. MR. FAILE: So Bernie makes a good 21 22 point. I probably should have pointed this out.

If you look at the end of the line dial back about 1 2 4 or 5 years to 2013, you'll see a very slow 3 increase and that's anywhere from almost flat -you know if that line was line was flat, we'd be 4 5 at zero. You see an almost flat line to it's starting to creep up a little bit but it's still 6 7 in the 1 percent, 1.5 percent increase. 8 To the left of that, you see a lot of 9 different shapes there as we've gone through the 10 years. One of the big questions for us and if we 11 had a crystal ball or if you guys have a crystal 12 ball and can give me the answer, I'd love it, is 13 are we going to see that -- what's the behavior of 14 that line in the next few years? 15 That's really important to us to know 16 should we be staffing up in advance of the trend? 17 Should we be figuring out other ways to compensate 18 if the trend is going down, et cetera? 19 MR. LANG: Are there discernable trends 20 if you look at individual technology center areas, are there trends that differ from what we see in 21 22 the aggregate?

1 MR. FAILE: Yes good question. So Dan 2 if you were to take the slide down and break it 3 down just by technology center, you would see a lot of different movement. If you move down to 4 5 the work groups, which are getting more into a monolithic block of technology and you compare 6 7 those across all the technology centers, you would 8 see a lot of movement there as well. 9 And again that's part of the very big 10 job ahead of us that patent ops works with our 11 Rick and patent admin to try to figure out how 12 many hires do we need, where do they need to be 13 placed, which is very critical. So we can chase 14 those down, so we can try to even out our pendency's across the spectrum as best we can. 15 16 We'll never have that perfect, just because of the 17 enormity of the cases that come in and the 18 different filing trends that you see. But if you 19 were to break this down you would see things 20 jumping up a lot more. 21 MR. LANG: Of course, you know, very 22 curious how it is of the different technology

areas, what's in the IT industry versus life 1 2 science. But another question, do you see 3 different trends in foreign filers versus U.S? 4 MR. FAILE: Not really, I believe we're 5 about 50/50 at the moment. We're going to talk a little bit in the afternoon session about some 6 7 international filing trends. There's some 8 differences there but we haven't seen much of a 9 change over the last few years. 10 And what I can do to your previous 11 question, maybe next time what I'll do is I'll 12 break this down at least by chemical, mechanical, 13 electrical, maybe a little bit more so you can see some of the different distributions depending on 14 areas. This is kind of just the largest block of 15 16 all incoming columns. 17 MS. JENKINS: Can you break it down -sorry -- can you break it down even further by 18 country? 19 20 MR. FAILE: I believe we can. Mark, do you if we can break down by origin? I'm pretty 21 22 sure we can do that.

1 MR. POWELL: Yeah, sure. 2 MR. HIRSHFIELD: We've been -- I don't 3 know off the top of my head what the percentages are, Andy is correct that we're not seeing large 4 5 shifts in percentages of applications filed from foreign countries. I know on the trademark side 6 7 there is with regard to China, there's many, many 8 filings. I think they've had a -- I don't 9 remember -- I think they overall have a 10 or 12 10 percent increase in filings and a bulk of that is 11 from Chinese filings. 12 I believe we're seeing a slight increase 13 of Chinese filings but nothing very significant, 14 but we can certainly follow up with those numbers. But we have not seen what the trademark side has 15 16 seen. 17 MR. POWELL: We in fact have those numbers this afternoon. We have some slides 18 19 showing the various percentages of breakdowns. That'd be at one or so. 20 MS. JENKINS: It's a common question 21

22 because people are obviously noticing the activity

in China and how their filings have significantly
 increased in China alone. And then how that
 impacts United States. And then obviously that
 impacts resources here at the Patent Office,
 examiners review. Great, thank you.

MR. FAILE: So, I'll just end with all 6 7 my quarterly ask that if there is any intel that 8 anyone can give us about filing rates, filing 9 trends, where we think things are going, it's very 10 helpful to us. That kind of feeds into kind of predicting what that line is going to do to the 11 12 right of where we are now; very hopeful for us for 13 setting staff levels, et cetera. Kind of make 14 sure or try to equalize in chase pendency's down, 15 so thanks.

MS. JENKINS: Any other questions for Andy? Thank you. Thank you Andy.

18 MR. FAILE: So now I'd like to introduce 19 John Cottingham, he's the Director of the CRU. 20 And we had a request last time; we went through 21 some of our design statistics for our design 22 TC2900. There was a similar request for the work

that John does in the applications in proceedings 1 2 that he handles in central re-examined unit, the 3 CRU. So John's going to walk us through that, so John. 4 5 MR. COTTINGHAM: Thank you, Andy. Like Andy said I'm John Cottingham, I'm the Director of 6 7 the Central Re- examination Unit. I'm here to 8 kind of give an overview of what we do in the CRU 9 and give some statistics and stuff. 10 First I'd like to go over the staff of the CRU. It consists of one SCS Director, 10 11 12 supervisory Patent Re-exam Specialists, 79 13 Re-examines Specialists broken out in the different specialties; 15 chemical, 49 electrical, 14 15 and 15 mechanical. And we have a dedicated tech 16 support staff with which includes one supervisory 17 paralegal specialists, 7 paralegals, and three 18 legal instrument examiners. We do not handle the 19 designs, 2900 handles all their re-examines and 20 reissues. Next, the proceedings that we handle in 21 22 the CRU include all ex-party re-examine

proceedings along with supplemental examination 1 2 proceedings. We just recently couple of years ago 3 took over all reissue applications filed in utility applications and we still handled the 4 5 legacy Inter- Party Re-examination Proceedings. In 2012 the AIA came out and made some 6 7 significant changes. The Inter-Party Re-exam 8 proceedings are no longer available and they 9 became the inter-parties review proceedings and 10 were shifted to the patent trial and appeal board. 11 The AIA also introduced the supplemental 12 examination proceeding, which is a mechanism for 13 patent owners to have information considered, 14 reconsidered or corrected in an issued pattern. Next I'd like to go over some of the 15 16 filings in the Central Re-examination Unit. On 17 the left is the ex-party re- exam filing requests. It's broken out into the differing disciplines; 18 19 blue is the chemical biotech, red is electrical, 20 green is mechanical, and designs is the little purple one down there. So as you can see the 21 22 filings have kind of like -- the chemical and

mechanicals have kind of steadily stayed and the electricals have kind of tailored off in expertly tailored re- examines.

4 Supplemental file examination request 5 filings, since it was created in 2012 you can see 6 this kind of came out low and it kind of went up. 7 Supplemental exam's has just not been a popular 8 program at all. I think since 2012 we've had just 9 a little over 230 of them filed.

10 Next is just how often we find a 11 substantial new question in the ex- party re-exam, 12 which is on the left, and forward the supplemental 13 examination requests. In supplemental exploratory 14 exams we order and re-examine 95 percent of the cases and deny about 5 percent of the time. Where 15 16 in this supplemental examination request we will 17 find and SNQ with substantial new questions 71 percent a time and no SNQ about 29 percent of 18 19 time. But because there is a lot more party re-examines -- I mean the numbers can fluctuate a 20 lot -- the percentages fluctuate a lot more in the 21 22 supplemental exams area.

Next is the Legacy Inter-Parties 1 2 Re-examines. We still have some of these floating 3 around, about 167 of them. Seven are with currently with this Central Re-examination Unit. 4 5 The rest are either with the pending trial appeal board or at the CAFC at this time. We currently 6 have one inter- party's re-exam reopened after a 7 8 CAFC decision and six are currently stayed by the 9 PTAB.

10 Next, this is how long it takes us to 11 get to an order in a party reexamine and in a 12 supplemental examination certificate. In a 13 reexamine we're about 1.2 months to issue a grant 14 or deny a re-exam and to complete the supplemental 15 examination phase where at 1.3 months.

16 Time to conclude an ex-party re-examine 17 proceedings in supplemental examination request. 18 The left side, the blue side is for ex-party 19 re-examination. The top line is the time for all 20 ex=party exams to NIRC, which is the nudge to 21 issue a re-exam certificate and that includes 22 appeal. So you can see it's a much higher than if

we have an ex-party re-exam without appeal. It goes a lot quicker. We're right around 12 months or about a year to complete an ex-party re-exam from start to finish as long as there is no appeal in it. Yes?

MR. WALKER: Hi, John. So I have a 6 question from our colleague Jeff Sears who's on 7 8 the line but there's a there's a delay, I'm 9 watching the live stream and it's hard to keep up 10 to speed, so I have a question from Jeff. He 11 wanted about timing, so he said the CRU re-examine 12 supplemental exam, dependency from filing to 13 determination of SNQ and determination from SNQ to 14 NIRC is fast, roughly 12 months or less, during ordinary examination roughly 12 months to just 15 16 first action level and final disposal would be 17 lightning fast. So why is dependency so fast 18 compared to ordinary examination? MR. COTTINGHAM: We have a lot less 19 20 That's really it. We have a lot much cases. bigger volume in the patent court as opposed to 21

22 what we have. And then for the supplemental exams

1 without appeal we average about 9 months to NIRC 2 and you can see even with appeal it's not much but 3 you got to remember there's only 237 of these or so. So the numbers are just small. 4 5 There we go. On to reissue applications before the CRU. We assume all the reissue 6 applications in the spring of 2015. Examiners can 7 8 choose to either send any -- if they were in 9 prosecution examiners could send us the reissue at 10 any point in time in prosecution and we would take it and then we would take all new files reissue 11 12 applications. The idea was to make the handle all 13 reapplication so everything was uniformly done. 14 Here is reissue filings over the last several years since 2013. As you can see it 15 16 started off with the core, the gray is the 17 chem-biotech, blue is electrical, orange is the mechanicals, and then you can see designs kind of 18 19 creeping up in there a little bit. Now if you 20 look at the scale it's just -- that there's just not a lot of -- a lot of reissues compared to like 21 22 serialized filings. And as you can see, I mean

1 the RCE's -- the stripe lines are RCE filings and 2 the solid lines are the new filings.

3 This is the current inventory awaiting first action in the CRY. Again it's broken down 4 5 by discipline; we do not have the designs in this one since this is handled by 2900. So we're 6 7 pretty much holding steady. I mean we had a blip 8 up in '16 then and now we've kind of brought back 9 the inventory down a little bit in '17 and into 10 '18 as well. And that's all I have; any other 11 questions?

12 MS. JENKINS: I'm not sure you can 13 answer this but actually picking on something that 14 Bernie said and obviously the one office concept the Director has been speaking on, when you're 15 doing a PTAB proceeding, getting IPR, is there any 16 17 communication, a lot of working together if 18 someone files a reissue? I get the impression --19 and maybe this is totally wrong, that you really 20 operate as two separate areas.

21 MR. COTTINGHAM: We do operate in 22 separate areas. We do talk with PTAB on an

1 administrative level of like, hey we do have this, 2 we're just you know, but we do not talk substance 3 of the cases. The PTAB handles their proceedings and we handle our proceedings. 4 5 MS. JENKINS: I guess some of the comments that I have heard is obviously a reissue 6 7 is an option but then folks get concerned that the 8 reissue process may take too long. 9 MR. COTTINGHAM: We're actually pretty good at picking up the issues pretty quickly in 10 11 disposing of them. As you can see from our times, 12 I mean -- is it about a year? It's about a year 13 from conclusion to first action to a final 14 reissue. 15 MS. JENKINS: I think it's helpful for 16 the user community to hear that. MR. COTTINGHAM: Yeah we're very 17 responsive and pretty quick turnaround in this 18 19 area. 20 MS. JENKINS: Thank you. Anybody else; any other questions for John? All right, great 21 22 thank you.

1 MR. COTTINGHAM: Thank you. 2 MS. JENKINS: Who's next? Oh, Valencia. 3 MS. MARTIN-WALLACE: Next we have quality updates and before I introduce Marty 4 5 Rater, I just want to give a very quick update on our Step Program, which is a training program we 6 7 have for our stakeholders, specifically attorneys. 8 And just behind where I'm sitting is the Acting 9 Director of the Office of Patent Training, Debbie 10 Reynolds and our Ating Deputy Director, Gary Welsh 11 who have done an amazing job with this program. 12 It's a three day program where we step 13 our stakeholders specifically attorneys through 14 three days of how we train our patent examiners on each phase and it's been just overwhelmingly 15 16 successful to the point where we can hardly meet 17 the demand. We've reached out to now having them across the country; our regional offices each have 18 19 a step program. 20 So I just wanted to remind everyone of 21 it and also say because of the demand, we started

22 the program with newer attorneys within their

1 first three years because of the demand we're now 2 opening up to senior attorneys who would like to 3 attend as well. And our next one here at Alexandria campuses is in September and we're 4 5 still accepting participants in that. And we're 6 also going to have one at Chicago-Kent in November. So we're trying to reach out and meet 7 8 that demand of this particular program. 9 So next I would like to introduce Marty 10 Rater. He's the Chief Statistician for the Quality 11 Assurance Office and he's going to step through 12 some new improvements in our customer perception 13 survey as well as our latest results. 14 MR. RATER: Thanks, Valencia. Good morning everybody. So the Office of Patent 15 16 Quality Assurance obviously has their internal quality review program. We've talked about that a 17 couple times in recent meetings. As we go into 18 19 the fiscal year on that data, we're going through 20 a phase of calibration validation of that data. And one of those important steps in calibrating 21 22 the data to make sure we're on the same

wavelength, if you will with our customer is our in our external customer perceptions survey that we do twice a year.

So I want to show you a little bit about 4 5 It is about frequent customers and I'll go that. through these pretty quick. Just to give you an 6 7 idea though that of the folks that respond to 8 these surveys, we asked them to provide their 9 perceptions about the previous three months and on 10 average they have about 20 office actions that they have seen. So these are our customers that 11 12 are interacting with our office on a daily basis and that 20 office actions is kind of an 13 interesting thing as we get into a little bit of 14 15 the data here.

16 Overall quality, as you can see the 17 green line we've kind of climbed up and it's 18 stabilized. About 50 percent of our customers are 19 saying that quality is good or excellent. We've 20 got a steady line down there, that red line, 21 that's the folks that say quality is poor or very 22 poor. It be interesting -- I should have gotten

with Andy before this, right? Because if you 1 2 remember Andy's slide you remember that chart that 3 goes from 2009 up to 2018 where we're at and you know a 30 percent growth in filings and you take 4 5 everything else that we've considered over the time, you know CPC come in there. Mr. Walker 6 mentioned that we're into a headwind now on a lot 7 8 of stuff of case law. So maybe you look at this 9 in terms of that would maintain quality, at least 10 in the perceptions of our customers over that time 11 frame. It's not a bad way to look at this. 12 What we've done is modified like

13 Valencia mentioned, the survey a little bit to 14 kind of try to figure out what is happening behind these numbers and that's what I'm going to do with 15 16 the next couple of slides. So obviously the gap 17 in between those other folks that are saying that quality is fair. One of the other measures we do 18 19 in the survey -- although not showing it today is 20 we also asked customers, well do you at least have a sense is quality improving or is it declining? 21 22 Because obvious, right? Folks might be

-- I've had three years of bad service, I've had 1 2 three years of this one bad rejection, I can't 3 just get out of my mind. I'm going to continue to call you fair until I see something good. All 4 5 those people are at least willing to say quality is getting better. So we do see about 20 percent 6 7 of our customers do say -- and that's primarily 8 coming from those customers that are in that fair 9 or good group.

10 Which then brings up another thing, that 11 bottom line, do we just have 10 percent of our 12 customers that are responding to these surveys? 13 No matter what we do until we find what that item 14 is that we'll be able to satisfy him in terms of quality. They could be thinking in terms of --15 16 you know other issues come into play in what's in 17 their quality matrix, right?

I think you'll see as we kind of go through some of these more initiatives like customer experience, that's where we'll start to be able to explore those types of issues that might be keeping those folks at that 10 percent

1 and not willing to come out of here.

2 MS. CAMACHO: Bernie, I have a question 3 about who's responding to these surveys? When 4 you're talking about customers are you talking 5 about the applicants, the company, the signees, or 6 patent attorneys for example?

7 MR. RATER: So primarily this --8 obviously about 10 percent of our sample I think 9 responses are corporate attorneys that have had 10 filed -- our original sample frame is when we 11 build the sample frame that's over 12 month 12 period, did you have 6 or more filings that you 13 were in there? Obviously the largest pool of our 14 sample is coming from the registered agents and attorneys. That's where we what people were 15 acting as opposed to the total end user. 16

17 The problem is was we get to the total 18 end user, now they may be having the quality that 19 you add or detract from this system as part of 20 their decision matrix. So this is really the 21 examiners -- your interaction with the examiners 22 is what that is. And that's one of the things, as

1 we go back into this customer experience we've got 2 different personas and different customers, right? 3 Attorneys are a customer, agents, are a customer. You know Mindy's going to talk about different 4 5 customers in the process. Those were different sets of customers. That's something we would have 6 7 to explore a little bit further. 8 MS. CAMACHO: And how big is your sample 9 size? How many people are responding to this 10 survey? MR. RATER: So our sample frame covers 11 12 basically -- just give you a little idea of the 13 scope it covers about a 65 percent of the total 14 filings; you know it was touched by somebody that 15 said our sampling frame. And then we sample about 3000 of these frequent filers semi-annually. And 16 17 within that sample we have 50 percent of that 18 sample is in both waves in a current year, so that we have a little bit of carryover for 19 20 inconsistency. 21 MS. CAMACHO: Are they randomly 22 selected?

1 MR. RATER: Yes. 2 MS. CAMACHO: Are they across all tech 3 centers and then also do you find that -- are you getting the same responder's in the survey? 4 5 MR. RATER: So what we'll do is obviously a firm could have multiple agents and 6 7 attorneys in there. So first of all this survey 8 is administered by an external firm, Westat, we 9 contract out to do this survey. We select the 10 sample, it's weighted based on how much volumes of 11 filings you had and by technology so that this is 12 representative. Because we don't want to 13 overburden you all with surveys all the time and 14 we've tried to keep the survey short, we will rotate you out after a couple of surveys and give 15 16 one of your colleagues a chance to respond and rotate you back into the survey. 17 18 As you can see it's relatively stable 19 we're about plus or minus 3 percent on our

20 sampling years on this. The demographics -21 that's the other thing too, we ask our customers
22 to identify or our respondents what technology did

you file most of your applications or what were
 you speaking for, for this particular wave.
 They're not speaking to a particular unit, but
 they'll say hey most of mine were in chemical,
 they were in electrical or they were in mechanical
 disciplines.

So we don't see much variance based on the respondents through that as well. So it's been pretty stable and it's a pretty good indicator. And we obviously we weight the data back up so it's a representative when it comes back too.

13 And just an aside on that, any 14 nonresponse occasionally we'll stop and take a look at our non-respondents and I think it comes 15 into play with this, okay you didn't respond, 16 17 we've gone back was short survey's and say we 18 realize maybe didn't have the time to fill out our 19 15 questions or give this a whole lot, will you at 20 least answer our question about what his overall quality? Is it good, fair, or excellent? Our 21 22 nonresponse studies actually showed that our non

respondents were actually more satisfied about by
percent more satisfied than what -- so we like
to think they were catching this is a worst case
number and were catching the complaints, we may
not be not catching all the kudos. So by all
means I'll use this opportunity to solicit kudos
as well.

8 MR. KNIGHT: Thank you Marty. Am I 9 reading this correctly? The quality initiative 10 under Director Lee was started in around, let's say 2014 or 2015, and since that initiative there 11 12 hasn't been really an increase in the customer's 13 perception of quality, is that correct? 14 MR. RATER: Correct. At least in terms of the way the customer is defining quality. 15 We've seen to observe some internal metrics and 16 17 that's kind of why we're going to go - this is one of our calibration pieces. I think that's what 18 19 we're got to get into the customer experience and 20 try to identify what maybe these initiatives -and go back to what I said initially were these 21

initiatives that prevented us from dropping in

22

1 quality while we were doing all these other
2 initiatives to improve pendency.

3 Or to, you know all these pilots, or all these hiring programs and everything else that 4 5 we've done and all the different training that we've had to implement maybe that's where -- or 6 7 are the way the customers are looking at quality, 8 is it a long term, it is going to require us to 9 maintain this fantastic job we're doing for two or 10 three years before they're willing to give us that 11 thumbs up on this. I'm hoping -- that's what 12 we're hoping to see is a little bit of gradual 13 thing on that.

14 MR. WALKER: Marty, just quick question 15 on the bottom, you said the bottom numbers have 16 stayed steady for a while. Is there more follow 17 up to understand beyond the 15 questions, what are 18 those issues?

MR. RATER: Fantastic segue. So what I will do is go to this next slide. We changed -our so historically we've done the survey since about 2006. It was a pretty wide scope, kind of

1 just how happy are you, any big issues and so 2 forth? What we did is at the beginning of -- and 3 is the first survey that we've done with this new 4 scheme, we've actually gone to the customers now 5 and say just like we're doing on our internal quality reviews, we want to go by statute and tell 6 us how satisfied are you with the consistency, the 7 8 clarity, and correctness of each one of those 9 statutes.

10 And what this is, is kind of all just 11 coalitions bar and I'm probably have an unpopular 12 opinion here because I'm going to see the 101's at 13 the bottom that's going to say those aren't 14 important. These are items that are correlated with an overall customer perception. As you can 15 16 see the top 103 rejection, clarity, inconsistency, and correctness, 103 comes to the top. 17

18 This is not surprising for us when you 19 consider that of 9 finals and finals going out the 20 door, 75 percent of them contain a 103 rejection, 21 often contain multiple 103 rejections; 101's, I'll 22 be showing you a slide just in percent of total

rejections is only by 8 or 10 percent of total 1 2 rejections. But a 101 is only 15 percent of our 3 non-final and final rejections. Huge pain point and it might not be a key driver as well because 4 5 relict data in just a second. There's no variance, pretty much everywhere there's a large 6 7 bucket of people that are unsatisfied with 101. 8 And for all the data wonks out there, we 9 want variants and our responses so that it 10 correlates with the overall quality. So this is 11 kind of our first step to say what is driving 12 those numbers and I think 103 is one of the big 13 items. We are seeing that internally with some of 14 our quality reviews, just not only because of the volume of 103's but of the variance amongst our 15 examiners in the 103's. 16 17 MS. JENKINS: Question online -- and just a reminder that everybody in the online 18 19 audience, is that we do read your e-mails and we

21 as best we can. Is there a copy of the survey of 22 what the questions are that people can see what

try to incorporate your questions into the meeting

20

1 you're asking?

2 MR. RATER: I don't -- I believe we've 3 had it posted and I'm not sure, I will look into that and we'll get back to you. But yeah 4 5 absolutely, there's a -- it's going to be probably pretty evident here in about two slides. I want 6 7 to talk about 101 -- oh, I'm sorry, Dan. 8 MR. LANG: The information that you 9 showed in the previous slide is interesting but in 10 my mind I wouldn't call it exactly quality. To me it seems more like an applicant satisfaction 11 12 metric and you know they can tell you interesting 13 information as people comment on the kinds of rejections they're seeing and the examination that 14 are getting. But perhaps too cynical, I mean 15 applicants are more satisfied if they obtain broad 16 17 patents without much resistance from an examiner 18 and are less satisfied if they have difficulty 19 along those lines where maybe you know some of the 20 rejections we're getting are in fact quite 21 legitimate. 22 I think that if we want to measure

quality as it pertains to things that I think are very important to the office like reliability and certainty of patent it's going forward, you're minimizing the delta between results and examination and the PTAB, you need to measure satisfaction elsewhere in the system.

I mean what is the satisfaction, let's 7 8 say among patent lawyers who were doing studies 9 and figuring out you know are they able to assess 10 and advise their clients appropriately? What are 11 people encountering in litigation and other kinds 12 of assertion? And they think that those pieces 13 are very necessary for a fuller picture of 14 quality.

15 MR. RATER: Couldn't agree more. 16 Absolutely. This is just one piece and I think 17 this is going to be reported out with our internal metrics. It's got to be not only the internal 18 19 reviews that the operations does of their own 20 including all these different customer segments at different points in time where in that application 21 22 that thing needs to be measured.

We've struggled in the past a little bit 1 2 trying to conduct some sort of transactional 3 surveys. So we've got a little bit of a hesitation to respond while something is still in prosecution 4 5 and unspecific application but maybe the environment is more ripe for that now than it was 6 back when we first tried to do that back in 2004. 7 8 MS. JENKINS: I appreciate that comment 9 because I think people are just getting surveyed 10 to death. Everyone wants the survey; Uber wants a survey when you get out of the car. So if I think 11 12 you want people to really give you valuable input 13 and not be angry in the sense of what they're 14 saying in a survey that maybe if they were in a 15 better mood they might respond a little 16 differently. So I think it's something that you 17 always -- I think the office needs to be thinking 18 about is how do we do this differently so we 19 actually get valuable data right. 20 MR. RATER: And I think that's where we're kind of right now with this data is just 21 22 kind of to keep us a little bit in check or are we

-- is this identifying maybe something that we're 1 2 not measuring internally that we should be put in 3 a little bit of light on? Or is it seeing the same patterns? Are we totally missing something? 4 5 And like the 101's is a great example because we could easily talk ourselves into not 6 7 focusing on one on ones internally, at least from 8 the quality perspective because we can say, hey 9 it's 15 percent of non-files and files, let's 10 focus on the item that's in 75 percent. However 11 this survey at least identifies our biggest 12 comment is, hey we're seeing an increase in 101's, 13 we're seeing it over applied. 14 So that kind of at least puts us back in check to say well we do need to continue with our 15 16 internal review to focus on what is driving these 17 101's and are there any behaviors that maybe we don't think are happening. Because if we look at 18 19 101's and I'll throw this one slide up on 101's --20 MS. MARTIN-WALLACE: So this -- before you move there if I can just make one point, 21 22 Marty. So I think yours and Marylee's comments

1 are very valid and there are places where that as 2 well into making sure that we're meeting the 3 needs, we're improving in the appropriate areas. But one thing I want you to remember for 4 5 this data that Marty is going through is in order for OPQA the quality review is for us to know if 6 7 what they're doing and their results are valid, we 8 have to calibrate that with different points. And 9 this is one of the points for us that helps us to 10 calibrate whether what we're finding internally 11 through OPQA is valid. 12 MR. RATER: Absolutely and that's great 13 because now I actually showed the 101 slide and I 14 don't have to explain Berkheimer, which I couldn't do if I wanted to. This is just an idea, right? 15 16 So at the same time that they were saying over the three months, so it was January, February, March, 17 we had a lot of comments in there. We're seeing 18 19 an increase in 101's, we're seeing it over used. 20 We actually went into our big data environment and said, okay pull us all office 21

22 actions and what percent of all the rejections

that are made -- so there could be multiple 1 2 rejections in a case -- what percent of those 3 rejections were 101 rejections? And we've actually seeing a slight decline and actually the 4 5 fancy blue dotted line I put there is one that Berkheimer memo went out and we've actually seen a 6 slight decline in the 101's going out the door. 7 8 So again, all this back and forth, are 9 you right? And again, those comments could have 10 come from a very specific technology area, specific art unit, and could be absolutely true 11 12 but we want to look at this data back and forth. 13 And I've already spoke more on 101 than I ever 14 want to. 15 This is the first - remember I said we looked at correctness, clarity, and consistency. 16 17 So we did the survey is very simple, how often were the rejections you received under Title 35 18 19 years ago reasonable in terms of correctness? Then we asked about 102, we ask about 103, 112A's, 20

21 112B's and 101's. What you're going to see in the 22 green bar, that's the percent of the customers

1 that said, hey it's a reasonable in correctness 2 most of the time so you see 102's and 112B's about 3 66, 70 percent of our customers. Pretty happy 4 with that.

5 Look at the far right, that's our 101's. That's where we have our largest, if you will, 6 dissatisfaction or concern coming from the 7 8 customer base. Again it didn't correlate or it 9 wasn't a big driver of overall quality 10 perceptions. And also remember when I said 20 11 office actions, well keep in mind, so this 12 perception could be based on 102 or 101 rejections 13 they received in that period we're asking to evaluate. So this is the correct -- this data --14 15 and I know we have shared these slides so 16 everybody can look at these and wonder in a few 17 hours from now. Same thing you're going to see in the 101s and the terms of clarity. You're going 18 19 to see 102 rejections, 103, and you can see the 20 103 numbers now. That 56 percent agree that it's kind of clear or that it's most of all the time. 21 22 That's very similar to our overall customer

quality number, and you're going to see that with these 103 data points. And again, we're asking everyone about the office actions they saw. They probably saw 15, 16 103 rejections in this survey period versus 1 or 2 101s.

And then finally consistency, we do see 6 7 a lot of correction and clarity seem to (audio 8 drop), did I cut out there? Kind of goes hand in 9 hand in terms of our quality reviews internal, 10 that's what we see as well. Consistency's kind of 11 a new item we're trying to get our arms around, 12 and I know Dan's probably going to -- how do we 13 define consistency, how do we do this. So that's kind of new to us. But we do know that that has 14 historically been one of our drivers of overall 15 16 perceptions is I want some predictability. I want 17 some reliability when I go into this art unit and I don't want examiner A acting different than 18 19 examiner B.

20 So again, a very high level of measure. 21 And then this was end of '17, and this is just 22 kind of an idea of where we're going with this is

1 well, do we see similar patterns in that bar chart 2 on our left. Just shows you we've kind of got 3 this little U-shaped here when we look at it by discipline. Our compliance rates kind of showed 4 5 the same similar type of little U-shape. Are we are least in the right alignment or do we think 6 we're doing so fantastic in one area and the 7 8 customers think we're doing horrible? But yet, we 9 think we're doing awful in one area and we're 10 putting too much focus, and there's a customer 11 saying yeah, nothing to see here. Move on. We 12 want to be in alignment with what you want, and 13 this is kind of what we're doing. 14 So hopefully here at the end of '18, we've calibrated this data, our new quality review 15 16 in alignment with this customer. And I think that 17 is all I have. And we still have time for Mindy, I hope. 18 19 CHAIR JENKINS: We always have time for 20 Mindy. Marty, thank you. I also -- it is a team effort here. I also have an answer to the 21

22 question about the survey. If you search for OPQA

external quality survey on the PTO website, 1 2 hopefully you will find it, so. 3 MR. RATER: And hopefully it's the most recent survey. 4 5 CHAIR JENKINS: There you go. 6 MR. RATER: We will check that. 7 CHAIR JENKINS: If not, we'll touch back 8 in November. Great, okay, thank you, Marty, 9 appreciate it. Any other questions from anybody? 10 Okay. 11 Mindy, you want to talk about ombudsman? MS. BICKEL: I would in the few minutes 12 that Marty left me. Can I have the clicker? So 13 14 ___ 15 CHAIR JENKINS: We are running 15 minutes behind and so I will take away from their 16 17 lunch, which I'm sure they're already 18 anticipating. 19 MS. BICKEL: Oh, gosh, I'm sorry about that. So I am Mindy Bickel. I am the associate 20 commissioner for innovation development, and I 21 22 provide oversight to the Office of Patents

1 Ombudsman. And I'm just going to run you through 2 kind of a reminder of what we do, and then give 3 you a little bit of an update on what we're seeing now. So we started in 2010. 4 5 Our goal at that time was to help ensure 6 that the application process is working the way 7 it's intended to work. And that remains our goal 8 now. We address issues relating to applications 9 that have become stalled somewhere along the way. 10 It could be pre-exam, or OPAP could be in the 11 examination. 12 We track everything to ensure that we 13 meet the promise that we will address issues within ten business days, and then we also look at 14 trends to see what kinds of inquiries we're 15 16 getting. And that helps us inform some training 17 or updating issues that could be useful. 18 We do follow the standards of practice of the International Ombudsman Association. We 19 are outside of the operations area, so we are, in 20 21 that sense, independent. We advocate for the 22 process. So we don't advocate for the person

1 who's called us, nor do we advocate for the 2 office. So we try to just make sure that the 3 right people are addressing the issue, and in that way we're neutral and impartial, and we provide 4 5 confidentiality. You can contact us and remain confidential. We'll put your issue into the 6 database and use it for tracking trends, but we 7 8 won't go further in addressing your issue unless 9 you agree to waive confidentiality.

10 This is our process. Essentially the applicant or attorney will contact the Patents 11 12 Ombudsman team and they will respond within one 13 business day. So it could be by phone, could be 14 by email. And then the issue that they raise is routed to the most appropriate person who can 15 16 handle it. So if it's in a technology center, it 17 will be routed to someone within the technology center. If it's in OPAP, it will be routed to 18 19 OPAP.

20 This is just the structure of the 21 office. We have our team, and then we have 22 business unit reps in every part of the patent

office. So in the technology centers we rely on 1 2 experienced SPEs or quality assurance specialists 3 to handle the issues that are raised to us. We have every division across patents, or across the 4 5 Patent and Trademark Office, actually, is represented. We have people who can help us if we 6 get a question on maintenance fees. We have a 7 8 representative if we get a question regarding 9 PTAB.

10 So we have a network everywhere and we 11 use them. If we get an inquiry that's related to 12 the substance of examination, we do send that to 13 the technology center, and there the quality 14 assurance specialist, or the experienced SPE, will 15 work with the SPE of the examiner who is examining that case. And they will resolve that issue 16 17 together within the technology center.

And we do remind people that Patents Ombudsman is not a substitute for responding to office actions by the statutory deadlines. It's not a substitute for appeal or petition. And it's mostly certainly not a substitute for

communicating directly with the examiner, SPE, or
 TC director. And the TC directors strongly
 encourage people to contact them directly if there
 is an issue during examination. They do want to
 help and we've heard that from them that they
 encourage people to contact them.

This is how you find us. We are on the 7 8 website, and if you go to learning and resources, 9 and the inventor and entrepreneur page, under 10 there you can get to Patents Ombudsman or you can 11 go from our home page. If you scroll down a 12 little bit you would see a -- see more patent 13 resources, I believe, is what it's called, and you 14 can get to us that way. Once you get to our page, you can contact us through the website. You can 15 16 choose to contact a particular TC rep if you know 17 that that is where your issue rests, or you can contact the central team, and we'll route the 18 issue to where it's best handled. 19 20 You can tell us to -- what your phone

21 number is, to call you back, or your email 22 address, and the best time to reach you.

Actually, I did want to note it's probably very
 hard to see, but there is some blue links on the
 bottom of the page towards the bottom. And they
 relate to this slide.

5 So one of the things I mentioned is that we like to look for trends. What are we seeing 6 and what does that tell us about ways that we 7 8 could help improve? And the by far, most common 9 inquiry we receive is status request, which is not 10 really a true ombudsman kind of issue. Nothing to 11 work out there, there's just you don't know how to 12 find that. And so we added links to the Patent 13 Ombudsman page that what's the status of my 14 application and when will I get my first office 15 action. So before you hit the send button, you 16 can probably get the information faster if you 17 just get it off of our page. So that's one improvement we made to try to help smooth things 18 19 along.

20 The other thing we see increasingly are 21 inquiries regarding the ADS. And people have some 22 trouble filling that out correctly. And so we've

done a couple of things to aid the external 1 2 customers in filling that out. So we have done 3 some inventor info chat and a quality chat. We are developing an online CBT that explains how to 4 5 fill out that form, and we're also providing information and outreach material. And I think 6 that one is a really good example of how we've all 7 8 sort of working together with the folks in Rick's 9 area in OPM, the application assistance unit team 10 is working with Patents Ombudsman to sort of see what we see and what we can do about that. 11 12 When you contact us, of course, if you 13 want us to help you, you need to provide some 14 information about your application, brief description of the inquiry, telephone number, and 15 16 email address. We do caution people not to provide too much information in an email because 17 we -- if it's too detailed, we might have to make 18 19 that of record and so we just want very brief 20 information like you have a guestion about an office action, or you have a question about 21 22 maintenance fees. And we'll talk to you about

1 that.

2 You can actually reach us between 8:30 3 a.m. and 8 p.m. courtesy of the regional offices who will answer the phones after 5 p.m. east coast 4 5 time. And they will also route the issues. They'll put them in the database and route them as 6 7 we do. And this is my contact information if you 8 have any questions. 9 MR. WALKER: Hi, Mindy. I have a 10 question from our colleague Jeff Sears. Can you 11 give some examples of situations you've seen where 12 contacting the ombudsman has been helpful? So 13 obviously not like status inquiries, like people can find that online but --14 15 MS. BICKEL: Sure. 16 MR. WALKER: -- like give us some good examples of where the -- contacting the ombudsman 17 has really been helpful. 18 19 MS. BICKEL: So there's a number of --20 probably the examination process is what most people want to hear about. And I think there are 21 22 numerous situations in which someone might have a

difference of opinion on a position, and getting the experienced QAS involved in speaking with the SPE and taking another look at the application may help move things along. It may be that the examiner is correct, but they find some way to maybe help move the application a little bit further.

8 So those things are really handled in 9 the TC. We stay out of the substance of the 10 examination, but we do hear things, and move that along to the TC. One thing I will say that we 11 12 haven't heard is people coming back to us saying 13 well, that wasn't helpful. You know, you weren't able to address the inquiry, and we didn't make 14 15 any progress.

So we have really great folks in the TC who really look into it. And I think help make progress.

19 MS. MARTIN-WALLACE: So just to add a 20 little to what Mindy was saying. She mentioned 21 earlier that we have tentacles across the entire 22 agency, specifically in the TCs, the experienced

supervisors and quality assurance specialists that
 work with us are actually part of the program.
 They are our ombudsman representatives and there
 are two representatives in each TC.

5 So it's not just passing it on to them, 6 but they actually have been trained through the ombudsman program on how to address it as well as 7 8 how to work with the inquiry, or the person with 9 the concerns, as well as with the examiners and 10 the supervisors that it's directly related to. 11 And we have received really positive feedback, not 12 only from the people who have used the ombudsman 13 program, but actually supervisors and examiners within the TC as well who are -- want to do the 14 right thing, and may not necessarily even know 15 16 that -- how far the issue has gone. So working 17 with the ombudsman representatives in the TC has really helped that. 18

MS. CAMACHO: Mindy, thanks for the presentation. I think this is a program that not a lot of people out there know about. I understand that this isn't a substitute for going

1 to the examiner or the SPE or TC. What would you 2 say as far as what would be the standard process 3 that you would hope that the applicant would go through? First contact their examiner, if they 4 5 don't get any movement there as far as getting the -- keeping the ball rolling in the examination, 6 7 then go to the SPE, then go to the TC? Or at what 8 point at which should they contact you? 9 MS. BICKEL: So they can call us at any 10 point, of course, or contact us at any point, but 11 we really do encourage people to go to the 12 examiner and then the SPE and then the TC 13 director. They do want to assist and I think really realistically, contacting us, those 14 substantive issues are still going to go back to 15 16 the TC. That's where that chain of command is 17 where that kind of decision needs to be made. Is there something that, you know, needs to be 18 19 changed in the office action or not? 20 So sometimes people, I think, maybe have a misunderstanding that we're going to take a 21 22 separate look ourselves over at our core team. We

aren't doing that. We are relying on the team 1 that we have and all the TCs to work with the 2 3 chain of command for the examiner who is working on that application. And sometimes there's a 4 5 miscommunication. As sometimes, Valencia said, maybe there's a training issue for somebody, but I 6 7 mean, I think generally those things could get 8 worked out if people went to the SPE and the TC 9 director if they couldn't work it out with the 10 examiner. MS. CAMACHO: So would you say is it 11 more for when there's perhaps a bump in the 12 13 process versus substantive issues? MS. BICKEL: So I can tell you how it 14 got started or why it got started. 15 16 MS. CAMACHO: Perfect, thank you. 17 MS. BICKEL: So the reason it got started is because the commissioner at the time 18 19 was hearing from people, when she would go out and speak, I have a problem and I don't know who to 20 call to help me solve it. And so she came back 21 22 and said, we need to start a Patents Ombudsman

program and so we did launch that. And that was why. It was really for those quirky things that you didn't know who to call. So you called us and then we had to figure out, well, who does this in the office?

But then it's kind of evolved into lots 6 7 of status inquiries. We get more pro se 8 applicants contacting us than attorneys I think 9 still; is that correct? Okay. So it's about 10 even. And you know, some of the calls that we get are to the substantive examination, but I wouldn't 11 12 say that those are the majority. The majority are 13 status inquiries or other things like that. 14 CHAIR JENKINS: So what Mindy is not sharing is she would be the one that you would --15 she answered the phone. So when I first started 16 17 using the program, I'd get Mindy on the phone. 18 MS. BICKEL: That's right. 19 CHAIR JENKINS: And then I'd call for 20 something else and I'd get Mindy again. And that's how I got to know Mindy. So this is really 21 22 -- we were joking this is kind of her baby to

speak, and so it has evolved from, I know when we first started using it, so yeah, so very funny. But one thing I was wondering, too, is, again, it's been a phone type of response. Has it gotten a little bit more email oriented, or is it still mainly people picking up the phone and wanting to talk to a person?

8 MS. BICKEL: I think it's mainly people 9 picking up the phone and wanting to talk. I mean 10 sometimes we have a situation where someone's 11 frustrated because they couldn't figure out where 12 to go to resolve their issue. And they need to 13 vent for a little while to someone on the phone. 14 So I did, for the first two years, I answered all the calls myself, and there were times when there 15 would be 45 minutes of I'm so frustrated, I'm so 16 17 frustrated, and then 5 minutes of this is what I 18 need to resolve the issue.

19 So we really can help with that. If you 20 don't know who to call or what -- who can help you 21 address that issue. That's a really good place 22 for us to be because we can do that so you don't

have to get frustrated at not knowing exactly who 1 2 handles that. 3 MR. GOODSON: Well, I commend you for your credentials in counseling and social work. 4 5 MS. BICKEL: Thank you. MR. GOODSON: More specifically, if, you 6 7 know, a lot of the stuff is cut and dry. What 8 about the question of obviousness? Can y'all be 9 any help with that? 10 MS. BICKEL: So again, that would be something if we got somebody sending us an inquiry 11 12 with regard to an application and they disagreed 13 with the examiner's position on obviousness, we 14 would send that over to the TC, to our representative, which that would be an experienced 15 SPE or a QAS in that TC. That person would look 16 17 at the application in conjunction with the SPE of 18 that examiner. And they would address that issue 19 with the applicant. You're welcome. 20 CHAIR JENKINS: Great. And I wasn't on the phone with her for 45 minutes just to be 21 22 clear.

1 MS. BICKEL: No it wasn't Marylee. 2 CHAIR JENKINS: Any other questions? 3 No. Mindy, thank you. Thank you for the quality team. Thank you, Valencia. Always interesting 4 5 and new developments and much appreciated, and I hope the user community is listening so yeah. 6 So I believe next on the schedule, I 7 8 think Mindy actually has gotten us a little closer 9 back to our scheduled time, so thank you. It 10 looks like I have David, PTAB? So I'll do a 11 precursor. So I was very lucky, David and I 12 several, several months ago were talking about and 13 where it came from was what we were describing as 14 fact and myth about issues before the PTAB. And so I immediately said, David, why don't you come 15 16 to New York and we'll do a fact or myth 17 presentation. And David graciously, with all of his travels, somehow fit us in, and we did the 18 19 presentation actually last week, last Monday, with the IIPS which is a local IP bar association in 20 New York. And it was very well received. Now I 21 22 will qualify that, that we did, through the

association, provided a hot buffet dinner and wine 1 2 and beer. So that may have been why it was so 3 well received, but I think from that David said let us consider doing this for the PPAC 4 5 presentation, too. So we're going to do a variation on it. 6 7 So with that, if you start with the agenda and 8 then I'll try to help with the questions, so. 9 MR. RUSCHKE: Sure, thanks, Marylee. 10 Okay, we'll just go with this. As Marylee noted, this is -- this stemmed from a lot of our studies 11 12 that we've been doing, and one caveat that I 13 always mention when we do start talking about statistics is statistics are statistics. And we 14 try to present as much data as transparently as we 15 16 possibly can to the stakeholders. So we do have a 17 revamped website where we have all of our studies on there, but sometimes the message gets lost 18 19 perhaps. 20 And again, sometimes the message is indeed in the eyes of the beholder. So what we're 21 22 trying to do, again, is present as many statistics

as we possibly can in the most neutral form that we can in the most easily accessible way to the stakeholders. So with that, it's going to be a very heavy statistics presentation, but hopefully the way Marylee and I have essentially bundled the questions together, I think it might make a little bit more sense to folks listening online.

8 So again, let's see, there we go. 9 Generally, we'll follow this agenda item. We've 10 been spending a fair amount of time as the ex 11 parte appeals as we'd like to but also, of course, 12 on AIA trials. We will spend a little bit of time 13 on the studies that we've done. Again, all of 14 these statistics and data studies are on our website. The SAS guidance, I'm not going to spend 15 16 an inordinate amount of time on SAS unless we get 17 a lot of questions on that. It is a hot topic, 18 that's for sure.

We have provided guidance via chats with the chief as well as agency-issued guidance. The director already this morning did talk about where we stand with respect to the claim construction,

notice of proposed rulemaking, and then of course, we always end with upcoming events and developments. So with that, I think here we go. CHAIR JENKINS: Okay. So question, the ex parte inventory has been decreasing rapidly over the past few fiscal years. Will PTAB run out of work?

8 MR. RUSCHKE: We don't think so. One of 9 the things that you might not be aware of is that 10 we do have a board executive side of the board that's the non-judicial side. And one of the 11 12 things that's very critical is to try to estimate 13 our workload based on what we get in and what, of 14 course, what our firepower is in terms of the judges that we have and the jurisdictions that 15 16 they're working on. We have modified that 17 considerably over the last year or two to try to be much more targeted in our ability to forecast 18 our workload. 19

20 This is, indeed, the graph. We've 21 probably seen this before, and you can see that 22 four or five, well, five or six years ago, fiscal

years ago, we were at a high of over 26,000. Now at that point we use to call it a backlog. Now we actually call it an inventory because we're down in the FY18 to just below 12,000. Now we get approximately 1,000 in a month, so we're reaching generally steady state when it comes to our input as well as our output.

8 So we have about 12,000 in right now. 9 We get 1,000 in a month. And we're trying to --10 instead of as you can see how the curve is coming down. Instead of having it come down 11 12 precipitously, you can see how it's been leveling 13 out. And so with our improved model that we have 14 on our firepower with the judges, we're able to target that. Essentially, we're trying to get 15 down to that even, steady state. So whatever we 16 17 get in we'll be able to get out simultaneously. 18 CHAIR JENKINS: So question, do 19 appellants still have to wait two and a half years 20 for a decision on their ex parte appeal? MR. RUSCHKE: Actually, no. They don't 21 22 have to wait two and a half years. And I might

1 say that that's actually being somewhat generous. 2 There were cases that we had pending at the board 3 much longer than two and a half years, let's just -- to be perfectly honest. And that was some 4 5 practitioners have told us that they actually like 6 that. That they use the appeal process as a way 7 of parking an application and waiting to see how 8 the technology developed, those sorts of things. 9 Our goal is to come down to a one-year 10 pendency. Right now this slide shows where we are 11 on pendency based on technology center. Just to give you a little bit of -- it's a little bit of a 12 13 busy slide, but what this does, the colored slides 14 correspond to the present pendency within that technology group. The gray bar behind it, and 15 16 then the number above that is showing the pendency 17 exactly a year ago.

18 So you can see that within all of the 19 technology centers, generally we have decreased 20 the pendency year over year, in some cases fairly 21 dramatically. The bar on the far right-hand side 22 shows the overall pendency for all technologies

1	which says that a year ago our average was about
2	18 months. Now we're down to 15 months this year.
3	And you can see it does vary by technology group,
4	and we'll get into that a little bit here. But we
5	still have a lot of work to do, I think, in the
6	business method and mechanical areas as well as
7	bio/pharma and chem to some extent. But we're
8	doing quite well in the four electrical computer
9	technology centers which you can see in blue where
10	we, again, are targeting essentially a year
11	pendency.
12	CHAIR JENKINS: Question, how has the
12 13	CHAIR JENKINS: Question, how has the PTAB been able to reduce appeal pendency?
13	PTAB been able to reduce appeal pendency?
13 14	PTAB been able to reduce appeal pendency? MR. RUSCHKE: One of the things that was
13 14 15	PTAB been able to reduce appeal pendency? MR. RUSCHKE: One of the things that was sort of a byproduct of the AIA, and having to ramp
13 14 15 16	PTAB been able to reduce appeal pendency? MR. RUSCHKE: One of the things that was sort of a byproduct of the AIA, and having to ramp up hiring with respect to the AIA post-grant
13 14 15 16 17	PTAB been able to reduce appeal pendency? MR. RUSCHKE: One of the things that was sort of a byproduct of the AIA, and having to ramp up hiring with respect to the AIA post-grant proceedings was that we had when we were hiring
13 14 15 16 17 18	PTAB been able to reduce appeal pendency? MR. RUSCHKE: One of the things that was sort of a byproduct of the AIA, and having to ramp up hiring with respect to the AIA post-grant proceedings was that we had when we were hiring a lot of judges in the early year, the 2012-2013
13 14 15 16 17 18 19	PTAB been able to reduce appeal pendency? MR. RUSCHKE: One of the things that was sort of a byproduct of the AIA, and having to ramp up hiring with respect to the AIA post-grant proceedings was that we had when we were hiring a lot of judges in the early year, the 2012-2013 timeframe, when they came onboard, they don't

hiring a lot of electrical judges at the time, 1 2 that's how the electrical backlog of inventory, if 3 you will, came down significantly. And so that is how we have been doing that generally. But more 4 5 specifically, we have instituted a couple of programs. One is called a quarterly appeals 6 7 closeout goal. And what this does it helps reduce 8 the judge's backlog with respect to the oldest 9 cases first.

10 And we began this about six months ago. 11 And we are, again, trying to reduce that very low 12 tail, there's a very few number of cases but the 13 ones that have been pending for an extremely long 14 period of time. We want to get those out 15 frequently. And you can see here in this graph 16 that tail, which is essentially in the green; we've essentially reduced the tail as of July 2017 17 in the blue down to July 2018 in the orange. And 18 19 you can see that differential between the two 20 years where those oldest ones have been targeted and been making sure that the judges work on those 21 22 first prior to working on any new cases.

1 So again, what we're trying to do is get 2 rid of the old cases first. It seems fairly 3 obvious but not always easy to do and this closeout program has, indeed, I think done a good 4 5 job with that. So you can see we have successfully targeted this oldest appeals reducing 6 that tail. And we've reduced the maximum, and 7 8 this is an overall maximum pendency was 36 months. 9 We're down to almost two years now, year over 10 year, just in about the six months that the 11 program's been in place. 12 The other program that we've done, and 13 we've been doing this for about a year now, is the 14 technology rebalancing goal. And if you remember on the TC pendency slide, we were doing quite well 15 on the electrical arts, but still needed to do a 16 17 fair amount of work in the business methods side in particular. And so what we tried to do is 18 19 redistribute the firepower, that's the judges' 20 workloads, to bring the pendency difference between the appeals into closer alignment. 21

22 And what we had seen, again, was that

1 the electrical pendency was reducing significantly 2 where the business method firepower relative to 3 intake was rapidly increasing. The results of this after a year are shown in this slide here. 4 5 You can see that prior to that line, that vertical 6 line in the middle, prior to the rebalancing, we 7 were seeing while the inventory was decreasing, 8 the difference between electrical in the blue, and 9 then business methods in the orange were 10 diverging.

11 And so when we rebalanced the firepower 12 with respect to the judges' jurisdiction, you can 13 see that over the years since we've started now, 14 we're bringing -- we essentially slowed down the electrical decrease, but we've also then narrowed 15 16 the gap with the business methods while keeping 17 those moving forward. So it's -- I think it's working quite well, but as you can imagine, we 18 still have a fair number of business method cases 19 20 that we're still working on. So that's where we're at right now on the ex parte appeal pendency 21 22 and inventory.

1 CHAIR JENKINS: So I'm just going to 2 stop there for one second. Any questions before 3 we jump to AIA? No? 4 This I think is really helpful. I think 5 people are always sort of feeling the ex parte appeals are a little bit of a stepchild. So it's 6 7 good to hear that no, it's not, and we pay 8 attention to that as well in trying to move the 9 ball forward, so. 10 MR. RUSCHKE: Absolutely. CHAIR JENKINS: Okay. So moving right 11 12 along, question, IPR filings continue to grow. Are third parties filing any PGRs or CBMs? 13 14 MR. RUSCHKE: The data's still fairly consistent that there is not a lot of filings 15 16 happening in PGRs and CBMs, but we have broken 17 out, as part of our analysis trends as making sure 18 that we can divide things out by trial type, and 19 here's a slide that you can see. Of course, we 20 are talking orders of magnitude difference between PGR, CBMs, and IPRs. 21 22 The growth rate in IPRs since FY,

essentially, FY14, essentially we're getting 1 somewhat of a little bit of a sinusoid. So FY14 2 at around 1,300, up to 1,700 in '15, 1,600 in '16, 3 back up to 1,800 last year, that was our largest 4 5 filings of IPR year over year. This year you can see that little dot over there. That's through 6 7 the third quarter of our fiscal year. We are 8 showing about 1,100. 9 So annualizing that data from FY18, we're probably going to end up somewhere around 10 1,600 perhaps. So again, a little bit of a 11 sinusoid, but it definitely, if you draw a midline 12 13 between the last four fiscal years, we're averaging right around 1,600 IPRs a year. It's a 14 little different when you look at the PGRs and 15 16 CBMs. 17 Again, very small numbers comparatively, but PGRs, year over year, you can see it 18 increasing. I'm not sure if we're -- again, if 19 20 you look at it just up until FY17, one might conclude that it's doubling over and over and over 21 22 again year over year. Again, small number so it's

hard to say. Right now at the end of Q3 we're
 essentially the same number where we were at last
 year.

4 CBMs you can also see we had a high back 5 in FY14. Those have steadily fallen over the 6 years, and right now over at FY18 we are standing 7 at three-quarters of the way through the year at 8 around 30. We did try to provide some additional 9 data, let's see; here we go, by technology. We 10 also had a request from stakeholders that they 11 like to see the petitions data broken out by 12 technology.

13 No surprise. We have seen electrical 14 and computer data against seeing somewhat of a sinusoid, but that is indeed, by far the largest 15 16 technology centers that we have before the board. 17 That is followed by business methods and mechanical. Again, that's fairly stable year over 18 19 year. I would point out the purple line there, the bio/pharma. That is one line that does seem 20 21 to be increasing year over year. It might be 22 slight, but that definitely does seem to be

1 increasing.

The chemical line also may be slightly, that's in green, slightly increasing, but again, not by much in comparative to the electrical in order of magnitude less. We do include the designs, but they are essentially in the single digits.

8 CHAIR JENKINS: Question, is the AIA 9 trial institution rate as high as it was when the 10 board started conducting trials nearly six years 11 ago?

12 MR. RUSCHKE: It's not as high. This 13 slide, we have broken out again to help with folks 14 look at it on a year over year basis. And indeed, in very small numbers, but the very first year and 15 into the second year, we were in the 87 percent 16 17 and 75 percent range for institution rates. And 18 that essentially has now come down over the years 19 and we are hovering down in the low sixties on a 20 regular basis year over year.

Now of course, we all know the SupremeCourt came down with the SAS decision drastically

impacting our institution phase and the way we've 1 2 been instituting case will remain to be seen how 3 these are going to be instituted at this rate changes. We've just gotten done with a number of 4 5 judicial conferences in all of our regional offices, and it was very interesting. SAS, of 6 course, is a high priority and a very much of a 7 8 hot topic for all of our practitioners. And we 9 have been hearing from petitioners some 10 interesting changes, potentially, in their behavior and their reacting to the SAS decision. 11 12 I also might want to say we, again, in 13 the interest of transparency and providing as much information as possible, we have broken out 14 institution rates by technology now. And again, 15 16 we're trying to make everything color-coded. 17 Overall, again, it's right around 61 percent, but you can see that in the bio/pharma, which is the 18 19 purple line, and the green, which is the chemical 20 line, those are showing slightly lower institution rates versus the electrical, mechanical, and 21 22 business method institution rates.

Now I was looking at Jennifer, at her 1 2 expression. I think that does surprise a number 3 of the bio/pharma-chem folks, but that's the data that we're seeing that there does seem to be 4 5 generally a lower rate on the chem pharma bio side compared to other technologies. 6 7 MR. WALKER: No, I said now because if 8 you look back to FY17 it was actually the highest. 9 MR. RUSCHKE: Correct, which is 10 important. That's why I think that it's important 11 to provide stakeholders with the technology 12 breakout as well as the year over year breakout. 13 That helps a lot. CHAIR JENKINS: Let me go to the next 14 question. I don't know if this is the right time 15 16 to ask you this but one of the questions that 17 several stakeholders have asked is how is, and I 18 know you have addressed this in different ways, 19 but so how is the PTAB getting this information to 20 examiners, to other parts of the office? What you're doing, how is, like, how is this with 21 22 quality? I think maybe another -- maybe you

addressing it might be an interesting explanation 1 2 as well so. 3 MR. RUSCHKE: Just in terms of the data, Marylee, or just in terms of the --4 5 CHAIR JENKINS: Yeah, because I think, again, we go back and Bernie's raised this too is, 6 you know, the perceived inconsistency between you 7 8 spent all this money trying to get a patent. 9 You've worked with an examiner to get it allowed. 10 Again, you've spent a lot of money, and then you get to the PTAB and it doesn't go very well. And 11 12 so how are we making all -- and the director is 13 back. How are we making -- what steps are we 14 doing to try to make this a better process? 15 MR. WALKER: And, David, could I just 16 add because I was just reading some of the 17 questions, and it does go to what the director said this morning about the one office concept. 18 19 And I think you talked before a little bit, maybe could refresh the discussion about the feedback 20 loop to the examining corps from PTAB, and you 21 22 have other slides coming up to show the number of

1 claims that are --

2 CHAIR JENKINS: And I also think, too, 3 people we -- you also have if there's an application that's pending, that's related to a 4 5 patent that's being reviewed for IPR, that information is then -- Andy is shaking his head 6 7 yes. That information is then shared with that 8 examiner on the continuing application. I think 9 it's interesting. I think you really have to keep 10 repeating the message so.

MR. RUSCHKE: Sure, yeah. Thanks for 11 12 that. Thanks for that. So we have a number of 13 different ways to work with the patents group. 14 And as you mentioned, I'll just pick up on the last one. There was a pilot program that was put 15 in place so that the examiners who were working on 16 17 a continuation application or CFP in the same family would be aware of all of the art that was 18 19 being cited in the IPR. 20 I believe that's actually an automated

21 system now so it pops up on the examiner's screen 22 right away. And I think -- and we provide the

largest paper. So we provide the petition, we provide the response. So we provide all of the substantive papers, not the procedural stuff, but the substantive papers to the examiners in the family so that they're aware of what the PTAB is doing.

7 I believe the patents have done a study.
8 Sometimes of course it might not be relevant if
9 the patent or the applicant is pursuing claims
10 that are somewhat different than what we're seeing
11 at the board. So it may or may not be relevant,
12 but at least we're providing the information to
13 the examiner on those same claims.

14 One other thing that we do fairly frequently is we do help out on the training of 15 16 the examiners with respect to not just the board procedures, but what we're looking for, let's say, 17 in an appeal brief, for instance. And also what 18 we would then recommend from an examiner answer 19 20 standpoint. So we're helping the examination people figure out what we're trying to do to make 21 22 sure that there is that communication between the

1 board and the examination corps.

2 One of the other things that we're doing 3 actually with Valencia's group, and it stems from our provision 325(d) in our statute, is again this 4 5 notion of we don't want to be redoing the work that has already been done by the agency. So if 6 7 the same or substantially the same other arguments 8 have been looked at by the agency, either through 9 patents or the CRU, or frankly through the board 10 in another IPR, we want to make sure what 11 proceedings and what overlap we've seen so that 12 we're properly applying that 325(d). And we're 13 engaged in a study right now with Valencia's group 14 to look at what is actually happening with respect to the work that's being done with the patent 15 16 group, and then what the board sees it down the 17 road. 18 MS. MARTIN-WALLACE: So David, if I

19 could just add to that --

20 MR. RUSCHKE: Please.

MS. MARTIN-WALLACE: -- a few examples
of how we collaborate together. So as David said

the training that we do together, we've also worked together on some webcasts for our examiners, for training for examiners as well as public webcasts that we've done together. We meet frequently.

We actually have three tiger teams that 6 7 are working together between PTAB and patents 8 working on case studies, working on development of 9 new programs and initiatives for reaching out to 10 examiners and having discussions. And we've had graciously offered by David and his team, we've 11 12 had some appeal hearings where we've had examiners 13 who were invited in to witness them so that they 14 can see firsthand what's happening to their cases 15 post issuance.

16 So quite a few, as well as we have 17 frequent meetings where Andy Faile, Bob Barr, and 18 I meet with David's senior team to discuss some of 19 the issues that are happening. What we're seeing 20 and some of the issues that the judges are seeing. 21 So we actually have a lot of ways that we're 22 collaborating right now along the lines of what

1 Bernie was offering. 2 CHAIR JENKINS: All right, so moving 3 along, yeah? 4 MR. RUSCHKE: Okay. 5 CHAIR JENKINS: Question, is PTAB invalidating nearly all challenge patents? 6 7 MR. RUSCHKE: I would say that that's 8 not true. 9 CHAIR JENKINS: I will say that he just 10 laughed sitting next to me. I just want you to 11 know that. 12 MR. RUSCHKE: But this is something that's -- that we hear quite frequently, and 13 14 sometimes it comes out either nearly all or 15 sometimes it's 80 percent, 90 percent. We do hear that fairly frequently. And I think it's 16 17 important to address. Now here's our famous, or perhaps infamous, waterfall slide. Again, this 18 19 was a dataset that we wanted to put out there, but 20 this is a cumulative dataset since the beginning of AIA. This is not year over year. But it does 21 22 show you that filing a petition, 8,700 to date,

only 2,200 have reached final written decision 1 2 where you would actually have a decision on 3 patentability. So there's a lot of things that happen in-between. 4 5 The red is, of course, the pre-institution data, the blue is the 6 post-institution trial data, a number of those 7 8 cases settle, a number of those cases aren't 9 instituted. As you saw overall, we're seeing about a 60 percent institution rate. In a number 10 11 of cases, a small number of cases then also get 12 dismissed or reach request for adverse judgments, 13 et cetera. 14 So what we've been trying to say, though, and maybe this is an interesting slide, 15 16 too, just on a settlement piece, typically overall 17 it's about a third of the cases settled. But again, let's try to break this out year over year, 18 19 and we have in blue post-institution, red 20 pre-institution settlements. Right now we're settling in at around the low twenties. We're 21 22 right around 23 percent settlement overall.

1 We, of course, are aware that some folks 2 do not view settlements as a positive necessarily. 3 But I think in terms of advising your client, this data, hopefully, can be helpful and say that at 4 5 this point, these are the settlement rates that we are seeing in AIA trial work. But I do want to 6 say, this is probably -- this next slide is a 7 8 fairly new slide that we've broken out again, year 9 over year, to try to put a little bit more 10 granularity on the data that we present. And I do want to address this issue of 11 12 nearly all patents that are challenged are found 13 unpatentable at the PTAB. You can imagine where 14 that started from. If you recall the institution

rates initially were around 87 percent. So that was right back in FY14, 87 for 75 percent. So there was a very high likelihood that you would be instituted on and this slide here is showing once you are instituted on, what are your chances of survival as a patent owner at final written decision.

22

And you can see that the data has

1 changed year over year. But you can see in those 2 early days, indeed, the invalidation rate was 3 quite high. And frequently, people would lump the no claim being found patentable, and the some 4 5 claims being found patentable, that's the purple line, together, and there's where you could get 6 this 85, 80 to 90 percent invalidation rate. I 7 8 can see how in the earlier years that narrative 9 took hold, but I think this important part of this 10 data is showing that in the top red line where we find -- which is essentially year over year, when 11 12 we find in our final written decisions that no 13 claim is patentable, that has essentially been 14 dropping since FY15 by about 15 percentage points from 73 percent down to 58 percent. 15 16 Not too unsurprisingly, where we have found all claims patentable at final written 17

18 decision over the last two fiscal years has 19 actually increased by 15 percent, from 12 percent 20 to 27 percent. So the initial gap, which was 21 essentially 61 percent, is between the red line 22 and the blue line in FY15, has now been

essentially converging in FY17 to around 21
 percent. That's a fairly significant shift in
 what the PTAB is finding at final written
 decision.

5 We're still seeing overall that there's mixed results in about 15 percent of all cases. 6 But this is a result of making sure that when you 7 8 look at the data year over year it might be a 9 little bit different trends than if you look at 10 the bulk data, because any change that we're doing now in 1 or 2 final written decisions or even in 11 12 100 written decisions that we do a year, is not 13 going to affect the 2,000 written decisions that 14 have been going on since AIA.

So I do highlight this slide because I 15 16 think it points out how, indeed, the early 17 narratives about the high invalidation rate could easily have taken route, but that I advise folks 18 to look at this slide and see how that's changed 19 20 year over year particularly if you go from a 61 percent unpatentable versus patentable delta two 21 22 years to essentially a 31 percent delta year over

year in FY17. Is that clear? I know it's a lot 1 2 of data there, but I think it's a message that we 3 try to get home, and sometimes it doesn't necessarily get out there because people are using 4 5 cumulative data from the beginning of AIA, and that will give you very different results. 6 7 Whereas if you look at this year over year trend 8 data, that actually is showing, I think, somewhat of a different story. 9 10 MR. WALKER: And David, I get -- it's very interesting. I guess you would say that's a 11 12 proxy for improved patent quality? 13 MR. RUSCHKE: It could be. MR. WALKER: Because the institution 14 15 rates are also dropping, and so the no claim 16 patentable is also dropping, all claims patentable 17 increasing, so you have three data points there that would show presumably that patent quality is 18 19 increasing, right, or no? MR. RUSCHKE: Well, again, part of you'd 20 have to look at it, Mike, since IPRs could be 21 22 patents that issued many, many, many, many years

ago, you'd have to actually get into -- you have 1 2 to parse it out as to which -- when they issued, 3 if you will, and do that sort of overlay. But generally, you might say that, but I would just 4 5 caution jumping to that necessarily without knowing exactly when the patents issued. 6 7 MR. LANG: From our viewpoint, I mean, 8 the primary filter is actually before the petition 9 stage when petitioners decide whether or not to 10 file, and it could have been early on in the procedure people didn't have a lot of experience 11 12 with it. They were reluctant to. Then they saw 13 that it could be successful, and they became more 14 optimistic, and filed more, and that naturally dropped the institution rate a bit. That's one 15 16 possibility.

MR. RUSCHKE: Yeah, we've heard that aswell.

MR. LANG: But overall, I think your message is a very correct one, and I think that refocuses it on people that this is, in many ways, a balanced procedure that gives people, both

patent owners and petitioners, a fair shot. I 1 2 mean, we can certainly all be upset in individual 3 cases where we, as a petitioner or as a patent owner, weren't successful, and I've certainly had 4 5 some of those to complain about myself. But I see this as a procedure that's very successful and 6 7 important piece of our patent system, and should 8 continue, and there may be changes, but hopefully 9 they won't take away from that successful record. 10 MR. RUSCHKE: Well, I do want to reiterate what you say, too. Again, statistics 11 12 are statistics except if you're the one that falls 13 on the other side of the statistics. And so that 14 is we completely understand that. So that's why 15 it -- and we've been -- and the director's been 16 meeting with a number of stakeholders where they 17 have actually brought in data to us saying like 18 that's -- your data's all well and good and we 19 understand that, but this is our personal 20 experience. And I have to say, those interactions 21

22 with those stakeholders where they've actually

gone in and looked at their portfolio, their
experience before the board, that's been very,
very powerful to us. It actually does inform you
that the experience that chose clients and those
attorneys in those companies are actually dealing
with on a day-to-day basis. So that's, I think, a
very, very helpful piece.

8 And just to close out the one answer on 9 this question, we have this slide. We're trying 10 to revamp it a little bit. This actually, what we 11 call our ultimate outcome for patents and AIA 12 trials. So now this slide is looking at from the 13 very beginning, when the petition is first filed, 14 to the final disposition at the end of the trial 15 phase.

16 What happens to your patent along that 17 way? And again, it's all built off that waterfall 18 data. And we provided this data based on a per 19 petition basis, which is in green, and a per 20 patent basis, which is in blue. And we've 21 defined, essentially, a patent being unchanged 22 from beginning to end, meaning you didn't get

instituted on. The case was settled, or claims
 were found patentable at the final written
 decision stage.

So there's a number of different ways 4 5 that your patent remains unchanged throughout the 6 entire process. And throughout the entire PTAB process, we're finding 58 percent of patents, 7 8 that's the blue bar, which translates into 69 9 percent of the petitions filed. Your patent 10 remains unchanged. Now of course, we've heard 11 again that we probably shouldn't be -- some people 12 feel that we shouldn't be including settlements in 13 this data. Of course, your patent does remain 14 unchanged. It's hard for us to say whether any settlement that you reached was a positive 15 16 settlement for you or not.

17 So we are going to try to carve that out 18 of our data to make it very, very clear that the 19 things that it -- were influenced by PTAB, we had 20 control over, versus what you, as parties, settled 21 out as. But I do think it's an interesting slide, 22 going again, to the analogy of at what point of

the trial what do you advise your client. The message that we're saying, when you get a petition filed on day one, this is the dataset that you might want to look at in analyzing the advice you give to your client.

The bottom two bars are, again, is where 6 7 we have essentially found that all claims are 8 unpatentable, and we do that in 21 percent of all 9 petitions filed, excuse me, 29 percent -- 21 10 percent of all petitions filed, and 29 percent of all patents filed. So again, we're trying to 11 12 provide data in different formats to you at 13 different stages of the proceeding that help guide you and the work that the IP community is doing 14 15 with their clients. 16 MR. GOODSON: Can you back up one slide? 17 MR. RUSCHKE: Sure.

18 MR. GOODSON: I find this fascinating, 19 your last set of points, that I would expect some 20 claims to be in-between all and no, and it doesn't 21 turn out that way. And to me that's -- it seems 22 out of kilter. On the other hand, I think it's

proof that the system is working. People are
 looking -- the judges are looking at these claims
 very seriously.

MR. RUSCHKE: Well, thanks, Mark, and I 4 5 would point out, I, too, find that interesting, too, that the mixed results has just been fairly 6 7 stable. I think we're going to have to be -- keep 8 a close eye on this, though, because SAS, with the 9 binary decision, is going to impact this data. 10 So it's somewhat unfortunate because 11 that's going to be April 24th, 2018 is going to be 12 a big statistical divide on not only on the 13 institution rate, but on exactly what you're 14 seeing here, because whereas before, we might have carved out certain grounds and not gone forward 15 16 with them. If we do decide to go forward, we're 17 going to be bringing in grounds that previously we might not have brought in. 18

19 So I think you're going to find the 20 mixed results to go up. That's my prediction 21 right now, just as a result of the Supreme Court 22 decision. And that goes along with what the

1 director has been very, very strong on, and I 2 think it's the right way to go, of course, is to 3 provide to the patent owners and the petitioner, at the decision to institute stage, as much 4 5 information as we can with respect to both patentability and unpatentability at that 6 preliminary stage. But make sure that both 7 8 parties understand where we're going forward. So 9 that when we do go forward you can understand, we 10 have to find at least one claim, one ground to 11 have a reasonable likelihood of unpatentability, 12 but maybe not the rest of it, and the rest of it 13 will come out in the statistics, Mark. And I 14 think that's a really good point. Thank you for 15 raising that.

16 CHAIR JENKINS: So before we go on to 17 the next subject, on online comment/question 18 jumping back to the interplay between the PTAB and 19 the examiners. And questioning the fact that if 20 the examiners have the expertise in the subject 21 matter, and they've reviewed art, and then that 22 same art goes to an AIA trial, and shouldn't there

be some difference given by the judges to the 1 2 examiner and the review. And to be fair, too, I 3 mean, the examiner is spending a significant amount of time, probably doing some sort of 4 5 exchange, both by filings and possibly by interviews in person. That they really have --6 they have the record, so to speak, so. 7 8 MR. RUSCHKE: Yeah, that is a great 9 question, and to some extent it's -- we've heard 10 from certain stakeholders as well, particularly in 11 bio/pharma and the chem group to some extent. A 12 lot of those patents have been examined for a long time. So there is a lot of art that has been 13 found. There's a lot of art that has been 14 considered. With respect to this level of 15 16 deference, I point out the following. 17 In about the last six to eight months we have put out seven, I believe informative 18 decisions on the factors that we will look at with 19 20 respect to reviewing an examiner's work product. And those factors, of course, include the level of 21 22 analysis that the examiner did, was it in-depth,

1 was it cursory, was it just on an IDS, was it on a 2 large IDS, was it on a small IDS, those sorts of 3 things. Cited in a foreign search report, the similarity of the references that were being shown 4 5 versus what was found with the examiner. I mean, petitioners have figured this 6 out to some extent, right? If you put the exact 7 8 same art in front of us that the examiner looked 9 at, that's a harder -- that's an uphill battle as 10 opposed to if you find other art. Now that said, if it's similar and we've also had one of our 11 12 factors uses the word cumulative, if it's 13 cumulative art, that might be, again, a reason why 14 we do not institute because the office has already 15 looked at it and analyzed it. 16 But the question that you raised, I

think, is very important is this level of deference. You will see in our cases that there is some ability to try -- that we're trying to find and hone in on the standard of looking at the examinations -- examiner's work product, and what level of deference that deserves. And it does

1 deserve deference, of course. Now what we're 2 encouraging patent owners and petitioners is to 3 help us in that process.

4 I would point you to a case, an 5 informative case, Becton Dickinson, which lists the factors that we have been looking at with 6 7 respect to 325(d) which is revisiting the 8 examiner's work product. And in that list of 9 factor, nonexclusive list of factors, we talk 10 about what level of error that we would have to essentially look at on the examiner's side were we 11 12 to go forward.

13 We, actually, would like to have the 14 stakeholders' help on formulating what that means to them and what level of deference we should be 15 16 giving to the examination corps. It's -- we 17 already give a level of deference, and we have 18 seen that in a number of situations on 325(d) 19 where we did not go forward on those grounds 20 because the examination corps had already looked 21 at that.

22 Big caveat, once again, April 24th SAS.

We have used 325(d) frequently in order to limit 1 2 the range of issues and only go forward on those 3 -- I think that's me. If somebody could turn off their livestream I think that's -- there's a delay 4 5 and that's what we're hearing. Thank you. SAS is creating some issues on 325(d) 6 7 where before we would not go forward on certain 8 grounds. Now we have to go forward on certain 9 grounds if we decide to go forward at all. So 10 that's creating some strange dynamics on this 325(d) side that certainly hasn't been 11 12 anticipated, I think, by the Supreme Court and 13 SAS. 14 MR. KNIGHT: David, I think it's a -- I don't expect you to answer this right now but I 15 think an interesting legal issue arises on that 16 17 deference question because I understand how under 18 325(d) you don't have to look at our -- already 19 looked at by the office. But to give deference to what the examiner did kind of I wonder how that 20 would work under our preponderance of evidence 21 22 standard in the statute that the board must

1 determine patentability by a preponderance of 2 evidence, and whether that's consistent with 3 giving deference to the examiner's opinion. MR. RUSCHKE: That's exactly right, but 4 5 again, you know, you divide it out that -- we get to the preponderance piece if we're in trial. 6 Before that when we decide under 325(d) whether to 7 even go to trial, those factors and that level of 8 9 -- and maybe deference might not necessarily be 10 the word, but how are we going to analyze the 11 examiner's work product. And again, we find from that the petitioner, frankly, and then the patent 12 13 owner in response, the petitioner is saying he 14 clearly erred. He made an error, referring to the examiner, he overlooked, he misapprehended. So 15 16 there's a lot of different word -- verbiage that 17 have been used.

And again, it's -- I think it'll fit fine with the preponderance standard which is post-institution. What we're trying to find out is what level of, you know, what factors, and what level of analysis, frankly. The example, again,

that we have seen is if the examiner had an IDS 1 2 with only three references on it, and those are 3 the 3 references before us, that's a different situation, perhaps, than when there's 1,000 4 5 reference IDS and those 3 references are somehow 6 in here, but the examiner never applied it. Clearly, and I think in the informative 7 8 decisions that you've seen, when the examiner has 9 looked at that reference, and has found those 10 claims patentable, that is a situation that is 11 right for 325(d) where we will not go forward and 12 institute on those claims, all pending SAS. 13 CHAIR JENKINS: Want to move on, yeah? 14 MR. RUSCHKE: Sure. 15 CHAIR JENKINS: So motions to amend. 16 MR. RUSCHKE: Hot topic. 17 CHAIR JENKINS: So question, under what circumstances will the PTAB grant a motion to 18 19 amend? 20 MR. RUSCHKE: As the director said, we have been looking at PTAB up and down, every which 21 22 way, and this topic is indeed a hot topic. And at

1 our judicial conferences that we've taken through 2 all of our regional offices as well as here, we 3 spent an entire hot topic session in the afternoon 4 trying to get feedback from the stakeholders as to 5 what they were looking for in a revised motion to 6 amend practice.

As the director noted, this is something 7 8 that's a very high priority for him, and also for 9 the board, and hopefully you'll be seeing 10 something on this from us soon. But one of the hallmarks, again, that we've seen, and this is 11 12 from our motion to amend study. We have to have 13 compliance with, at a minimum, with of course the statutory provisions, 101, 112, 102, 103, 14 otherwise we will just not grant the motion. 15 16 And as a result of that, you can see in 17 this slide that the reason we haven't been granting those motions to amend are these 18 19 statutory and regulatory reasons. And that, 20 again, it's not complying with the basic statutory provisions, or underneath 316 where there was not 21 22 a reasonable number of substitute claims, the

claims weren't narrow, or there wasn't written
 description support. There was new matter for the
 proposed substitute claims.

So the reasons we're denying the motions 4 5 is not because we don't feel like it. It's actually when you do the analysis, just as the 6 examination corps would do it, it would not pass 7 8 those patentability requirements in the statute. 9 Now that said, and this is where the director, I 10 think, is honing in and asking PTAB to take a look 11 at the amendment practices, why is that? Why are 12 there not -- why is there not an ability for the 13 patent owner to amend claims in a way that 14 actually complies with the statute? And again, the highlights that he 15 16 mentioned this morning, I would like to reiterate. 17 There is the requirement of trying to get all the work done with the one-year period, that's for 18 19 sure. But again, is it a way that we can provide

20 multiple opportunities for the patent owner to 21 amend, provide guidance earlier on in the process, 22 so that the patent owner doesn't get a decision on

all claims, including their substitute claims, at
 the final written decision stage.

3 So it's those inputs that we've been receiving from stakeholders, I think, that have 4 5 been informing, as he mentioned, how we would modify the amendment process to make it a robust 6 7 process so that patent owners can, indeed, know 8 what they need to do in order to meet these 9 statutory requirements. I will say, this is 10 post-Aqua Products on this slide. There are very 11 few that have been filed from day one. There just 12 has been, and that's what this slide shows year 13 over year, fiscal years.

We've always been right around 50 or 60. 14 Aqua Products came down October 4th, which, 15 16 luckily for us, is actually right at our fiscal year. So this is an easy dataset to look at. So 17 FY17 is pre-Aqua Products. FY18 is post-Aqua 18 19 Products. This data is only through the first 20 half of the year, and you can see that there might be a slight uptick, that since the burden was no 21 22 longer on the patent owner, per Aqua Products,

1 that there might have been a slight increase in 2 motions to amend being filed.

3 Now of course, those have to work themselves through the system. So we're not sure 4 5 if the burden being removed from the patent owner is actually making a difference as to those 6 7 motions to amend, whether they're granted or not, 8 so stay tuned. But this is at least a little bit 9 of data post-Aqua Products indicating that there 10 might be an uptick in motions to amend being filed by patent owners. I know we're -- I just want to 11 12 point out as, well, we did have an informative 13 decision, if you're not familiar with it, Western 14 Digital.

15 This is actually to replace some of the 16 precedential and informative decisions that we had 17 out there where the burden was placed on the patent owner. So those have been de-designated, 18 19 and this one has been designated in its place. I 20 highly recommend that you go through this as both patent owner and petitioner. We're trying to 21 22 include this informative order in the vast

1 majority of our cases to provide guidance to you. 2 And again, it just helps provide where we are at 3 this point after Aqua Products. CHAIR JENKINS: Okay, multiple petitions 4 5 studies, question, are gang tackling and serial petitioning prevalent at the PTAB? 6 7 MR. RUSCHKE: This is something we hear 8 a lot of. And we still hear about it quite a bit. 9 I think when we put out our initial multiple 10 petition study about a year ago that was fairly 11 helpful. Trying to at least frame the conversations and frame people's discussion on it. 12 13 But again, there's going to be a wild 14 card with SAS. And petitioners' behavior is going to be very, very interesting to see if they are, 15 16 indeed, filing more petitions, perhaps more petitions and more focused, fewer petitions, the 17 exact same number of petitions. We just don't 18 19 know. So this multiple petition data study which 20 is through a year ago of 2017, we'll have to see how SAS affects this going forward. 21 22 But generally, this multiple petition

1 study, this is where we're talking about, on this 2 slide at least, the petitions per patent, and of 3 course, this is very important that we get the right denominator. This is the number of 4 5 petitions per patent. So this is -- goes to the notion that patent owners are feeling that they 6 get hit with one petition, and if that one doesn't 7 8 stick then there's another one, and then there's 9 another one that, and another one that. 10 And what we're seeing with the data is 11 that quite a few, about 87 percent of them, patents challenged by PTAB by one or two 12 13 petitions. Some people might say that two 14 petitions is too many, but that's what we're seeing. When we're seeing these serial petitions 15 16 over and over and over again, it does to get 17 fairly low percentages about four percent. We're only seeing about one percent in those higher 18 19 numbers, and then seven or more is essentially 1.3 20 percent. So that's what we're seeing in terms of the serial nature of petitions that patent owner 21 22 has to see petitions over and over and over again.

In terms of gang --1 2 MR. KNIGHT: David? 3 MR. RUSCHKE: Yes, sure. MR. KNIGHT: You know, one thing that I 4 5 think would be interesting, I don't know if you have this, is when, you know, when multiple 6 7 petitions are filed, is the patent owner asserting 8 the petition in subsequent suits against multiple 9 parties, because that would be completely 10 justified. MR. RUSCHKE: Right. Well, I have a 11 12 little slide on that later. 13 MR. KNIGHT: Okay. 14 MR. RUSCHKE: It's a little bit -- we 15 can get that data to some extent because they have to tell us if there's, you know, co-pending 16 17 district court litigation. But it's not 18 incredibly easy for us, necessarily, to include that in the dataset. But we do touch on that a 19 20 little bit which I think is an important point. 21 This next slide, though, goes to the 22 gang tackling of it. And again, this is a

1	situation where codefendants, as Bernie just
2	raised potentially, somehow working together in
3	order to gang tackle a single patent owner. And
4	what we are seeing is 85 percent of patents are
5	challenged on a single by a single petitioner.
6	So it's one petitioner, one patent owner. The
7	largest gang, if you will, according to this is
8	eight. And seven and eight, well, actually, it
9	looks like from five, six, seven, and eight those
10	sorts of gangs are fairly small numbers. Again,
11	85 up to 95 percent are either challenged by one
12	or two petitioners.
13	CHAIR JENKINS: Is that in a particular
14	could you say that's in a particular
15	technology?
16	MR. RUSCHKE: You know, that's I
17	would love to have this broken down by technology.
18	We don't. What we do have broken down, I'm not
19	sure if I have my data in this slide, like I don't
20	think I do oh, I do actually, are orange
21	book-listed patents. Now those get at the
22	technology piece and it's fairly easy for us to do

that because we -- if they're listed in the orange 1 2 book we know what they are. The rest we have to 3 actually manually hand count and figure out what technology they go to and divide out the data. 4 5 So I do have orange book-listed data on that. Let me see if I have the -- I don't have 6 that in the slide deck, but it is on our website. 7 8 And we have done very similar data for the 389 9 orange book-listed patents that are -- that have 10 come before the PTAB. And if I remember correctly, I don't want to misspeak on that. 11 The 12 numbers are fairly similar but not identical. So 13 maybe I'll just refer you to the slides online as 14 opposed to trying to remember off the top of my 15 head and misspeak. 16 CHAIR JENKINS: Want to go to the next 17 question? 18 MR. RUSCHKE: Please. 19 CHAIR JENKINS: Are petitioners filing 20 serial petitions and relying on previous PTAB decisions to inform their later petitions? 21 22 MR. RUSCHKE: So this is the second bite

1 at the apple problem, and also known as the 2 road-mapping problem. We've seen that 3 unfortunately quite a bit. Again, perhaps patent owner might have sued somebody post DI, in which 4 5 case, I've -- if you were defending that lawsuit, I could see why you would want to look at the DI, 6 7 and then that might not be anything that the PTAB 8 can do. But what this graph shows is when the 9 petitions are filed, and that's what we can look 10 at.

11 Anything before the patent owner preliminary response, and certainly before the DI, 12 13 I don't think should be looked at as road mapping 14 or second bite of the apple. Now the reasoning why they filed multiple petitions we're not sure 15 16 of, although under General Plastic, factor five says please tell us why you filed a second 17 petition because we want to know, and that's going 18 19 to be part of our analysis. But about 80 percent 20 of the petitions are filed without the benefit of seeing the POPR or the DI. 21

22 What you really need to look at is that

1 16 percent in that red line -- in that red pie 2 piece. Those are the potentials for road mapping. 3 It doesn't mean that there's road mapping happening. There could be subsequent litigation. 4 5 There might be additional claims being inserted in the litigation. There might a change in claim 6 7 construction that occurred during the litigations. 8 Hard to say, but this is the data that we're 9 generally seeing in terms of road mapping and 10 second bite at the apple.

11 The other one, the next slide here, 12 which is, I think, kind of interesting, takes a 13 little bit of explaining, but it goes to this 14 whole notion as well when you talk about rounds of petitions. Rounds of -- essentially a round is 15 16 filed essentially before receiving a DI on one of those petitions. So this, again, goes to the fact 17 that 95 percent of petitions are filed before the 18 19 petitioner has a first round and has been able to see a DI. 20

21 So again, this is saying that there 22 might be road mapping, and there might be a second

1 bite at the apple happening, but at least under 2 this definition of how we look at the roads pre a 3 DI, there isn't a lot of that happening. But again, if you were in the situation where that is, 4 5 and we've heard from certain industry groups that this is definitely happening, this, at least, on 6 an overall basis, we're not seeing it. It might 7 8 be different by different industry areas. 9 CHAIR JENKINS: Changing top -- oh, 10 Jennifer, you have a question? No? Okay. 11 Changing topics, yeah? Expanded panel study, question, does the PTAB expand panels to reach a 12 13 particular result in a case? 14 MR. RUSCHKE: So again, expanded panels have been a hot topic as well on and off. The 15 16 director addressed that this morning, and so I'm not sure I'm going to spend a huge amount of time 17 on it. This results from some of our standard 18 19 operating procedures all of which are under 20 review, and in particular, how we designate -- how we do paneling, expanded paneling, precedential 21 22 and informative decisions are all part and parcel

1 of this process of reevaluating SOPs.

2 My only message here in answering this 3 question is that we do find this to be, when we've expanded panels, not only the expansion itself to 4 5 be rare, but again, to get a particular result is even rarer. And in the just over two years that 6 7 I've been the chief judge, we have never expanded 8 a panel in order to change the underlying result. 9 And in fact, if you look at the entire history of 10 AIA, we have expanded panels in only two instances, in only two, to where the result, the 11 12 underlying result, was changed, and that was upon 13 rehearing. And it was the same issue which is 14 same party joinder which is another very hot 15 button issue at the board. 16 So this slide here is just saying

17 essentially, if you look at the numbers, you know, 18 we've done of 6,000 decisions on institution, 23 19 have been expanded. Results, underlying results 20 haven't changed. Interlocutory orders, again, 21 thousands of interlocutory orders, we can't even 22 count them. It's happened about 31 times and

we've never expanded in over -- in about 2,000 1 2 final written decisions. So it is, indeed, rare 3 and even rarer to change the underlying result. But all of this is under review so stay 4 5 tuned. Hopefully, you'll be seeing something very shortly that will help clarify this and help 6 7 clarify the precedential process as well. 8 CHAIR JENKINS: Great. Okay. Moving 9 forward, going back to the orange book comment 10 previously in the study, question, are AIA trial 11 results for pharma patent owners worse than for 12 other technology areas? 13 MR. RUSCHKE: So again, if you're the 14 person that's patent is found unpatentable, yes. They are worse. We have to look at overall 15 statistics. When we look at our overall 16 17 statistics here on the right-hand side is all other technologies. We've been able to carve out 18 19 the orange book-listed patents. Again, if you 20 recall from our earlier stage, we're seeing at least right now, again, this is cumulative data, 21 22 where we find mixed results on all technologies in

about 15 percent of the cases. Again, this is
 cumulative data.

3 The dark blue is 66 percent where we find no claims patentable and 17 percent to have 4 5 all claims patentable. If you break out the orange book-listed patents, that's the donut on 6 7 the left-hand side, we're seeing two trends. One 8 is it's much more balanced. It's much more of a 9 50/50 split on patentable and unpatentable for 10 orange book-listed patents. And you don't find 11 those mixed results very much. It's either all or 12 nothing on the orange book side where we're 13 finding on all technologies there could be a 14 possibility for mixed results.

I do have this slide here which, in the 15 16 interest of time, I don't think we necessarily 17 need to go through, but as again, this is talking about when you have an orange book-listed patent, 18 19 and you're originally challenged at that very 20 first petition stage, we're seeing 83 percent of those patents being unchanged by PTAB all the way 21 22 through the process. And in 14 percent, that's

1 the dark blue wedge, where we're seeing all orange 2 book -- all instituted claims being held 3 unpatentable. So again, looking at the entire timeframe of whether they're changed and unchanged 4 5 by the PTAB. CHAIR JENKINS: Okay. So going to a new 6 7 topic studies, is the PTAB conducting any other 8 studies? 9 MR. RUSCHKE: We're constantly 10 undergoing a lot of -- looking at a lot of 11 studies, and one thing we have been getting some 12 feedback on is what would you like us to be 13 tracking with respect -- when we have these major 14 decisions such as SAS and such as Aqua Products. So if they have any suggestions, please send them 15 16 to us because it is a data piece that we -- it's 17 better to get ahead of that. It's much easier if there's something that you're interested in 18 19 particularly that we want to take a look at. 20 A couple of studies that we do have ongoing is a parallel proceedings study where the 21 22 goals to exploring the interaction between the

parallel proceedings, that's the AIA reexamine, 1 2 reissue, and this is a joint effort between PTAB 3 and CRU. And also we do have one here underneath the section 325(d) study which is, again, 4 5 coordinating with patents to look at when the examination corps looks at something, and 6 7 underneath our statute 325(d) how much should we 8 be reevaluating and redoing the examiner's work 9 product. So those are the two big studies that we 10 have ongoing both with intersecting with patents. 11 CHAIR JENKINS: Any idea when you'll be 12 completed with the study? 13 MR. RUSCHKE: Well, we would have had 14 them completed but for the Supreme Court, unfortunately. Our workload increased, and maybe 15 16 just to give you a head's up, again, I know in the 17 interest of time merely I was just going to say, you know, on SAS the simple -- I know this is a 18 19 hot topic. We did put out guidance, but just so 20 that we're all on the same page, when we looked at our existing workload in April when it came down, 21 22 18 percent of all of the petitions where we had

already instituted on, we hadn't instituted on all
 claims. In 18 percent of all those petitions we
 hadn't instituted on all grounds.

4 So 18 percent claims, 44 percent grounds 5 that required rework by the board. That's a fairly big lift. The judges have been doing quite 6 an amazing job on making sure to try to get that 7 8 all taken care of, to make all of our existing 9 cases SAS compliant. We did have two chats with 10 the chief, both on April 30th and June 5th. We highly recommend if you missed those, they're 11 12 actually -- the transcripts are available online, 13 including, not only the guidance, but also 14 frequently asked questions. And you can see that on our redesigned website. If you look on the 15 right-hand side column, and you'll see these FAQs 16 17 for SAS that we've been putting out to try to provide additional guidance to all stakeholders. 18 19 It is a moving target, and it is 20 evolving over time as we've seen and heard from the stakeholders when we've been out at our 21

22 judicial conferences. Strategies are changing so

1 we shall remain to be seen. And so this will need 2 to be updated. We're hoping to do another one 3 hopefully in August. So stay tuned and we'll give you more information on that. 4 5 MR. WALKER: David, excuse me, a 6 question from the audience was when can we expect 7 the PTAB to issue opinions under SAS, or the 8 timing? 9 MR. RUSHCKE: So that's a really good 10 question. So luckily to some extent, you know, this federal circuit -- well, they've been 11 12 remanding a number of cases to us particularly in 13 those situations where at least one party has 14 asked for a remand. But they've actually been providing some guidance to us underneath SAS. 15 16 In fact, you know, they did make a 17 decision fairly quickly sort of affirming our 18 initial guidance that not only claims, but also 19 all grounds needed to be included. So I have to 20 check to be honest with you, Mike. I mean, we did use the six-month extension period in about a 21 22 couple dozen cases where we were just not able to

get the final written decision out in the year 1 2 deadline because of all of the extra work that 3 needed to be done because of SAS. And I would bet in about a third of all of our hearings we 4 5 actually postponed those hearings in order to make sure that we were able to have, essentially, a 6 7 single hearing on all the grounds and all the 8 claims. So we would have, essentially, one record 9 going forward.

10 I have to get back to you on that. I 11 think there have been perhaps some cases going 12 forward on SAS. Are you talking about final 13 written decisions? Yeah. I'm not sure about how 14 many of those we've had. Certainly, we've had 15 decisions to institute under SAS go forward. I don't know the exact number of those, but since 16 17 April, everything that was pre-DI has been SAS 18 compliant at that point.

19 CHAIR JENKINS: Actually, Julie has been 20 listening. Julie, you want to ask your question 21 now? You hear me? You want to introduce yourself 22 if you're able to? No? Okay. I know she's

there. She's been emailing me. Okay. Why don't we keep going?

3 MR. RUSCHKE: Sure. The last is the 4 NPRM which the director touched on. We are very 5 heartened that we got 374 comments received. Very, we really, I think that really is a 6 7 wonderful testament to the director's reaching out 8 to the stakeholders and engaging them on this 9 issue. And as he mentioned, we are working 10 through the comments that we received. We will be 11 responding as soon as we can, and again, you'll be 12 hearing from us, I think, shortly on the NPRM as 13 we get through that.

14 And last but not least, just to wrap 15 this up again, this is our revamped webpage. If you're missing what PTAB is doing and want to know 16 17 what PTAB is doing, I highly recommend you make 18 this your favorites. You can see upcoming PTAB events there. This is an old slide shot where we 19 20 had the chat with the chiefs. As I mentioned, we're probably going to have another one here in 21 22 August.

1If you're worried about missing these, I2highly recommend that you subscribe to the PTAB3email blast. If you're unfamiliar with that, I4think you just Google on the website email --5MR. BOALICK: It's the subscription --6MR. RUSCHKE: Subscription --7MR. BOALICK: -- the USPTO subscription

8 center.

9 MR. RUSCHKE: And there'll be a list of 10 subscriptions or email blasts that you can get. Just sign up for PTAB and then all of this stuff 11 12 will just come directly into your inbox, maybe too 13 much, but again, if we make cases precedential or 14 informative, if you have a chief chat, if there's guidance going out, all of that sort of stuff, 15 16 that's a great way to get information right 17 directly into your inbox. And you can sign up for patents, too. And with that, I think we're at an 18 19 end. 20 CHAIR JENKINS: I just want to commend

21 the PTAB and all of its efforts, and David going 22 out and really trying to engage with stakeholders,

getting the message out. Often very difficult 1 2 with rule changes and new decisions coming down, 3 but in trying to keep the user community informed, I think highly commendable. I do believe you 4 5 should take a couple of days of vacation, so but for the user community it's all on the website. 6 7 It's all accessible. And it's just something that 8 we all should be appreciating for the level of 9 commitment from your group and you. 10 MR. RUSCHKE: Well, and thanks, I appreciate the invite up to New York. That was a 11 12 very nice crowd and it was a really nice 13 organization that we hadn't had exposure to 14 before. And I think the wonderful part about that is these sorts of environments where you really 15 get to have a discussion, and you have hard 16 17 questions being asked, right, I mean, there's a 18 lot of hard questions about PTAB that get asked. 19 And the more information and the more we can get 20 out and handle those questions the better. So I appreciate the opportunities as well. 21

22 CHAIR JENKINS: Thank you. We're now

1 going to go to finance so, Tony?

2 MR. SCARDINO: Let me try that again. 3 Good morning. All right. Always hard to follow 4 such a great act in David Ruschke but I'm going to 5 try anyway, at least talk about a different 6 subject matter.

7 Typically, we go through three fiscal 8 years concurrently. We're living in '18. We are 9 preparing for '19 and we are developing the '20 10 budget. So we'll go through that a little bit. 11 Fee collections are just about as we planned them, 12 off by like four -- short \$4 million which is more 13 or less a rounding error. We can make that up in 14 a day, so I don't know what it will be by the end of the year, but we are basically collecting fees 15 16 according to plan. And as Andy mentioned this 17 morning, filings are up a little bit, which is a positive sign. So we're happy to see that. 18

19 Spending is also pretty much according 20 to plan. So you'll see here we are going to end 21 the year, we think, as of today, with an operating 22 reserve of roughly \$280 million. Our goal was to

end with a \$300 million operating reserve, so we would like to see that a little higher, and I'll be talking about that later in my slides as to how we're going to address that.

5 The 2019 budget, Congress has acted, both chambers, the House and the Senate, back in 6 7 They marked up our -- the president's budget May. 8 request. They actually gave a -- provided a 9 funding level a little bit below the president's 10 request, \$46 million lower. All this really means is if we do collect greater than what they 11 12 appropriated, we would transfer money into the Patent and Trademark Fee Reserve Fund and then 13 14 access through a reprogramming notification. So 15 it's really just a cash flow issue. We'd get 16 access to the money in the fall as opposed to 17 during the fiscal year in September.

18 So not a major challenge for us, but we 19 would be planning accordingly in terms of the 20 spending side. Also the Senate report had some 21 concern about the IP attaches, that they've 22 consistently been asking us about, keeping that in

1 mind.

2 The 2020 budget, that is due to the 3 Office of Management and Budget the second Monday in September. So we're busily drafting that. 4 5 PPAC will see a draft mid-August so in a few weeks. We appreciate your comments, understand 6 7 that you don't have a lot of time to review it, 8 but if you have any questions, please let us know, 9 happy to get comments and feedback. That goes to 10 OMB in September. They then review it for the fall. We go back and forth with them. We 11 12 actually give them updated modeling projections 13 and then we get what's called a final mark close 14 to Thanksgiving time. And then we start developing the president's budget request to 15 16 Congress. That'll be due in February. Strategic plan, the director last week 17 had a town hall where he basically went over the 18 19 specifics of the strategic plan to all staff. We had about 4,000 people, our staff, that were 20 actually either in the room or on -- doing via the 21 22 web. So it was very successful and Drew and Mary

also presented on the specifics of our strategic 1 2 plan. That will be also provided for public 3 comment later this summer, and then we believe we will be releasing it in final draft -- in final 4 5 form this fall. So you'll see that soon. MR. WALKER: Tony, excuse me. So a 6 7 question just about how is that going to be 8 available for public comment? 9 MR. SCARDINO: It'll be on our website. 10 MR. WALKER: Just be on your website? 11 So people will go there, look, and then there'll 12 be some time line to provide time --13 MR. SCARDINO: Right. On there they'll 14 be afforded the opportunity to provide comments. Yeah, and then fee setting authority, as we've 15 16 been remarking every quarter, it is still 17 anticipated to expire, fee setting authority, on 18 September 16th, 2018 after seven years at sunsets. 19 There are a couple of bills that have been 20 introduced, one in the Senate, one in the House, to extend fee setting authority; one for eight 21 22 years, one for ten years. So we're anxiously

1 anticipating that or hoping for that.

2 As you know fee setting authority 3 provides us the opportunity to ride out -- you know, help create the operating reserve which 4 5 helps us ride out any ups and downs with fee collections, and also introduce new fees, as well 6 as tailor some fees for sometimes for aggregate 7 8 recovery of costs, and sometimes for specific 9 recovery of costs. So that's actually a good 10 entrée into -- I don't have a slide, but yesterday 11 I noticed a public hearing was published in the 12 federal register. This august body will be 13 championing a hearing on September 6th. So we'll 14 be back together in a little more than a month, and basically it will be to comment on our latest 15 16 proposal to set or adjust patent-related fees 17 pursuant to our Section 10 fee setting authority 18 that would expire on September 16th. So the increased revenue would enable us 19

to continue improving a lot of information
technology that I know David Chiles will speak to
later today including using things like artificial

1 intelligence for search in a patent examination 2 field. So before you ask questions, some people 3 would ask, well, you just set new fees in January. Why are you starting this process over again? We 4 5 are starting this process over again because it's about a 30-month process. It takes a long time 6 7 and it's for good reason, because we get a lot of 8 public comment throughout the process, and we try 9 to incorporate that so that any fee proposal that 10 does go final has input from all interested 11 parties.

12 So the last time we set fees, they went 13 final January of 2018. We started that process in 14 2015. We had a hearing in November of 2015, the PPAC did, you may recall. So it took us over two 15 16 years after that hearing to actually put final new 17 fees into place. So that's why we're starting the process now. So we anticipate that new fees would 18 19 go into place fall or winter of 2021 actually, in 20 fiscal year 2021. But we're starting that now to 21 get there.

22

So in terms of process forward, the fee

proposal will be published no later than August 1 2 29th. We have to give at least a week, but we 3 anticipate that it'll be actually available earlier than that. Can't give you an exact date, 4 5 August 29th, of course, is still almost four weeks away. We will get it to you before then. We just 6 7 have to go through some logistics and making 8 things 508 compliant so the public can see it. So 9 it'll be on our website, public comment, and then 10 hearing will be held on the 6th, and then the public will have a week to provide comments. And 11 12 then PPAC will have till November to provide a 13 report based upon comments and feedback that you 14 get, just to kind of lay that out. 15 Testimony at the public hearing, written 16 comments will be the first, but not the last, 17 opportunity for public comment. So as I 18 mentioned, that's why it takes 30 months. We will 19 have a couple of different bites of this apple. A 20 notice of proposed rulemaking, or NPRM, is anticipated to be published in late summer of 21 22 2019, so roughly a year from now. A 60-day public

comment period will follow the publication of the 1 2 NRPM, so the public will have another opportunity. 3 And then we'll take that input into consideration for when we draft our final rule. 4 5 Final rule will probably be summer or fall of 2020, and then there's another 60-day 6 delay between that and when the final rule goes 7 8 into place and new fees will be established. So that will bring us to the fall or winter of 2021. 9 10 CHAIR JENKINS: Tony, obviously, maybe 11 we can just step back a minute. The PPAC is an 12 advisory committee to the U.S. Patent and 13 Trademark Office. It's roughly been in existence 14 for almost 19 years. We exist by charter which is accessible on the PPAC webpage, for further 15 16 reading, but one of the parameters for being an advisory committee is that we are subject to 17 working with the office with respect to any 18 19 proposed fees. And putting together -- having a 20 hearing, and it's all based on timeline, and also putting a report that we then submit to the office 21 22 based upon what happened and the comments that we

1 get.

2 So obviously, this, for the user 3 community who's listening, this is an important aspect of our committee, and we take this role 4 5 very seriously. So one thing I want to share, too, is I actually -- Esther Kepplinger was chair 6 7 at the time, but I ended up having to do the 8 hearing that day. And one of the things that I 9 was disappointed in was the response from the user 10 community to comment on the past fees. So I encourage those who have an interest about 11 12 commenting about the new fees, to be aware that 13 they can provide testimony during our hearing on 14 September 6th, and we encourage folks to please do 15 that. 16

Because I think it not only is helpful for us in drafting a report to the office that we think will be meaningful, but also it's helpful for the office to hear what the user community is either indirectly or directly saying to us as a committee. So I think that's important to transcribe.

MR. SCARDINO: We completely agree. I 1 2 think the whole process is better with the more 3 input that we get. Just want to remind folks that at the hearing we're there to introduce and 4 5 explain any fee proposals but not to have an actual dialogue of answering questions there. 6 CHAIR JENKINS: Right. Yeah, point well 7 8 It's not an exchange with the office. taken. 9 It's an ability to let the office hear your voice. 10 MR. SCARDINO: Yep. CHAIR JENKINS: So that's a very mindful 11 12 point to raise. I think the other thing, though, 13 I think people forget. I know you gave a brief 14 outline over what transpired and when the fees were proposed three years ago. But I think maybe 15 16 you might want to step back just a little bit more 17 and explain the importance of why the September 18 16th date is so important to us, and how Congress 19 has not acted in a proper fashion in order to us 20 to be able to continue to have fee setting 21 authority. 22 There are, I mean, Dana will report on

1 this later, but there obviously are two bills in 2 committee, one in the Senate, one in the House, 3 but Congress has not acted on this. And one thing that the reason -- one of the key reasons for us 4 5 having a hearing is because we need to plan ahead, and you have to have a hearing in order to have 6 some sort of fee adjustment. But if you don't 7 8 have authority anymore you have to do it before 9 the 16th. I commend Congress to work now, this is 10 a hugely important element, not just for the 11 office, for the user community, and it's quite 12 disappointing that they have not stepped up to the 13 plate on this. So but can you explain a little bit more 14 about why it's so important for the office to have 15 16 fee setting authority? 17 MR. SCARDINO: So there are many reasons why it's important to have fee setting authority. 18 19 Before we had fee setting authority, we had the 20 ability to raise fees across the board, it was called a CPI adjustment, right, and that's not 21 22 targeted. So in other words, if a fee was

misaligned, oh, they'll just continue that or make it worse every year by possibly us increasing it by roughly inflation. With fee setting authority, we have the ability to adjust fees, which is we can introduce new fees, we can eliminate fees, we can adjust them up or down, right?

So the whole idea there is we can then 7 8 encourage let's say good behavior, right, if we 9 want to try to streamline the pan examination 10 process, for example, we can charge greater fees for things that maybe would clog up the system a 11 12 little bit. So it's basically good government. 13 Any good organization would want to have the 14 ability to adjust their pricing so that you have 15 the most efficient process.

So sometimes we do introduce a new fee, and we would like to get closer to full cost recovery. And we're trying to get a balanced process. What we always want to keep in mind, the whole philosophy is low barrier to entry. So patent applications, filing, search, and exam are less than full cost, and then we make that up on

the back end with maintenance fees and kind of along the way. It's a good system. Most countries do this, but it's certainly not perfect. So the ability to adjust that at times is helpful especially as we may see the business model change a little bit.

7 We are noticing that third-stage 8 maintenance fees are ever so slightly changing a 9 little bit. We're seeing less being paid which is 10 fine. We just need the ability to then change our business model a bit, because our costs remain our 11 12 costs. There's no cost to a maintenance fee. The 13 cost is, of course, all on the examination side 14 and issuance. So if we get less money on the maintenance side, then we need to make -- possibly 15 16 charge a little bit more on the upfront side. So 17 without fee setting authority we would not be able to do that. 18

MR. WALKER: All right, Tony, just to underline something you said earlier. I mean, I'm reading the federal register notice and it says that the proposal for fees will be published by

August 29th. I think some people may have read 1 2 that on August 29th. MR. SCARDINO: No, no, we will --3 4 MR. WALKER: Well, I'm just saying that 5 because with the Labor Day holiday you're saying 6 7 MR. SCARDINO: Yeah, absolutely. 8 MR. WALKER: -- you have like one week 9 that's hardly enough time so --10 MR. SCARDINO: Yep, yep. MR. WALKER: -- the feedback from the 11 12 community we received is sooner the better. 13 MR. SCARDINO: Right. I am absolutely 14 committing to giving it to you before then, I just 15 can't give you the exact date. Some of it's not within our control, but the parts that are within 16 17 our control, and the folks -- the parts that are 18 within our control are going faster than we 19 anticipated. So that we will get you something 20 hopefully, knock on wood, much sooner. I just can't you an exact date. 21 22 CHAIR JENKINS: And just to be clear,

1 too, the hearing that we have on the 6th is open 2 to the public. You may attend. MR. SCARDINO: It will also be webcast 3 for you to look at. 4 5 CHAIR JENKINS: It'll also be webcast. You cannot give testimony. As we try to do during 6 7 these meetings, generally, Mike and I are fielding 8 emails and trying to include them in the 9 discussion as well as other committee members as 10 well. We will not be able to do that during the 11 hearing. 12 MR. SCARDINO: Correct. 13 CHAIR JENKINS: So you can listen but you won't be able to send me emails. Just you 14 15 can, but I won't answer them. 16 MR. SCARDINO: But people can attend, and then they can actually speak. 17 18 CHAIR JENKINS: Exactly. 19 MR. SCARDINO: Yes. 20 CHAIR JENKINS: Exactly. MR. SCARDINO: This is our third 21 22 go-round of public hearings on setting fees. So

we're still mastering this, but that is how the 1 2 process works, correct. 3 CHAIR JENKINS: Exactly. Okay. Anything else from the committee on this very 4 5 important topic? No? Mark? 6 MR. GOODSON: Oh, just a quick question. 7 There is the meeting the 5th through 6th of 8 September? 9 CHAIR JENKINS: The 6th. 10 MR. SCARDINO: 6th. 11 CHAIR JENKINS: Thursday. 12 MR. GOODSON: And is that for the PPAC or the finance committee? 13 14 CHAIR JENKINS: Ah, it's for everyone. It's for the entire PPAC. It's from 9 to 11 on 15 Thursday morning, and, yes, it's for the entire 16 17 committee to participate so, and the public, so, Jennifer. 18 19 MS. CAMACHO: Just one point of clarification. They can't -- folks who are 20 watching on the webcast can't send you emails, but 21 22 can they speak or --

1 CHAIR JENKINS: No. 2 MS. CAMACHO: No, okay. So it's a 3 listen only? 4 CHAIR JENKINS: Yes. 5 MS. CAMACHO: Very good, thanks. CHAIR JENKINS: Anything else? Okay, 6 7 Mike? 8 MR. WALKER: Just one thing. A little, 9 maybe a little lack of clarity on the federal 10 register notice because it does say that members of the public can submit written comments on the 11 12 PPAC's website, but then later it also gives 13 written comments may be submitted to fee.setting@uspto.gov. So I guess there's a 14 15 couple of avenues where that information can come 16 in just to be clear. 17 MR. SCARDINO: Thanks for the clarification, yes. Both are available. 18 19 CHAIR JENKINS: Tony, anything else? 20 MR. SCARDINO: No, I just want to thank the committee in advance. I know there's a lot of 21 22 work ahead between that hearing, your report, your

annual report, so we appreciate all of your 1 2 assistance and help there. And we are here to 3 provide any assistance you may need. 4 CHAIR JENKINS: Great. Okay. Great, 5 thank you. With that, I do note the time is 11:58, woo hoo hoo, so we're not that late. 6 7 We made up some time, thank you all. We are going 8 to start promptly, promptly, at 1:00, so lunchtime 9 now. Thank you. 10 (Recess) 11 MS. MAR-SPINOLA: Yeah, I'm on. 12 CHAIR JENKINS: Hey, oh. 13 MS. MAR-SPINOLA: Can you hear me, 14 Marylee? 15 CHAIR JENKINS: Yeah, I hear you. Wow. 16 And Jennifer said we could start, too, so great. 17 Julie, why don't you do me a big favor and tell us 18 who you are and so we can acknowledge you in the 19 record for participating? 20 MS. MAR-SPINOLA: Okay, great. Shall we start? I don't think the web -- let me refresh 21 22 that, too. But good afternoon, everyone. This is

Julie Mar-Spinola, Chief Intellectual Property 1 2 Officer and Vice President of Legal Operations for 3 Finjan Holdings. That was long. Our offices are here in Palo Alto, California. I apologize for 4 5 missing today's meeting. I had intended to be there, but we just had some flight complications 6 7 midway. So, thank you very much. 8 And also, I just wanted to say I 9 couldn't connect in or be heard during the PTAB 10 presentation, but I want to thank David and his

team, particularly Janet Gongola, for putting

presentation in a different format which I thought

was pretty effective. And I hope the external

together the slides and presenting today's

stakeholders feel the same way.

11

12

13

14

15

16 CHAIR JENKINS: Julie, thanks. Noted 17 and yeah. We're trying -- over the past year, I 18 don't know if folks have noticed, but we really 19 have tried to change the way the PPAC operates. 20 Our meetings have been different in the sense that 21 our topics have had more attention, so we've had a 22 little longer to talk about issues. We've really

been listening to stakeholders and addressing 1 2 questions. In fact, two of the questions from the 3 afternoon session in particular were based on committee member input as well as stakeholder 4 5 input. So, continue to reach out. We're trying to read your emails during the meeting as best we 6 7 can and if we can fit in some questions during the 8 meeting on your topic, we will try.

9 And so one thing, though. The Federal 10 Register Notice for the finance hearing, I just want to just clarify a point that we were talking 11 12 about before. Just want to note that in order to 13 testify during the -- our public meeting for fee 14 setting, there's certain requirements in the 15 notice and I just want to read them quickly to be 16 clear.

17 "If you do want to present oral 18 testimony at the hearing, a request in writing 19 must be submitted no later than August 29th. 20 Requests to testify should include the following: 21 The name of the person wishing to testify; the 22 person's contact information, telephone, and email

1	address; the organization the person represents,
2	if any; an indication of the amount of time needed
3	for the testimony. Requests to testify must be
4	submitted by email to Jennifer Lo at jennifer.lo,
5	L-O, at uspto.gov. Speakers providing testimony
6	at the hearing should submit a written copy of
7	their testimony for inclusion in the record of the
8	proceedings no longer no later than September
9	13th."
10	So, please, if you are even considering
11	participating, please read these rules in more
12	detail. So, it will not be the possibility of
13	folks attending the meeting and being able to
14	testify without prior notice to the office. So,
15	just to be clear. Okay?
16	So, with that, we're going to launch
17	into the international portion for the afternoon.
18	Welcome. Welcome, Shira. Welcome, Mark. So,
19	boy.
20	MS. PERLMUTTER: Well, good afternoon,
21	everyone. I'm going to touch on three topics.
22	One is to talk a little bit about the Standing

1 Committee on Patents at the World Intellectual 2 Property Organization. Second is to shed some 3 light on what's happening with patent filings 4 relating to China internationally. And then just 5 a couple of miscellaneous points to make you aware 6 of.

So, just to start with, the Standing 7 8 Committee on Patents or the SCP. The real 9 question is, what is the Standing Committee 10 (laughter) on Patents and what on earth is it 11 doing in Geneva these days? It's not something we 12 talk about very often and as I describe it, I 13 think you'll understand why at this point. So, the Standing Committee was established in 1998 and 14 15 the idea was just to have an ongoing Committee -there is also one on trademarks and one on 16 17 copyright -- that would discuss issues as they 18 arose and provide some guidance about the development of international patent law. 19 20 And in the beginning, it was, in fact, discussing quite substantive topics, including 21 22 harmonization of national law as well as

procedures. But that's broken down a bit. So, let's -- just to give you an idea of what happened, in the beginning, the SCP was, in fact, talking about harmonization and the Committee produced the text of what became the Patent Law Treaty and began to discuss a Substantive Patent Law Treaty.

8 But unfortunately, over time an impasse 9 emerged between developed and developing countries 10 with developing countries very much wanting to minimize the scope of patent rights and minimize 11 12 enforcement of patents. And so that really led to 13 a halt in what in WIPO terminology is called 14 normative work or norm-setting, in other words, anything having to do with setting international 15 16 frameworks and rules.

17 So, what we've been doing to get past 18 this impasse is to move to what everyone calls a 19 balanced workplan and, of course, the word balance 20 is always key. No one can be against balance. 21 And the idea behind this workplan is just to have 22 items on it that all countries at different stages

1 of development are interested in. So, at the 2 moment there is five topics: Exceptions and 3 limitations to rights, patent quality including opposition systems and work-sharing, patents and 4 5 health, confidentiality of communications between 6 clients and patent advisors, and technology transfer. Now, before this makes you very 7 8 nervous, just to stress on all of these topics the 9 work that's being done is studies or experience-10 sharing rather than, again, a norm-setting kind of exercise. 11

12 Oops. So, there are a few challenges --13 I won't go into this -- where people have proposed 14 various things that we don't find acceptable, including doing further work and adopting the 15 16 recommendations of the UN High-Level Panel on 17 Access to Medicines. And at the moment, what is happening, we just had a meeting a few weeks ago 18 19 and the Secretariat presented two updated 20 documents of past studies. One is on the Regulatory Review Exception or Bolar and the other 21 22 is an updated Study on Inventive Step. And then

1 members describe their experiences with

2 cooperation in search and examination, with making 3 patent information publicly accessible, and with 4 ensuring the confidentiality of communications 5 between clients and patent advisors.

And going forward, next meeting will be 6 7 in December and yet more documents and 8 experience-sharing. So, the Secretariat is going 9 to produce a new document on the research 10 exception and an expansion of the Inventive Step 11 Study including as it applies in the chemical 12 sector. And there will also be a session for 13 patent practitioners to come in and talk about 14 their experiences in negotiating license agreements. So, some of this is just useful from 15 16 an educational perspective and making sure that all countries have a chance to hear about best 17 practices and about what is happening, including 18 in the United States. 19

20 So, just finally, as you can tell a bit 21 from this description, the status quo at the SCP 22 at this point is a bit of a truce between opposing

1 factions and we're trying to do two things. At 2 the moment, what we're trying to do is to focus on 3 non-sensitive technical matters so that we can make some progress on a number of things and then 4 5 to see if we can foster an overall positive environment for resuming normative work, for 6 example, things having to do with substantive 7 8 patent law harmonization. 9 Now, what's interesting is, a lot of 10 that substantive patent law harmonization 11 conversation has been going on outside of WIPO in 12 Group B plus primarily and that's been because we 13 couldn't make progress at WIPO, so a smaller group 14 had to get together and try to take that forward.

15 But if it could be shifted back to WIPO, we could 16 expand it and that would be positive, as well. 17 So, at some point we hope that will happen and we 18 do see that a number of countries, especially in 19 the developing world, have more developed and more professional IP Offices. A number of them have 20 transitioned to become emerging economies and so 21 22 we also see some light at the end of the tunnel in

terms of a more positive attitude to being able to 1 2 work together on these substantive issues. 3 So, I don't know if there's any questions about the SCP. That's a very brief 4 5 high-level overview of what it's doing. Okay. So, to move on to China -- think 6 7 I -- yes. So, there's obviously a tremendous 8 amount about China and the press. A fair amount 9 of it relates not only to the overall trade issue, 10 but to a lot of the IP and technology transfer issues involved in some of the trade disputes 11 12 currently underway. And we are doing some --13 spending some time looking at the data about what 14 China is doing in the patent space around the world. So, what I'm going to do is to show you 15 16 some information about filings out of the United 17 States and then Mark in his presentation will talk about what we're seeing here at the USPTO. 18 19 So, first of all, if you look at these 20 numbers, in 2016, worldwide patent filings exceeded 3 million, so they're going up 8 percent 21 22 -- more than 8 percent higher than 2015. And as

you can see, the growth was driven overwhelmingly 1 2 by China and about 40 -- almost 43 percent of the 3 total worldwide patent filings were filed in China. So, that's quite a number. If you look at 4 5 the filing trends for the IP 5 Offices, it's quite dramatic. That red line, of course, is China and 6 7 you can see it going dramatically up and 8 overtaking the other countries. And one point I 9 wanted to make, as dramatic as that looks, the 1.3 10 million applications from China reflected on that 11 graph include only invention patent applications. 12 And if you added utility model and design 13 applications, the total would be three-and-a-half 14 million, so almost three times as high. So, quite 15 dramatic numbers. 16 And then if you look at the patent applications at SIPO in China itself, there has 17 been a substantial increase over the past decade. 18 19 So, what's interesting -- well, it's all 20 interesting, but (laughs) one of the interesting statistics is that while the filings from 21 22 non-residents have increased, they are by far

dwarfed by the filings from China itself and 1 2 that's over 90 percent of the filings are from 3 Chinese applicants. So, we -- while we're trying to figure out exactly what that means, we suspect 4 5 that it's because of government subsidies that are provided at the national, provincial, and 6 7 municipal levels and that's a major driving force 8 in these high numbers.

9 In terms of the fields of technology --10 oh, sorry. Let me first go to this. This is 11 grants. So, the increase in filings has been, of 12 course, accompanied by a growth in grants. And 13 one other point, because we suspect that so many of the filings in -- by Chinese applicants are 14 driven by the subsidies, there is also some reason 15 16 to think that the commercial value of many of 17 these patents may be low. You wouldn't take from 18 it what you would take from a filing without a 19 subsidy as to the potential value of the 20 invention.

21 And then we've looked at the fields of 22 technology and much of the growth is in the areas

of computer technology and medical technology. 1 2 So, for computer technology, it increased between 3 2015 and 2016 by 62 percent. And medical technology increased in that same period by 20 4 5 percent. So, again, all of these numbers are really quite remarkable. 6 7 And then finally, the last slide, PCT 8 filings. So, again, these numbers are going up. 9 We keep hearing this from WIPO every time (laughs) 10 we talk to them. And so in the international field -- in the international space, Chinese 11 12 filers are obviously very active, as well. 13 They're catching up with the United States and we 14 are seeing that the annual rate of growth is more 15 than 10 percent, so the numbers continue to rise. 16 So, I -- Mark, do you want to just talk 17 about -- before I go to my other matters, do you want to talk about the staff or shall I finish 18 first? 19 20 MR. POWELL: Yeah, I can.

MS. PERLMUTTER: I'll finish and thenwe'll go to your slides.

MR. POWELL: Oh, okay. Either way. 1 2 MS. PERLMUTTER: Yes. 3 MR. KNIGHT: Can I ask a question? So, for the U.S. Patent system, should we just be 4 5 happy to collect all the Chinese fees or is there a negative impact, do you think, on the -- on U.S. 6 7 Innovation and the U.S. patent system --8 MS. PERLMUTTER: Yeah. 9 MR. KNIGHT: -- by all these filings? 10 MS. PERLMUTTER: I mean, I think that's what we're trying to understand and I don't --11 12 Andy, do you want to say anything about it? You've been doing some looking at this. 13 14 MR. TOOLE: Right. 15 MR. POWELL: Andy, I would just add that 16 when you see what's going on here in the U.S., 17 which is a very granular look at national filings 18 here in the U.S., it'll show what of that big red 19 streak is actually winding up here as a cross-20 filing. So, noting that we've presented. I'm sure Andy has some economic insights, as well. 21 22 So, Andy.

MR. TOOLE: Sure. I -- and I think that 1 2 the biggest concern is about patent quality and 3 there's some evidence that all of the spike in China is not driven by high-quality patents. The 4 5 jury is still out; there's no final conclusion. But some initial evidence from some academics has 6 7 shown that there are fewer claims per patent that 8 are being filed in China. 9 So, in terms of what's happening in the 10 United States, it really comes down to what we're being sent and what we're reviewing. It's 11 12 obviously a bigger workload for our office, but 13 it's hard to say right now how it's going to 14 impact innovation in the United States. I mean, again, the tradeoff is that there's a patent right 15 16 given and there's disclosure. If they're 17 disclosing something valuable, we can get a 18 benefit from that; if there's a patent right 19 given, then that's going to give them some 20 exclusivity. MS. PERLMUTTER: Yeah. But clearly 21 22 there is a question of what will be the impact

competitively of the relative amounts of 1 2 innovation going on in both countries. And, 3 Larry, I didn't know if you all know Larry Lian from our China team. 4 MR. LIAN: Yeah, thank you. Without 5 getting into too much detail, but the very least, 6 7 if you get a lot of patents, no quality, no 8 (inaudible) commercial value, at the very least 9 it's a burden on your freedom to operate opinions. 10 MR. WALKER: Now, on the issue of burdens and freedom to operate, one thing I've 11 12 heard anecdotally from people in the IP community 13 is that a number of these patent filings in China 14 are copies of older granted U.S. patents from U.S. Patentees that are being filed in China, granted 15 16 in China, and then being waived at companies 17 outside China. And so now these U.S. companies are faced with having to deal with invalidity 18 19 trials in China for inventions they made on 20 patents they had and it's a huge burden. Is there some way the office is helping to address that 21 22 issue or have you seen it, I should say that, I

1 guess?

2 CHAIR JENKINS: It is -- so, I can --3 personal experience. Even more than that, they file here on issued patents here which they have 4 5 copied and then you have to challenge those patents before they go any further in the 6 7 prosecution system and then they don't want to 8 give up the U.S. patent application they filed 9 because there's a timing issue over money that 10 they obtain supposedly based on Chinese subsidies. 11 So, it's a really complicated, expensive, "I see 12 this coming onto the horizon" issue. And even if 13 you look at the small microcosm of the trade mark 14 issue that they're presenting, I mean, this is what -- this is even more cumbersome, more 15 16 time-consuming, more expensive. So, sorry. 17 MR. HIRSHFELD: Can I --18 CHAIR JENKINS: Yeah. 19 MR. HIRSHFELD: -- chime in? 20 CHAIR JENKINS: Sorry. Oh. MR. HIRSHFELD: One point is, I believe 21 22 what Chair is talking about, most of the numbers

1	are international numbers or numbers in China and
2	at WIPO; Mark does have numbers on U.S. filings.
3	So, before we draw too many conclusions about
4	Chinese filing in the U.S., let's listen to those
5	numbers because I think the change right now is a
6	lot less in the U.S. in terms of Chinese filings
7	and what we're seeing worldwide. Just my
8	perception, but Mark will have those numbers.
9	MR. WALKER: Well, he's pulling
10	putting it together. To be clear, my question was
11	on Chinese patents in China.
12	SPEAKER: Right, right.
13	MR. WALKER: Okay, yeah.
14	SPEAKER: Right, so
15	MR. SEIDEL: Well, can I just one
16	more opinion back to Bernie's original question.
17	No, I don't think we're okay with just taking the
18	money. Right. And if you go back to Tony's
19	presentation, our fee structure is set up so it's
20	a lower bar for entry, so we'd be putting in a lot
21	of we would not get cost recovery for examining
22	potentially applications that are not going to

1 mature into patents.

2 MR. KNIGHT: Right. That's a great 3 point because you recoup the money on the 4 maintenance fees. Yeah. Great, Rick. That's a 5 great point.

MR. LIAN: Very quick. I kind of 6 7 forgotten the original question, but let me just 8 (laughter) share just a matter quickly. It 9 happened actually way before I joined USPTO 10 programs, practitioners holding two copies. Unfortunately, I didn't take a picture or take a 11 12 (inaudible) patent. Utility model patents that 13 Shira mentioned, which is a form of unexamined 14 patents, a public program, two patents literally 15 identical, each with (inaudible) utility model 16 patent, so it does happen. I don't know -- I 17 don't have any number to what extent. SIPO has 18 been doing something. I'm not sure how effective it is, but let -- let's move on and we can talk 19 offline on the details. 20

21 MS. PERLMUTTER: Yeah. And point taken 22 and we will look into it and report more back to

you. So, we're aware that this happens. We need 1 2 to think about what more can be done. 3 CHAIR JENKINS: Another question from, actually, Julie. Are there numbers showing how 4 5 many of the PCT filings by Chinese residents designate the U.S.? And maybe it's something --6 7 if you don't have it, then maybe it's something we 8 could do --9 SPEAKER: As a national stage entry? 10 MR. PEARSON: I mean, they all designate the U.S. 11 12 MR. POWELL: Yeah. Charlie points out 13 _ _ 14 SPEAKER: Yeah. MR. POWELL: -- that they all designate 15 16 the U.S. --17 SPEAKER: That's right. MR. POWELL: -- in the current system, 18 19 so. 20 MR. PEARSON: The numbers of entries, that's the other issue and I think we do have that 21 22 information; I don't have it with me.

1 MR. POWELL: Yeah. 2 SPEAKER: Okay. MR. POWELL: We can --3 SPEAKER: I prefer the chart. 4 5 MR. POWELL: -- get that information. SPEAKER: Yeah. 6 7 MR. POWELL: If you don't have it, it's 8 all right. 9 SPEAKER: You know what we're trying to 10 say. 11 MR. POWELL: Yeah. 12 SPEAKER: Thanks. 13 SPEAKER: Yeah. 14 SPEAKER: -- and then I'll make my two 15 other --16 MR. POWELL: Perfect. Okay. Let me --17 SPEAKER: You can skip by -- yeah. MR. POWELL: Okay. While we're on the 18 topic of Chinese data, I just wanted to share with 19 20 you a few things here. There we go. And I know this looks like an EKG of a heart patient, 21 22 (laughter) but if you just kind of follow the

general slope going on here -- if you look at, for 1 2 example, design filings of the USPTO, over the 3 last several years they've been generally quite up and we've had to increase our staff of design 4 5 examiners and so forth accordingly. If you take a look at the Chinese 6 7 filings and this is not showing up, as far as the 8 dates. They're the same timeline. Over the last 9 four or five years, they have gone up, as well. 10 But if you look at the numbers on the left-hand 11 side, we're less than 200 a month on average right 12 now. So, it's not -- in the trademark area 13 apparently, they're getting really flooded with 14 trademark applications, but ours have gone up, but 15 not nearly to the extent of that. This -- because of a broader question 16 about just filing generally, this shows serialize 17 filings, okay, (inaudible) at the USPTO. Just a 18 19 reminder, serialize means having a new serial

reminder, serialize means having a new serial number, which means that we're not talking about RCEs. RCEs, particularly when they were lots of

22 them, really skew the numbers, but think of this

1 as new inventions. Looking on the left, filed 2 domestically, okay? No foreign priority, usually, 3 62 percent. And that's actually up, which kind of sways the other way on the arguments that American 4 5 innovators are giving up on the patent system. This -- that's actually up. So, that's on the 6 7 right-hand slide. It's 38 percent of our new 8 inventions are received from foreign offices or 9 from foreign applicants.

10 Let me -- just because this is kind of 11 small, I'm going to go to the next one. Of those 12 38 percent, these -- this shows who's who. Okay? 13 So, of our foreign applications, 38 percent come 14 from Japan and the previous slide noted that overall that's 14. And that's actually way down 15 16 because for years and years and years, fully one in five of our patent applications were of 17 Japanese Oregon -- origin. Consider Canon and 18 19 Toshiba, big consumer electronics area. So, Japan has leveled off. Korea has kind of come into the 20 patent system, I would say, over the last 20 21 22 years, okay? And as you know, they're -- have

1 gotten very patent-savvy and patent- litigious, 2 for better or worse.

3 Now, you see, China is up, okay? And of all our foreign filings, they constitute 12 4 5 percent. Okay? And again, going back to this slide, that's 4 percent of our filings overall of 6 7 new inventions, say. So, they are going up, but 8 at least currently today it's not overtaking us. 9 What I don't have here and we will try to get --10 we will get you for the next is where the rate of 11 grants here because I think that begs to the 12 quality, as Andy pointed out and others and Bernie 13 and others. They're just filing stuff here and 14 letting it go abandoned and not getting grants and what's the point? This just burdens our system 15 and our fees. If they are, then we'll have to 16 17 see.

And you actually have to look at this stuff because certain countries -- so, for example, Denmark, okay? Their grant rates are what you call surprisingly low and the reason is, is because they're heavy into medical devices,

okay, which is a very high-litigated, competitive, 1 2 got to keep the broad claim field, and the rate --3 rates aren't high there. So, you actually have to look at the subject matter as well as the country 4 5 of origin tried to have any good (inaudible) MR. HIRSHFELD: Hey, Mark. Can I jump 6 7 in? Do you have the slide on the monthly UPR 8 filings or --9 MR. POWELL: Yeah, I thought I did. It 10 was the first one (crosstalk) MR. HIRSHFELD: -- on the first one 11 12 because I think that's an --13 MR. POWELL: Oh, there. Yeah, I'm sorry it got skipped over. Yes. I think it would be 14 good -- I think it's helpful that -- to talk about 15 16 what this slide is. 17 MR. HIRSHFELD: Okay. 18 MR. POWELL: Because this puts into 19 context the discussion we were having about trying 20 to increase in U.S. Filing from China. MR. HIRSHFELD: Right. 21 22 MR. POWELL: And this will put that into

1 context --

2 MR. HIRSHFELD: Okay. MR. POWELL: -- and --3 4 MR. HIRSHFELD: Yeah. 5 MR. POWELL: Okay. UPR is really all filings including RCEs, just to keep it simple 6 7 like that. And as you can see, it's -- we've been 8 generally up 1 percent, as a whole office. 9 China's up. They -- again, but not huge volumes, 10 okay? For China, which is a huge country, we're looking at 1,500 filings a month. That is not 11 12 very much, okay? Now, and so we're not getting 13 the big piece of that worldwide streak that Shira pointed out in her slide from -- and then again, 14 15 we need to see what exactly is happening as 16 outcomes for those, so. 17 MR. LANG: Are these statistics based on the (inaudible) location or the inventor location? 18 19 MR. POWELL: This is based on priority, 20 okay? MR. LANG: Priority, okay. 21 22 MR. POWELL: And it's good -- that's a

good question because you can look at filings from 1 2 whatever in so many different ways. Priority is 3 somewhat accurate, right? Although, a filer can file here without claiming priority no matter 4 5 where they're from, right? You can look at the first- named inventor, you can look at -- and 6 particularly PCT, you can look at the company 7 8 filing because you can file as a corporation in PCT; it could be Siemens, but all the researchers 9 10 are in Palo Alto. Okay? So, there are different 11 ways, many different ways to look at it. So, 12 you're never going to wind up with the same 13 numbers, but in proportion by ratio it comes out 14 about the same for everything. MR. LANG: But to be clear, if a Korean 15 16 company, let's say, files in the United States and 17 Korea simultaneously for whatever reason, that's 18 not going to count as a Korean --19 MR. POWELL: Correct, correct. However, 20 that is so rare, simultaneous filing. And it's

21 really been an interesting subject and discussion
22 among offices about what day is it. Okay.

1 (Laughter)

2 MR. HIRSHFELD: Mark --MR. POWELL: So --3 MR. HIRSHFELD: -- I'm going to --4 5 MR. POWELL: Yeah. Go ahead. MR. HIRSHFELD: Sorry. I didn't mean to 6 7 cut you off if you were still --8 MR. POWELL: Yeah. It's all right. 9 MR. HIRSHFELD: Just a couple of points 10 about these two graphs, because I -- first of all, 11 I think that they give you a visual which might 12 not be entirely accurate because of the scale. 13 So, when you look at the Y axis, it's very 14 different in the total filings and just those from 15 China. But when you actually do the math, so to 16 speak, right, we have last year, as Mark pointed 17 out on another slide, about 4 percent of the total filings are from China and about a decade ago was 18 about 2 percent. 19 20 MR. POWELL: Right. MR. HIRSHFELD: So, again, that's a --21 22 it's a slight increase, but somewhere around 2 or

4 --1 2 MR. POWELL: -- more than 10 years ago, 3 but it's still only 4 percent. 4 MR. HIRSHFELD: -- you can -- right, 5 right. So, I'm not trying to draw any conclusions 6 from that. I just want to make sure we're talking 7 about accurate numbers. I --8 MR. POWELL: Right. 9 MR. HIRSHFELD: I know Shira before and 10 her team were talking about worldwide numbers and 11 filings in China and those are much long -- much 12 larger than the increase we're seeing in the 13 United States. The only point I'm trying to make. 14 Will we see that is something that we're watching for. We certainly -- as I said before, trademarks 15 16 have seen a huge increase. The -- are they a 17 leading indicator of what's going to happen to 18 patent -- or to patents? We don't know, but it's 19 something we're paying attention to. 20 MR. LANG: Last time, we talked a little bit about a problem of bad machine translations 21 22 from, well, out of the non-U.S. Filings. Is that

```
1
      something that has a geographic footprint?
 2
                MR. POWELL: Did you say machine
 3
      translations --
 4
                MR. LANG: Yes, yeah.
 5
                MR. POWELL: -- as far as search tools?
                 MR. LANG: Well, machine translations --
 6
 7
       I mean, the -- you just -- bad quality
 8
      translations being filed.
 9
                MR. HIRSHFELD: So, I --
10
                 MR. LANG: (Inaudible) priority
11
      elsewhere and, I mean, is that -- is there a
12
      pattern where certain countries are (inaudible)
13
                MR. HIRSHFELD: I don't know the answer
      to that question. We certainly have a significant
14
      problem of U.S. Applications being filed at our
15
16
      machine translations that absolutely drives
17
      examiners crazy and I was an examiner, as many of
18
      us over --
19
                MR. POWELL: Sure.
                MR. HIRSHFELD: -- here and we all
20
      followed that issue.
21
22
                MR. POWELL: Right.
```

MR. HIRSHFELD: I don't know if it's 1 2 from any particular areas or not; it's actually a 3 really good question for us to look into. 4 MR. POWELL: I will jump in, though, and 5 at least from the IP 5 Offices and the Global Dossier environment. Each of China, Korea, and 6 7 Japan provide machine translations and they're 8 actually quite good. I mean, not great, but 9 they're better than, like, Google Translate where 10 you get just random, you know, and they can't even translate French, right? (Laughter) But the 11 12 Japanese particularly have been working for so 13 many years on their AIPN system, they call it. That -- that's a dictionary basis on this very 14 15 ban-oriented, so. 16 MS. CAMACHO: Mark, I --17 SPEAKER: Okay. I'm going to --MS. CAMACHO: I have a quick question. 18 19 I always -- we have an agreement with China on the 20 Patent Prosecution Highway, right? Is --21 MR. POWELL: Yes. 22 MS. CAMACHO: -- that right? So, have

we seen any increase in request or petitions under 1 2 that program? 3 MR. POWELL: Not any more than normal, no. It's kind of whittling out because our first 4 5 action pendencies have gone so far down, they're simply less available. And as you may know, in 6 7 China they do not act on a case until it's public, 8 so they don't do anything until 18 months. And 9 we're already at 16 months first action pendency, 10 so they're generally not going to be available for 11 (inaudible) 12 MS. CAMACHO: Do you know if China has a foreign filing license requirement? 13 14 MR. POWELL: I'm sorry? 15 MS. CAMACHO: Do you know if China has a foreign filing license --16 17 MR. POWELL: I am certain they do, yes. 18 MS. CAMACHO: They do? 19 MR. POWELL: I believe just about every 20 ___ MS. CAMACHO: So, it's --21

22 MR. POWELL: -- country does.

```
MS. CAMACHO: -- mostly likely --
 1
 2
                MR. POWELL: Yes, yes.
                MS. CAMACHO: -- that be filed in --
 3
                MR. POWELL: Yes.
 4
 5
                MS. CAMACHO: -- China?
                MR. POWELL: Yes.
 6
 7
                MS. CAMACHO: First filed in China.
 8
      Yeah, got it. Thank you.
 9
                MR. POWELL: Okay. I'm going to turn
10
      this back over to Shira.
11
                MS. PERLMUTTER: We're keeping this
12
      exciting by going back and forth. (Laughter) I
      don't need the slide.
13
14
                MR. POWELL: Oh, okay.
                MS. PERLMUTTER: It's okay, so --
15
16
                MR. POWELL: Okay. I thought that's --
                MS. PERLMUTTER: Just --
17
                MR. POWELL: -- where you were, but
18
   (inaudible)
19
20
                MS. PERLMUTTER: Yeah. No, it is. So,
      I just wanted to alert you to two other things.
21
22
      One is that we are very closely following a
```

1 proposed waiver from the supplementary protection 2 certificates in the EU. I don't know how many of 3 you are following that and interested in it, but it's the mechanism through which the EU extends 4 5 the term of protection for regulated products that 6 are undergoing a marketing approval process. 7 And the Commission has proposed this 8 waiver that would let producers of generics and 9 biosimilars manufacture medicines for purposes of 10 exporting them to countries in which the patent or 11 the extension of the -- through the certificate 12 has expired. So, it allows some manufacture ahead 13 of time for purposes of exporting later. 14 So, we're worried about the proposal, we're worried about whether it might be extended 15 to other countries, that other countries would 16 17 say, "This is a good idea," and so we're following 18 this very closely and discussing it with the 19 European Commission and the member states. So, I 20 did want to mention that. And then last but not least, as you 21 22 know, we're doing a lot of work in different parts

1 of the agency on the patentable subject matter 2 issues and one of the things we're doing is 3 planning a workshop with our colleagues from other IP Offices on that subject in October to talk 4 5 about experiences, laws, and practices in each of our countries and determining subject matter 6 eligibility in areas such as life sciences and 7 8 computer-related inventions. So, this will be an 9 opportunity to really talk to each other 10 informally and openly and exchange experiences and 11 information. We really are interested in making 12 sure we understand the rationale and the policies 13 behind each country's practices in this area and we think it'll be very helpful for all of us. 14 15 MR. WALKER: Shira --16 SPEAKER: Go ahead. 17 MR. WALKER: -- just a quick question before Mark has started. So, this relates to the 18 19 IP attachés and their diplomatic status. So, it 20 was mentioned in Tony's slides -- I don't think you were here, but Tony had it in his slides, he 21 22 mentioned it. I don't know if it was more

appropriate for you or Dana, but we talked before 1 2 about elevating the rank of IP attachés so they 3 could deal with the higher-level counterparts in these foreign governments. Any updates on the 4 5 status for that, the question from our audience? MS. PERLMUTTER: Nothing new yet. We're 6 7 certainly still very interested in it and I know 8 we have a lot of support and a lot of places for 9 doing it because we think it would really enhance 10 the effectiveness of the attachés. So, it's still 11 something very much on the agenda that we're 12 pursuing. But no immediate developments, at this 13 point. MR. WALKER: And is there anything user 14 community to do to help the office on this or no? 15 16 MS. PERLMUTTER: Well, that's a good question. I think just expressing your views 17 wherever appropriate and possible. 18 19 CHAIR JENKINS: We supported the 20 designation in the PPAC report last year. 21 MS. PERLMUTTER: That's great. I 22 remember that. Maybe again this year.

1 (Laughter) Thank you. 2 MR. POWELL: Okay. Now that we've 3 concluded all of our statistics here, I can skip to the -- (laughter) office meeting. Okay. Let 4 5 me just skip through this -- here we go. Okay. I wanted to talk about a couple of programs here, 6 7 just to give you quick updates. 8 As you may remember, we've had 9 collaborative search pilots going on with the 10 Korean and Japanese offices. We've been exploring 11 that possibility with other offices including 12 Germany and the UK. Those are in the Paris route, 13 okay? Over the last several years, we've also 14 been working in the PCT system to try to see what we can do in-so-far as collaborative search and 15 16 exam in that environment. In the past, we've had 17 two pilots limited to -- actually, to Korea and 18 the EPO (inaudible) for which we have results. It 19 was suggested, I'm not certain by which office, 20 but it was agreed to that we should try something in IP 5 to see to what extent anything new could 21 22 be learned or the system improved. So, beginning

1 at the 1st of this month, we're undertaking a -2 what we call a PCT Collaborative Search and Exam
3 or CS&E Pilot to assess what can be done in the
4 PCT among multiple searching offices.

5 Essentially, without getting into too 6 much detail, an applicant has to opt into this. And in this process, a -- the initial ISA, the 7 8 selected ISA, will conduct a search and share 9 those searches with each of the other IP 5 10 Offices. It would be designated as peer 11 searchers. Who would then comment, supplement, 12 add to a common search report to be provided to 13 the applicant. And it's not a great number of these coming up and I'll -- think I've got a slide 14 to show that, earlier. Or rather, later. 15

16 Okay. So, the number of applications 17 will be 100 per initial ISA, main ISA. Okay? So, 18 that in the end, each office will handle 500 cases 19 total. We actually have already gotten 18 20 applications, which surprised me because it's very 21 difficult to get the word out. Although, this is 22 a free program. In the end, what will the results

1	be? Will it be that there is some measurable
2	improvement over a collaboration with only one or
3	with only two other offices? What will have cost
4	offices to do, right, for whatever benefits that
5	might accrue? What have or could be the savings
6	and prosecution cost that were I'm not sure
7	what happened to the slides.
8	(Laughs) I'll just keep talking.
9	The slides disappeared. (Laughter)
10	To what degree would applicants
11	actually save money by not having
12	an enormity of subsequent
13	prosecution costs in multiple
14	national phase offices? And I'll
15	keep talking. Oh, there we go.
16	Look at the at least with the
17	background back. Let me just take
18	my slides up here real quick.
19	CHAIR JENKINS: Well, I'll help here a
20	little bit.
21	MR. POWELL: Okay.
22	CHAIR JENKINS: So, one thing that I've

struggled trying to understand why the user 1 2 community is not more responsive to these 3 collaborative programs. It's -- you get to fast track, for the most part. You -- there's a free 4 5 element involved; you don't have to pay for it. MR. POWELL: Right. 6 CHAIR JENKINS: You get your patent 7 8 application arguably faster, I guess you could 9 say. But it just has not had the buy-in, so --10 and I know you and your team have worked very, 11 very hard --12 MR. POWELL: Right. 13 CHAIR JENKINS: -- to try to get the 14 message out in a variety of different medium. 15 MR. POWELL: Yep. And Drew has talked 16 about it and Andrei doesn't agree. It's just the 17 general conservative nature of the IP community, 18 right? It was the same with PPH and it's kind of 19 before my time, but I hear it was the same with 20 the PCT, that Former Commissioner Mossinghoff, who was around when that started, was -- after 40 21 22 years, I could count them -- count the numbers of

1 ones we had on both hands and that was it. And -2 but then now, PCT of course is more -- most of the
3 (inaudible) around the world.

4 Ah, we have slides again. But yeah, I 5 think it's just getting the word out. It was the same with the Patent Prosecution Highway. What 6 7 really helped was to have a user advocate of the 8 PPH to really -- office is going to talk a lot, 9 but we had Alan Casper of Finnegan who's a 10 well-known speaker and he was a very big advocate 11 for that program. So, we're hoping to find a good 12 advocate in the IP sector. Perhaps Marylee could 13 be the main one to preach the gospel of Collaborative Search and Exam. 14 15 CHAIR JENKINS: Mike just nominated me. 16 MR. POWELL: Right. MR. VIDOVICH: I nominate --17 MR. POWELL: So --18 MR. VIDOVICH: -- the PPAC. 19 20 MR. POWELL: No, but you're right. It's just a matter of getting the word out and getting 21 22 some success stories and then getting people to

talk about them, right? And while the 1 2 improvements in quality ought to seem obvious, you 3 have to study this stuff because you need to know to what degree and why. Is it truly our lack of 4 5 access to this body of foreign prior art, a detriment to doing thorough searching here? 6 I mean, and again, to what degree will a 7 8 filer save money in the end, having reduced 9 prosecutions of cost and all of the national 10 offices into which he files? And if we charged a 11 fee for that, the savings and prosecution cost 12 could far outweigh that and it would -- it could be worth it to the outfits. And so those are 13 14 things we're trying to explore here. But you're 15 right, Marylee. I think it's just a matter of 16 staying out there and ringing the bell about it, which we will continue to do. 17 18 Okay. Let me see. I think I pretty

19 much covered -- of course, we have on our website 20 international cooperation on the left. You'll 21 find a whole segment about this in there, as well. 22 Right there, PCT Collaborative Search. And then

you'll find the information on virtually all of
 our program.

3 Just a very brief update. We've talked about this before. This is the Access to Relevant 4 5 Prior Art, kind of a benign name. But what it is, is, of course, trying to use electronic means to 6 7 help applicants comply with their IDS burden by 8 putting into the application file information that 9 we already have access to so that the applicant 10 doesn't have to file an IDS in a certain case. This is actually a pretty complicated project and 11 12 it is tied to our improvements, to a degree. What 13 we're starting with is we're starting with 14 applications in the 120 chain in the U.S., okay, 15 because there's no database issue with the 16 information that we already have. With that, we 17 will have built a platform for other information 18 to be added to, as we go down the road.

19 There is a tie into the development of 20 our search, our new patents and then search namely 21 in the loading of documents. We do have access to 22 citations, for example, in the Global Dossier.

But what we -- what is needed is the actual 1 2 documents themselves to the extent that we can get 3 them. And hopefully, we will be able to in subsequent phases make those machines searchable. 4 5 But my point and my presentation here was just to be very brief and to let you know is 6 7 coming out and I believe there's going to be a 8 Federal Register Notice that should be out very 9 shortly on the beginning mechanics of it, so 10 please take a look at it. And we hope to get people to find interest in that. I would think 11 12 that they would. (Laughs) 13 MR. WALKER: On the point of interests 14 in it, I have a question from our colleague, Jeff Sears. Access of Relevant Prior Art, will the 15 16 office engage in any commentary regarding the 17 impact of automatically importing prior art into 18 the file (inaudible) on the Rule 56 duty of disclosure? 19 20 MR. POWELL: Okay. So, Rule 56 and the Doctrine of the Duty Disclosure is a judicially 21 22 created doctrine and we cannot change that. Okay?

We can help applicants reduce their burden in 1 2 complying with it. Right? That's really the 3 simple answer there. Now, it may be that as we go along changes to rules with 98, 99, they could be 4 5 tweaked to account for any process mechanisms that need to occur. What we're trying to figure out 6 7 now is the applicant office examiner interaction 8 in terms of timing, notification, and that sort of 9 thing. Those are not -- they're not simple issues 10 to iron out, so -- but no, we can't change the duty of disclosure itself, but we can hopefully 11 12 help reduce the costs in complying with it. 13 MR. WALKER: Yeah. No, I guess, it's --14 I mean, I -- this (inaudible), but I imagine question is whether or not the PTO could opine on 15 16 the fact that with prior art automatically 17 imported into the file, the need to do this is not seen by the office as a requirement to comply with 18 Rule 56. I mean, I don't know. 19 20 MR. HIRSHFELD: So, happy to opine on that, absolutely. Once we have it in the file, we 21

do not need applicants to submit it. Our plan for

22

1 the prior art project, and this is in the Federal 2 Register Notice, is to -- as Mark said, it's not 3 going to be all applications. We will notify the applicant that this information has been 4 5 automatically pulled in and therefore they do not need to do that, also. 6 7 CHAIR JENKINS: So, just to be clear, 8 too, and then because that information has 9 automatically been pulled in, the examiner will be 10 required to review that information automatically 11 pulled in. So, and normally in IDS, they check --12 MR. POWELL: Yes. CHAIR JENKINS: -- off the box --13 MR. HIRSHFELD: Correct. 14 CHAIR JENKINS: -- right? 15 MR. HIRSHFELD: Correct. 16 17 MR. POWELL: Yes. 18 CHAIR JENKINS: So, we'll get --19 MR. HIRSHFELD: That information will be 20 initialed and it will be put on the face of the patent when the patent (inaudible) 21 22 MR. POWELL: Right. It essentially

becomes an office citations of record, as an 1 2 examiner would do in the old Form 892 when he 3 cited prior art (inaudible), you know. 4 MR. HIRSHFELD: Yeah. The best way to 5 think of it is, we're doing the IDS submission, (laughs) right? At least for those references. 6 7 And once it's in the file, it will be treated the 8 same way as any other IDS submission. 9 MR. POWELL: I see Mark. You have a 10 question? MR. GOODSON: Oh. Just backing up 20, 11 12 minutes, a little more regarding machine 13 translation. I am curious as to how it works, to 14 what extent you know. As an example, we would -an electrical engineer, we talk about grounding. 15 In Britain, it would be called earthing. 16 17 MR. POWELL: Correct. MR. GOODSON: Okay. What happens when 18 -- is the machine translation, is it functional 19 20 translation or is it word-per-word? MR. POWELL: It actually depends on what 21 22 you're using the translation for, okay? So, if

1 you're trying to translate patent documents, the 2 best solution has been dictionary-based 3 approaches. And now the more sophisticated ones are using AI to improve their dictionaries, 4 5 whereas before dictionaries would be manually improved. So, over a long period of time, a 6 machine would translate, say, a Japanese document 7 8 into English, right? And as you may know, and 9 with Japanese, there are certain terms which there 10 is no Japanese word for and so you'll see a 11 document that goes -- you see the Japanese 12 characters, then you'll see "oscillator" in 13 English, right? And those are things that had to 14 be learned over time by a machine. Now, if you look at machine translations 15 16 for searching, WIPO has a really interesting 17 approach to this which I think is a really good one. Rather than trying to machine translate 18 19 databases of information, what they do is they 20 translate the search strings into the native languages of the databases of information. Right? 21 22 So, you type a search string in, it translates

1 that search string into Russian, French, whatever, 2 and then gets those databases in their native 3 languages. So, you need only improve the translation of the search developing tool rather 4 5 than trying to have to re-translate all of the 6 documents you have as machine translation improves 7 over time. So, it's an old (laughs) problem, but 8 it's actually doing quite well. 9 And what surprises me personally is that 10 there's not more just free machine translations 11 out there that are any good; there really aren't. 12 I mean, they'll -- they do some. Google 13 Translate's a very popular one and you can get it 14 on your -- you're going on a trip overseas, you can sort of get a translation enough where you can 15 16 figure out where you're going and not get lost. 17 But again, translating patent material is not really English. (Laughs) And it's kind of 18 19 technolegalese or it's patentese. There's no other language like it. So, yeah. 20 CHAIR JENKINS: Okay. Bernie, one more 21 22 question, then we got to move on. Yeah.

1 MR. KNIGHT: Okay, Mark. A little bit 2 off topic, but maybe related to the last question 3 is, the work-sharing initiatives are great. I was wondering, are there any initiatives with our 4 5 foreign partners to look at their IT systems to see if they're -- because I've always heard that 6 7 our foreign counterparts, their IT systems for 8 search examination and issuance are in some ways 9 superior to ours and I don't know if that's true 10 or not. But is there -- do you have any 11 discussions with our international partners about 12 sort of sharing software and that sort of thing 13 that might help our systems? MR. POWELL: Well, we do share a lot of 14 information about features more than anything, 15 16 right? So, and Rick can probably speak to this. 17 Every office is on its own IT road map, right? And it's supported by its own budget and by the 18 19 ambitions of the office and investments they want 20 to make in IT. Our office is on a bunch of legacy systems that we're trying to get off of. 21 22 Conversely, the EPO has embraced its legacy system

and they have no intention to get off of it, okay?
 Now, they may not be able to provide some of the
 features we'll be able to provide down the road
 and so on.

5 They really are different, right? They work differently. So, for example -- and 6 obviously, sharing software is a security problem 7 8 and everything else and that sort of thing, but 9 learning what they do. I mean, the Korean office, 10 for example, has always had really nifty search 11 tools where you drag the pointer over a thumbnail 12 to patent document and the abstract comes up. I 13 mean, just features and handy things like that, 14 that we try to share with our examiners and our test groups to see if those will be features that 15 they've -- they would find useful. 16

17 And IT is not easy, as Rick knows. And 18 I will share once again with you that the Japanese 19 spend hundreds of millions of yen on trying to 20 replace their system several years ago and 21 completely failed and had to start over, just 22 called it a loss. So, I don't know. Rick, do you

1 have anything you might want to add to that? 2 MR. SEIDEL: No, I would just say as we 3 talk about more and more work-sharing, 4 international cooperatives and so on, there's just 5 a natural tendency to have the discussions go into 6 IT. So, that happens all across the world. But I 7 think it might be a good segue into our next one, 8 talking about AI. I think AI is really -- the 9 Director mentioned it earlier as certainly a 10 priority. I think that would be a good topic for further discussion. I think that's maybe where we 11 12 hear a lot of things about different countries 13 kind of taking the lead. I'm not sure that's 14 necessarily true. I think we're all challenged with Mark's term of patentese. How do we make 15 16 machine learning better in this very complex 17 field?

18 CHAIR JENKINS: Great. So, we're going 19 to transition. (Laughs) Thank you. Thank you for 20 that segue. Shira, Mark, thank you so much. So, 21 now we're going to not go immediately to AI, but 22 we're going to talk about -- the economy? I don't

1 know. (Laughs) MR. TOOLE: Yes. Well --2 3 CHAIR JENKINS: You're going to give us an update. 4 5 MR. TOOLE: So --6 CHAIR JENKINS: Andy Toole. 7 MR. TOOLE: Yes. 8 CHAIR JENKINS: Based upon the 9 persistence of one of our --10 MR. TOOLE: Thank you. CHAIR JENKINS: -- Committee members, 11 12 Dan Lang, repeatedly -- and I --13 MR. TOOLE: Okay. 14 CHAIR JENKINS: -- do listen. So, we 15 find -- we have found time to bring you to the table, so to speak. So, you are Acting Chief 16 Economist for the U.S. Patent and Trademark 17 Office? 18 19 MR. TOOLE: Right, exactly. And thank 20 you very much. I really appreciate the opportunity, actually, to talk about the critical 21 22 work that the Office of Chief Economist does for

1 the USPTO and our stakeholders.

2 So, today -- let's see if I can advance 3 these slides. Oh, there we go. So, today I would like to touch on four areas. First, I would like 4 5 to set the stage by providing a little bit of background about the Office of Chief Economist 6 7 also referred to as OCE. You'll hear me saying 8 that. Second, I would like to highlight some of 9 the important ways that we contribute to the 10 priorities of the USPTO. Then, touch on some research work and just a couple of the IP findings 11 12 that we have. And finally, highlight some of the 13 ways we support and engage the stakeholders, which I think is pretty fascinating. 14

So, the Office of Chief Economist was 15 established in 2010 under the Former Director of 16 17 David Kappos. At that time and even today, we're 18 seeing significant worldwide growth in the use of 19 intellectual property. And the innovation 20 ecosystem in the United States, and actually globally, is becoming more complex. It's quite 21 22 clear that there's an ongoing need to understand

the role and contribution of intellectual
 property, not just patents but intellectual
 property more broadly, to innovation and economic
 growth.

5 So, as such, the Office of Chief Economist advises the Director and the Chief 6 Policy Officer, Shira Perlmutter, in four key 7 8 ways. First, we provide deep analytical 9 capabilities for USPTO initiatives. We undertake 10 research and analysis to shed light on the role 11 and impacts of intellectual property in the 12 innovation ecosystem. We monitor and interpret a 13 growing number of empirical studies that are coming out in legal, economic, and policy journals 14 and publications. And we also promote awareness 15 and understanding by providing better data --16 17 better access to quality data for our 18 stakeholders.

19 From an organizational standpoint, the 20 Office of Chief Economist sits within the Office 21 of Policy and International Affairs, alongside and 22 working symbiotically with the policy teams, the

Office of Governmental Affairs, the Global
 Intellectual Property Academy, and the attachés.
 When our office is fully staffed, we have four
 Economists, one Deputy Chief Economist, and one
 Chief Economist.

Importantly, I would like to emphasize 6 7 the value of the analytical capacity and research 8 work that we do. So, for instance, our work helps 9 to build the evidence base needed for improving 10 the intellectual property system. And an improved 11 intellectual property system will lead to more 12 reliable and predictable patenting and patents. 13 Our work helps to promote USPTO's 14 collaboration and integration in policy environments both in the United States and abroad. 15 And we also have a number of different types of 16 17 outputs that we disseminate through peer reviewed articles, working papers, and reports. 18 19 When I thought about priorities for our 20 office, I broke them into two groups: those that originate within the USPTO and those that 21 22 originate outside the walls of our organization.

So, with respect to priorities within USPTO, the 1 2 Office of Chief Economist continues to work on a 3 variety of different initiatives. Since the passage of AIA, we've worked collaboratively with 4 5 the CIO -- the CFO, excuse me, to support the fee 6 setting process. In particular, we're estimating elasticities to try to understand better how 7 8 applicants are responding to fee increases and 9 decreases.

10 The Office of Chief Economist is working with Patent Operations on a number of priorities 11 12 and issues. For the Examination Time Analysis Initiative, the OCE facilitated outreach to 13 14 external international experts in the areas of personnel economics and organizational incentive 15 16 systems. That effort culminated in two learning 17 events where we brought USPTO folks together with 18 four experts to share ideas and learn about alternatives. OCE continues to look into 19 20 examination incentives using quantitative modeling as part of that effort. 21

22 Under the Chief Policy Officer, OCE

administers the Thomas Alva Edison Scholars 1 2 Program, which was established in 2012. This 3 program enlists the services of academic researchers either as distinguished scholars or 4 5 research fellows. They come to the USPTO to study 6 issues that are important to the mission of the agency and in the public interest. So, for 7 8 instance, some of the things that the Edison 9 scholars have done for us in the past, they've 10 studied machine learning for prior art searching, 11 they've looked at patent allowances, patent claim 12 clarity, abusive patent litigation by 13 non-producing entities, and the impact of patents 14 on firm performance. Some of these findings are being used in a lot of our discussions with our 15 stakeholders and even by folks in the White House 16 17 and on the Hill.

18 We also respond in our office to a 19 number of other requests. We often provide 20 talking points to the Director and other senior 21 management, and we provide guidance to the Office 22 of Chief Communications Officer on a wide variety

1 of issues such as gender and diversity and 2 patenting, government interest patents, local and 3 regional trends in patents and trademarks. In terms of external priorities, we work 4 5 often with the Office of the Under Secretary and through that Office we get involved in White House 6 7 initiatives. I will mention two of them that 8 we're involved in a couple of minutes, but the 9 Former Chief Economist was a co-lead on USPTO's 10 Cancer Moonshot Patent Challenge which was part of the White House Cancer Moonshot Taskforce. 11 12 Working with the Office of Governmental 13 Affairs, we respond to different Congressional 14 initiatives. For instance, after the passage of AIA, there were a number of studies required to be 15 done by the agency. The Office of the Chief 16 17 Economist was deeply involved in those. We have some ongoing work with the Office of Governmental 18 19 Affairs right now. 20 Further, we work with teams in OPIA to

21 review and respond to policy positions and reports 22 for forums such as the G20. We respond to

international organizations such as the 1 2 Organization for Economic Cooperation and 3 Development and the World Intellectual Property Office, so OECD and WIPO. 4 5 Turning to some research, in collaboration with the Department of Commerce 6 Economics and Statistics Administration, OCE 7 8 originated a report series on IP-intensive 9 industries. This series compares a broad set of 10 performance indicators between industries that use IP intensively and those that do not, and IP 11 12 intensity is measured by use relative to 13 employees, so the total count of patents per 14 employee, for instance. Indicators that we've 15 looked at in those studies are direct employment, total employment, wages, contributions to value 16 17 added, gross domestic product, exports, and 18 imports. 19 The first study was released in 2012 and 20 was very impactful. Other jurisdictions did

20 was very impactiul. Other jurisdictions did 21 simulate the study, but I meant to say -- it's 22 stimulated studies there. So, for instance,

Europe and China, they also followed on and copied 1 2 our studies. So, in some sense it was both a 3 stimulation and a simulation. (Laughter) And we released an update in September 2016 of the 4 5 IP-intensive industry's report and that study showed that IP-intensive industries show growth in 6 direct employment, total employment, wages and 7 8 value added, and share of GDP. There was some 9 decrease in the value of service exports, however. 10 The 2016 update was and is being used to frame 11 policy and trade discussions by the White House, 12 members of Congress, and the U.S. Trade 13 Representative. We have a lot of other research at our 14 office. For instance, we have a new product 15 16 called Data Highlights in which is designed to be informative about IP data trends and is intended 17 to use graphics to illustrate those trends so it's 18 19 not a highly complex and overly sophisticated 20 statistical approach. One example is our recent Data Highlights report, Collaboration and 21

22 Ownership on Patents Issued to Chinese Inventors.

1 And in that, we trace Chinese inventor teams over 2 time and find out who they collaborate with and we 3 also look at the owner at grant of patents with 4 Chinese inventors to see if they're owned by U.S. 5 Or other national entities.

We have a substantial analytical report 6 which involves statistics on patent examination 7 8 quality, court litigation, and PTAB trials. We 9 created a primer on patent prosecution and the 10 examiner performance appraisal system to help those on the outside who are doing all of those 11 12 additional empirical studies and promoting them on 13 the Hill, for instance. We try to give them an 14 understanding about what's actually happening 15 inside the walls of the PTO.

16 One of the things that we found is that 17 many of the studies that are being done and are 18 critical of the USPTO, reflected a 19 misunderstanding of what actually is happening 20 with respect to patent prosecution and examiner 21 appraisal systems. So, we're trying to help build 22 out that knowledge and provide people with a

1 better chance of getting it right.

2 We have two new working papers. One is 3 the new metric on patent thickets, which is related to licensing and is used, of course, to 4 5 characterize the degree of transaction costs in secondary markets for intellectual property, so 6 7 when patents are sold, bought and sold. We have a 8 paper that looks at the trademark registrations among U.S. firms which derived out of a 9 10 collaboration with the Census Bureau. And many, many other things as well. So, I would urge 11 12 everyone to go to our website, 13 www.uspto.gov/economics, and just browse and find 14 the particular types of outputs that you're 15 interested in looking at. 16 We engage in a number of collaborative projects with the U.S. government and with foreign 17 18 entities. With the White House, we are currently 19 leading an interagency taskforce for the 20 Intellectual Property Enforcement Coordinator, the IPEC. That interagency taskforce is charged with 21 22 building out research capacity and research

findings in four critical areas of intellectual 1 2 property. One of them is counterfeit goods; 3 another, trade secrets; a third is patent litigation; and finally, commercial scale piracy. 4 5 We were also involved with the White House Lab to Market Initiative, which is intended 6 to facilitate the commercialization of federally 7 8 funded research and development and discoveries 9 that come out of that funding. We are engaged 10 with the U.S. Trade Representative in a Trade and 11 Investment Working Group. And we are 12 collaborating with the small business administration to look at the Small Business 13 Innovation Research Program and Small Business 14 Technology Transfer Program and try to shed some 15 16 light on the interaction of these subsidies for 17 innovation and patenting. In terms of international 18 19 collaborations, we're working with the UK IPO on a 20 joint economic study. We are contributing a chapter to a WIPO book that's looks at global 21 22 innovation in mineral mining. We're looking at

the U.S. Mineral mining innovations using patent data, of course. And we're also contributing to the World Trade Organization effort on trying to characterize trade and knowledge across national borders.

We support the stakeholders and engage 6 7 with stakeholders in a number of ways. We have a 8 newsletter that anyone can sign up for if they're 9 interested and it gets sent out roughly quarterly. 10 But one of the most important ways we engage with 11 stakeholders is through participation, organizing 12 and cohosting conferences. Our flagship 13 conference is the Northwestern University Searle Center USPTO Conference on Innovation Economics. 14 This is one of the two top conferences in the 15 16 world on innovation economics. It attracts 17 scholars from all over the world who present recent work on the impact of intellectual property 18 19 on the economy. 20 We also engage in various policy discussions at the Brookings Institution and other 21

22 places around, D.C. and other spots. We are part

of the OECD Statistics Task Force and the WIPO 1 2 Chief Economist Network. Those organizations 3 bring together economists and statisticians from 18 different IP Offices around the world on a 4 5 semi-annual basis for the OECD. And it's a way of staying in touch with what other offices are doing 6 7 and actually coordinating on data efforts, which 8 is one of their main priorities.

9 To save stakeholders' time and money, we 10 have created research-ready public datasets based 11 on USPTO public data. We actually facilitate the 12 use of the USPTO's public data by taking, let's 13 say, XML formatted datasets and putting them into 14 user- friendly formats and defining variables in a very clear way. This facilitates stakeholder use 15 of information. And finally, we also have 16 17 PatentsView. PatentsView is a visualization and analysis platform with over 40 years of USPTO data 18 19 on granted patents. So, let me take a couple of 20 minutes here just to talk about PatentsView. I think it hasn't been understood well enough. 21 22 So, PatentsView is a public-private

partnership and it's been formed with all of the 1 2 entities that you see on the slide, including 3 Berkeley and the American Institutes for Research. Below the title where it says public-private 4 5 partnership and to the right of PatentsView are five tabs. I realize that they're not very 6 visible; I apologize for that. But the first 7 8 three tabs are visualizations. The first one says 9 relationships, the second one, locations, the 10 third one, comparisons.

The final two tabs include what's called 11 12 list search and data sources and those two are for 13 sophisticated data users who want to create their 14 own database. They can do a list search, define the variables and the parameters, have it sent to 15 16 them through email, and they can do bulk downloads 17 of granted patent data through the bulk download page. And there's a community page, as well. But 18 within the first three tabs there are 19 visualizations and these visualizations are 20 supposed to help people who are unfamiliar with 21 22 patent data to really start to get to know the

1 data and understand patent information.

2 So, if you were to click on the 3 relationships tab -- that first one to the right of PatentsView name -- you would actually see this 4 5 graphic. This is a network visualization of the 100 top cited patents. The orange circles are for 6 assignees. They're sized by the number of patents 7 8 the assignee has. For instance, Apple, it has 9 11,213 patents at the time that this screenshot 10 was taken, which is late in September of 2017. 11 The blue circles are patents sized by the number 12 of forward citations and the yellow circles are 13 inventors sized by the number of patents that 14 inventor has participated in.

And one of the other features of this, I 15 16 should mention, is, we go through a disambiguation process where we link inventors by creating a 17 unique ID across different patents. And so you 18 19 can know that Andy Toole, Andrew Toole, Andy A. 20 Toole were the same inventor and not three different inventors, counted three times, but the 21 22 same inventor that was on all three patents. So,

that's called disambiguation. It's actually a 1 2 highly regarded value-add on the data. 3 To the right, people can click on a number of different filters. You can see that 4 5 it's shaped like the United States, so you can pick California and it would highlight the 6 7 California network graph. 8 I thought it would be interesting, in 9 this last couple of slides that I have, to 10 highlight some of the feedback from the user community. So, for instance -- and that's my next 11 12 slide, but I don't want to go there yet. That's a 13 good one, too. But for instance, one of our users in MIT says, "Thanks for making this a valuable 14 15 tool freely available to the public. As an academic researcher, I deeply appreciate and 16 17 strongly believe that public access to good quality data is a powerful accelerator of 18 19 scientific and technological progress." So, we're 20 getting a very positive reception among stakeholders. 21 22 And to further push that point,

PatentsView was featured in November 2016 article 1 2 in Scientific American in which these network 3 graphs of the inventor relationships within three companies were juxtaposed. So, for instance, this 4 5 is the network image for Facebook, but there was also one for Tesla and Intrexon and the inventor 6 networks and the kind of invention process at 7 8 these private companies were compared visually in 9 that article. Moreover, PatentsView was selected 10 by the Association of Public Data Users as the best visualization in the federal government 11 12 category for 2017.

13 I would just like to leave you with a 14 quantitative feel now for how stakeholders are responding to PatentsView. This is for the 15 16 Application Programming Interface, API, which is 17 used by developers to access data, so that's 18 another more sophisticated way which information 19 is distributed. And you can see here that we've 20 had -- in 2017 up through this date, again in September, a 74 percent year to date growth in API 21 22 usage, 104,000 queries per day, on average, and

27.9 million queries between January and September 1 2 of 2017. So, it's very busy. 3 Anyway, thank you very much. Appreciate this opportunity to talk about the office. 4 5 CHAIR JENKINS: So, unfortunately, we have three more topics and I need to get done with 6 7 them very quickly so we meet our timeline. And 8 clearly, clearly, we need to bring you back, so. 9 MR. LANG: Yeah, yeah, yeah. 10 CHAIR JENKINS: Very noted. MR. LANG: I'm going to hold off on my 11 12 questions of discussion because of what Marylee said, because --13 14 CHAIR JENKINS: Yeah. 15 MR. LANG: -- we're very -- very 16 interesting to hear about your work and I look 17 forward to talking more in the future. 18 MR. TOOLE: Thank you. 19 CHAIR JENKINS: So, can we jump right 20 into AI? 21 MR. TOOLE: Absolutely. So, most of the 22 conversation on AI is going to be with Tom Beach.

He's going to show us all sorts of really interesting and cool things. But what I would like to tell you about quickly is an event that we're planning. OPIA is going to be hold a conference on artificial intelligence in IP policy.

7 This event has been scheduled for 8 December 5th of this year and our purpose is to 9 explore these emerging capabilities in artificial 10 intelligence and try to understand how it might influence intellectual property policy. Now, you 11 12 know that OPIA has a number of policy teams and so 13 the structure of the event is actually going to be 14 panels by different policy teams. So, trademarks is going to have a group there, copyrights is 15 going to have a group, enforcement's going to have 16 17 a group, patents is going to have a group, 18 economics, and also we're going to have an 19 international panel to go ahead and try to explore this intersection between AI and intellectual 20 21 property policy.

22 Our audience is broad. I don't

1 anticipate the general public will be a large 2 fraction of the audience, but I think we will get 3 a lot of policy makers, law practitioners, and those others who are quite interested in what's 4 5 happening in this AI space. It will be here in 6 the Madison Auditorium again on Wednesday, 7 December 5th. And so that's the planned event, 8 and all of the great details of AI, Tom is going 9 to provide. (Laughs) Here. Yeah. Go ahead. 10 MR. BEACH: Thank you, Andy. My name is Tom Beach. I am one of our Portfolio Managers and 11 12 I serve another role as our Data Strategist. We have David Chiles here and Debbie Stevens. We are 13 14 all from OCIO. Just to give you an overview, this is a lot of information that we're going to try to 15 16 cram in 15 minutes, so bear with. I will attempt 17 the impossible. 18 So, we are -- where we are headed. 19 We're an agency that has been, previously, as 20 indicated, in a world of very descriptive

22 just assess sort of transactionally what we're

terminology, ad hoc reporting, and being able to

21

1 doing. And we need to move into a more advanced 2 and modeling and cognitive assistance space 3 because of the ever-rising oceans of prior art, the distribution of data sources and information 4 5 that's out there in the world. And so with that comes a definition, 6 7 right? So, AI is something talked about all the 8 time everywhere and everyone seems to have sort of 9 their own interpretation of what it is. So, I 10 picked a definition here. It's -- folks can read 11 it. Basically, that it's any machine that mimics 12 a cognitive function that humans associate with 13 other humans' minds. So, it can learn, it can 14 give you information. I also saw an interesting Tweet that's 15 sort of a little different than this about what 16 17 the definition is because we've got natural language processing, deep machine learning, word 18 19 embedding, these very complex concepts. 20 And the other one is, AI is not an inscrutable magic. It's not impossible. 21 It's 22 math and data and computer programming by regular

people, okay? This is the other definition. 1 2 People who make AI are not unicorns. They are 3 people who like math and data and computer programming. So, this is why we're going to see 4 5 this technology disperse and grow and be prolific, right? So, with that said, I'm going to move 6 7 forward in terms of what the agency is looking at 8 in terms of opportunities for AI.

9 Because this is scoped to PPAC, there is 10 obviously other areas about opportunity throughout the organization in our other 12 business units, 11 12 but I'm going to talk mostly today about what 13 we're looking at in terms of the patent world. And we're looking at people -- so, this sort of 14 creates a unique opportunity for us. We have a 15 16 highly structured workforce, we are well trained, 17 it's a rapidly changing environment, complexity of examination exists, and existing infrastructure in 18 19 next gen, as part of the IT updates that we'll 20 talk about next, are there to be put in place so we can have (audio gap) 21

22 So, I'm trying to move forward. So,

keeping that in mind, I really want to focus on 1 2 the fact that while we are represented here by 3 OCIO, this is a complete and utter partnership with patents. We are organization, right? We 4 5 need to solve the patent's business problems, right? OCIO is here to really provide the 6 technology, meet the needs, but along the way we 7 8 can sort of do proofs of concepts to validate, do 9 rapid prototyping in order for our agency to be 10 able to, as we want to do, leap-frog other agencies around the world and really get ourselves 11 12 to a state that really improves effectiveness and 13 creates predictability in terms of the outcomes of 14 our patents. And so these are some of the efforts 15 16 that have been ongoing and I'll draw your 17 attention at the bottom, which, I think, came up earlier, continuing to engage with IP Offices 18 19 regading -- regarding API activities and whatnot. 20 So, we do have a working group, too, as part of IP 5. It's the IT group, right? And so in that --21

those sessions that I have attended, we have

22

discussed from XML sort of data sharing all the way to AI. Every time I have gone and done a presentation there and participated in that, the feedback we get is we're doing far and above away anything that anyone else is doing.

Similar concepts. Today, we're going to 6 7 talk about two of them, classification prediction 8 and search. But other offices are doing trademark 9 image searching. There's a couple things that 10 everybody's doing, but they're looking at 11 different approaches. But we haven't given away, 12 of course, our secret sauce, but the conversations 13 have been very fruitful and very much sort of, "What are you doing next," and that's -- in fact, 14 we had one office ask if they could license what 15 we were developing. So, that should tell you 16 17 where we are.

All right. So, the areas of where we're trying to do AI efforts. As I mentioned, it's based on sort of the not- so-exciting world of ingestion; that's -- goes to data quality. If garbage in, garbage out, right? But then if you

get gold in, you get gold out. And so when we have a strategy around AI, we really need to double down on the fact that we can't build AI on something that's not really strong. It's not a strong foundation.

6 So, we're now taking an approach of 7 doing a due diligence strategy on what it is and 8 where it's going to play a role and where is it 9 valuable, right? And that goes back to theme of 10 proof of concepts, partnering, solving business 11 problems, and some of them are right here, which 12 are classification, automation, and patent 13 searching, a work product consistency and quality. 14 We've really on that initial scale I showed you moved to -- our world into big data environments. 15 16 We have these now. We have the analytic 17 capabilities that we've never had before. We're 18 able to sort of consume them and expose them in 19 ways to examiners that we just have never been 20 able to unlock. And so knowledge management's another one and continued effort around looking 21 22 at, what is the standard outside of the USPTO?

1 In fact, on our market research 2 engagements with companies, the feedback has been, 3 "Wow, you're one of the -- you're way ahead of other agencies." So, we take that as a compliment 4 5 in terms of where our strategy is, what are we trying to solve, and what -- where are we going to 6 7 qo. 8 So, now we're going to kind of go deep 9 real quick, so -- and fast. Continue, right? 10 Fast and deep. I -- I'm getting the cues. 11 So, pre-classification. So, this is an 12 example of how can we leverage AI for consistency 13 purposes, right? If we could all get around a 14 thing that gives us a predictable result -- and we 15 all know the complication around CPC; different 16 than USPC, right? It's the whole invention, it's 17 a series of symbols versus U.S. Classification, 18 which was the most comprehensive claim, right? 19 We've shifted. Paradigm shift, big problem, how do we solve? 20 Machine comes along and says, "I'm going 21 22 to take all these data sources," which you can

1	see, "And then I'm going to create over 300,000
2	CPC models for every single CPC classification.
3	So, any new document that comes in, I'm ready for
4	you. I know where to put you and I also know how
5	to rank you accordingly to give you most
6	comprehensive of the inventive feature overall.
7	And if you wanted one that was based on claims, we
8	could also do that." So, we're able to have this
9	sort of predictive model that we can use as a
10	feedback loop when it's exposed to the user
11	community, right?
12	But also, really, what's kind of cool
± 5	Due alboy learly, what b kind of coor
13	is, we're testing it out in ways that say, "Hey,
13	is, we're testing it out in ways that say, "Hey,
13 14	is, we're testing it out in ways that say, "Hey, maybe we can save us time and money or give us
13 14 15	is, we're testing it out in ways that say, "Hey, maybe we can save us time and money or give us recommendations," or really allow for what I like
13 14 15 16	is, we're testing it out in ways that say, "Hey, maybe we can save us time and money or give us recommendations," or really allow for what I like to call the 50-yard line. Let's start the
13 14 15 16 17	is, we're testing it out in ways that say, "Hey, maybe we can save us time and money or give us recommendations," or really allow for what I like to call the 50-yard line. Let's start the examination process with some pre-curated
13 14 15 16 17 18	is, we're testing it out in ways that say, "Hey, maybe we can save us time and money or give us recommendations," or really allow for what I like to call the 50-yard line. Let's start the examination process with some pre-curated information about the case. And the most
13 14 15 16 17 18 19	is, we're testing it out in ways that say, "Hey, maybe we can save us time and money or give us recommendations," or really allow for what I like to call the 50-yard line. Let's start the examination process with some pre-curated information about the case. And the most interesting thing here is that the success level

to be as good as that, right?

1

2 So, what we found is, where we are 3 today, by leveraging these sort of technologies, unsupervised ensemble algorithms -- I mean, I know 4 5 that sounds like gobbledy-gook to a lot of people, but ensemble's an important word. It's sort of 6 7 like allowing you to choose the best of result set 8 in any sort of real time, where AI is able to sort 9 of fight itself to find out the best answer and 10 compute over and over and over again. That's kind of the big mystery. They're just computing power 11 12 really, really, really fast and then says, "Your answer's this." I mean, it would have taken 13 14 somebody else hours.

So, where we're at was, the subclass 15 16 level looking at roughly 94 percent predictive 17 rate of finding the matching CPC code on the document. Not bad, right? So, this is some 18 19 technology we built at the group level, 87 20 percent, and it drops, right? And we get to the lower subgroup, that's -- that gets to be, "I put 21 22 it here, you might put it there." But at the end

of the day, if this is able to do this and we can dimensionally provide this information in examination, we're now helping navigate the examiner along the path of most consistent prosecution, right? Where you should be looking, where are similar places that you should also be looking.

8 And this will get into the concept of 9 patent searching. So, you can read all this; 10 you've probably seen it before. In short, what 11 we're really looking at is getting away from a 12 Boolean sort of text search and we do harness that 13 expertise, but what we want to augment in that is an important point here, right? We're looking at 14 augmentation and copiloting, right? We're not 15 16 looking at complete black box automation.

17 So, it's sort of, here is a system that 18 instead of just forcing you to come up with the 19 right words, it is introducing all these 20 suggestions of concepts and synonyms and I don't 21 mean just one word that matches another. Like, 22 conceptually, how is it used in that technology?

So, I use the example -- I worked in offshore oil 1 2 and gas. We had this thing called the Christmas 3 Tree. Sits at the bottom of the ocean, they made a movie about it when it blew up. But if I say 4 5 "Christmas" and no "tree," I don't get the result 6 sets I want. But I am on a system that not only 7 helps me do that. It already knows that that's 8 the technology I work in. So, what it's giving is 9 an extrapolation of the traits of the document. 10 Maybe a good analogy would be like it's 11 a library. Some of us may remember Dewey Decimal. 12 Right? It's the way you found that -- you either 13 had to know an author or sort of know a genre. 14 This, instead of that, would just say, "I like 15 books that -- investigations that happen in 16 Chicago," kind of a thing. And that way, it's 17 finding out a curated dataset based on concepts, right, and relevancy of those concepts, because 18 19 that's the mathy part. Right? You can take words 20 and make mathematical signatures. And so it's able to allow these traits 21

22 that an examiner would say, "Hey, I think this is

1 relevant or not. Give me some prepackage relevant 2 documents, give me a pre- search, " right? Because 3 the traits of this given application is matching up with all the traits of these other documents 4 5 without having started a search at all. So, you 6 start at a 50-yard line. But unique to that is, we want to tell you why it's relevant. We can't 7 8 just give you a list of documents and say, "Here 9 it is. Go." What it needs to be is something 10 that says why was this relevant so the examiner 11 could ultimately and always possess the power of relevancy to the documents to each other and the 12 13 value of them. So, again, a 50-yard line 14 approach. Oops. And so some -- and additional 15

16 efforts that are on the way. So, enrich citation 17 data is an effort to basically use emerging 18 technologies to meet harmonization needs. So, we 19 create and do 102, 103s, everybody else does XYAs, 20 and so instead of spending -- we're trying to look 21 at spending the right amount of funding to the 22 right IT versus looking at how do we extract

information out of what we have to meet these
 needs without creating newer and larger cost by
 using these kind of tools. This was able to allow
 us to meet those kind of harmonization agreements
 between offices by leveraging something called
 emerging technology.

So, browser-based cognitive assistance. 7 8 That was a mouthful. So, basically, what that 9 means is we transition in IT updates. The reason 10 it really matters that we have migrated off of our 11 legacy systems and into a browser-based system as 12 it unlocks a huge platform for us to be able to 13 leverage all kinds of resources. So, we can do 14 federated source researches based on web -publicly available information everywhere. So, 15 these kind of -- while they don't sound 16 super-exciting when I say it's web-base, what it 17 18 does change is that it allows us to create and 19 build machine learning AI capabilities. Parts of 20 the workflow process unlock them through a browser-base because PE2E tools, as the 21 22 examination tools are completed with our search

1 rollout, will all be browser-based, right? 2 And so what's really exciting is that 3 we're now able to get here and then we can do, as Director Iancu likes to say, leap-frog ourselves 4 5 into the next evolution. And we have already 6 shown progress in that. In our big data efforts, 7 we have been tremendously successful exposing all 8 kinds of information and we'd like to follow-up 9 with how that potential area goes. 10 The AI side of the House is really -- we 11 want to take a steadfast approach on a strategy that makes sense, right? It just doesn't -- like 12 13 I said, we want something that is a copilot that 14 doesn't diminish the efforts that the examiner does. So, an examiner always has to remain an 15 expert. We're very, very cognizant of the 16 unintended consequences, right, of making it so 17 it's codependent, right? We want copiloting. 18 19 Just -- I want to hit on some themes, right? So, and less of the tech talk, but it's 20 all in there if you want to read it. And looking 21 22 at also the term generator, that's just another

1 way of synonyms. We're looking at image searching 2 in unique ways. You can look at images by pixel, 3 but you can also, interestingly enough, look at patents as a closed domain because we have 4 5 figures, right? And figures with descriptions and 6 description terms. So, it's an interesting way of 7 also looking at image searching. So, now we can 8 find out other like figures based on this -- the 9 meta- tagging of the terms that were on in there. 10 So, there's a lot of interesting work to be done there. And we're looking at deep machine 11 12 learning chat bots. Basically, those are -- we 13 work in a closed domain. Again, what that means is the world of the MPEP is a given document and 14 if you kind of look at the sort of concept of 15 16 maybe a chat bot that you could just say, "What's 17 a 102," it tells you all the answers from the MPEP versus always having to go back to that, that 18 19 unless you type in a query correctly, you're going 20 to get the wrong result. What these machine learning capabilities 21

allow us to do is measure and harness what

22

questions are being asked, right, so we know what 1 2 the concerns are. Maybe need new training, right? 3 In this particular area, folks are asking a lot about it. So, these are just sort of explorative 4 5 areas for which the partnership, like I said at the beginning, is really critical. 6 7 With that said, I'll close this portion 8 out. Do I do it? Okay. So, go to the next one? 9 Okay. We're going to go straight to the next one. 10 All right. IT updates. Going to pull this out real quick. We have the same cast. Andy, you're 11 welcome to stay. It's fun that you're here. 12 13 (Laughter) So, this is our PE2 14 Examination Products, as many of 15 you already probably looked at this 16 information. I'm going to hit on 17 some of the highlights. I heard 18 earlier that there was talk about 19 RPA or the relevant prior art. 20 This is another example of this notion of getting information 21 22 quickly to -- and accessible to the

1 examiner to not only just have it 2 there, but to meaningfully measure 3 it so that we can create a baseline, right? What's a good 4 5 search, what's a 50-yard line for a jump-off point if we're going to 6 get into an evidence- based 7 8 decision around predictability of 9 patents. So, RPA's a good example 10 of leveraging that technology and exposing that information as far as 11 12 it goes with Docket Application 13 Viewer, item number one. And then official correspondence -- I'm 14 going to actually just sort of jump into these 15 16 slides because we want to go quickly. These are 17 some of the recent milestones. What is up here, in short, is that by the end of the calendar year, 18 19 the second of the third migration from a legacy system to a NextGen will be OC. All examiners 20 will be fully off of that, of the Examining Corps, 21 22 come December, which is huge. Right? That's a

big Herculean lift in things to the patent's 1 2 organization, in particular OPIM, for this 3 coordinated effort, right? This was -- we had some learning lessons 4 5 We had to pause for a minute and restart. here. And we were highly successful at that and I think 6 7 that demonstrates the fact that more than one 8 business unit wants to see the success of the 9 agency, right? We want to get it right. It's 10 been a theme that Drew has allowed as OCIO to have the opportunity to do and what's been really 11 12 effective, I think, for our leadership is that now 13 we have the opportunity to get it right before we 14 put it out there and before we get that sort of 15 first impression, right? So, that's been really 16 exciting for official correspondence. 17 We only have three TCs left, I think. It's the 3,900 CIU, 2,800, and 3,700. Did I get 18 that, Debbie? 19 20 MS. STEPHENS: (Nodding) MR. BEACH: Correct, good. All right. 21

Search. This is coming along. It's -- we want to

22

get it right, again. We've been doing a series of 1 2 stress tests. We actually took to the approach 3 of, "Please break it. We want you to break it. That's what a stress test is." We allow up to 400 4 5 users on at the same time to kind of come in there and either break the system and figure out what 6 7 the problem is before we try to scale and rollout. 8 And that's just -- it's been a coordinated effort 9 that has less stigma and more opportunity because 10 we're getting a lot of positive feedback from this 11 process.

12 And, in fact, one thing I would like to 13 add is, what was done differently with search than 14 we've ever done before is we looked at Parity Plus enhancement and have actually deployed them. 15 16 There's a highlight on text, on image, which was one of the top priorities for the Examination 17 Corps when they did deployment last week. So, 18 19 we're not going to sit here and measure ourselves that -- did we build the model A for it today just 20 like they did in 19-oh, whatever. We decided to 21 22 go with more of a -- an exciting round to go.

1 Twofold, adoption is part the equation, 2 but also, it's a long-felt need that we look at 3 the PE2E investment not just about the middle section. I think that's kind of how it was 4 5 explained, sort of the examination, but the future enhancements and then the other piece is, a lot of 6 the POM and infrastructure pieces that are sort of 7 8 long and overdue. So, while we concentrate mostly 9 on these efforts, there's a lot of other spend 10 that goes on to ensure that these systems will 11 continue to these systems will continue to 12 succeed. Patent Center is another one that we're 13 14 proudly moving along and we have some communication efforts, which I'm going to have 15 16 Debbie take a talk on. And just so you know, for 17 those that are using Patent Center, we're -- we went to DOCX. That's a big switch for us. That's 18 19 very important that we're able to get the text 20 starting at the beginning of the process and continue to have images necessary as the 21 22 authoritative source of data. It is an

opportunity for the agency to have different wins
 within our processing within the organization.
 And so that's a slow rollout and we're very
 excited about that. We can go to the next slide
 and allow Debbie to chime in.

MS. STEPHENS: Sure. Thanks, Tom. 6 So, 7 I think here it's kind of a little bit of an 8 infomercial for us. Our current PKI technology is 9 using certificates, authentication, and we're 10 moving towards the end of the lifecycle for that, so this slide speaks to that infomercial that we 11 12 would like to mention to PPAC and help socialize 13 that we really need your help in messaging to our 14 user community that the time is now to create your MyUSPTO accounts and start using those accounts. 15 16 As we mature not only the Patent Center tool as a 17 replacement for EFS Web, but the PKI certificate technology, we hope to have a full migration by 18 December 2018. 19

20 And so this slide speaks to our ask of 21 PPAC to go ahead and start creating your MyUSPTO 22 accounts, start using them. In October, we would

hope that you would have the account and start 1 2 migrating your certificates to that particular 3 technology and then in November have the sponsorship be ready for you to use. So, as a 4 5 user you would sponsor someone within your firm or company to act on your behalf. So, this is the 6 7 timeline that we're proposing. Again, the key 8 dates are now to establish your MyUSPTO account 9 and start using them. And then in October, 10 migrating them from the PKI certificate to the 11 accounts, as well as November, the establishment 12 of sponsorship, that's a part of the tool that 13 would be essential for our complete migration by the end of December 2018. 14 15 So, I just feel like it would be an

16 opportunity here to reach out to PPAC. We're 17 certainly, as a community, internally sharing that 18 message across all business units such that we 19 have a whole communication team touching all the 20 different business units and reaching out across 21 the USPTO engagement and outreach efforts to 22 socialize and stress the importance of the

1 engagement, as well as the migration and 2 sponsorship. So, I --3 MR. BEACH: Okay, thanks. MS. STEPHENS: -- appreciate that. Tom. 4 5 MR. BEACH: Yeah. Yeah, sure. Thank you. And last but not least, she's covered some 6 7 of the benefits that you guys can read. 8 Next, I'll talk about CPC collaboration 9 tools. There's continued work there, both on the 10 management and the collaboration tools. This allows us to get into this world of corrective CPC 11 12 classification because if a document's not in the 13 right place, it's hard to find. So, in short, basically what's going on here. So, when you work 14 15 internationally on these kind of topics, you really have to have sort of tools and databases 16 17 and a -- the ability to sort of have a common 18 cause and then sort of have a -- what I would call 19 a quality review, sort of. Do we both agree, as in the other offices, in ours that it's located 20 correctly in the same place? 21 22 One thing that's important to know is

1	that when we look at these analytical tools when
2	with CPC, you get a kind of comprehensive
3	symbol set and if a specification's just all about
4	semiconductors and how you make them and kind of
5	how it's made and then the first claim is that
6	just this a chemical formula. Right? We just
7	that's one of the things that we really want to
8	focus on, is that the subcombination combination
9	or the ability for the applicant to file basically
10	what looks like a chemical compound, even though
11	if you use the body of the specification as your
12	classification mechanism, it may or not have
13	pointed you in the right direction. So, I think
14	that's important to talk about.
15	Global Dossier, we did not have any
16	projects in FY 18, but we like to talk about it
17	because it's, I guess, the coolest thing that's
18	been done lately. So, there are projects in FY
19	19, so that's the good news for this one. So,
20	starting next PPAC we can report on Global
21	Dossier. I think we're looking at some alert
22	systems to make it a little more real- time,

knowing what's going on with other offices in
 terms of their prosecution efforts.

3 Legacy system retirements, this goes back to sort of the original point, which is, it's 4 5 been a bit of a road here, but we are starting to knock off some systems in the next year or two, 6 and I think that goes to the persistent effort of 7 8 the organization at large and working the business 9 unit to properly identify, migrate, do no harm, 10 and bring the best to bear, right? Because these 11 are complicated processes and we can't just turn 12 them on, turn them off, and they're very 13 integrated, which has been a challenge for us to 14 really say, "We're going to turn this off, but oh, by the way, it services other things." And it's 15 just -- it's a -- we were 3,000 people long -- not 16 17 too long ago and systems were built and they were built on top of that and built on top of that. 18 And so it's hard to do a heart transplant while 19 20 you don't have the other machine, hook it up. So, with that said, I will leave maybe 21 22 time for questions. Did I do it? (Applause)

Thank you. I know I talk really fast, so 1 2 hopefully that made sense. 3 CHAIR JENKINS: He brought us right on time. So, I've already negotiated with Dana while 4 5 we were sitting here that I promise Jennifer legislative initiatives reporting will go first 6 7 for November, okay? So, not last; Dana will go 8 first. And if IT would like to follow Dana 9 because you always get the short stick. I promise 10 you that, as well, for November meeting. MR. BEACH: Sure. 11 12 CHAIR JENKINS: So, with that. 13 MR. WALKER: Yeah. Just before David, Debbie, and Tom leave, just to say thanks for all 14 the work you're doing. And congratulations on the 15 16 OC retirement and maintaining the deadline in 17 December 2018 because we've been looking at that deadline, that deadline hasn't moved. And also, 18 19 for the user community, just a quick comment that 20 under Mark's leadership, our Subcommittee, we give a lot of, I'd say in diplomatic terms, frank 21 22 feedback to the IT Committee or the -- then the IT

1	Subcommittee and David and the team are very, very
2	responsive. We have got a great process for
3	keeping up-to- date with your projects. So,
4	thanks for that dialogue because we do hear a lot
5	of feedback about IT systems and we pass them
6	along and the team has been very responsive to
7	what we say. So, thank you for that. Really
8	MR. BEACH: Sure.
9	MR. WALKER: been good working with
10	you.
11	MR. BEACH: Good team.
12	CHAIR JENKINS: Thank you.
13	MR. BEACH: Okay.
14	CHAIR JENKINS: Dana.
15	MR. COLARULLI: So, the first thing I'll
16	say is I probably could speak as fast as Tom does.
17	SPEAKER: Now you don't have to.
18	MR. COLARULLI: I guess now I don't have
19	to. Second I'll say is, I hope there will be
20	sufficient activity, Marylee, between now and
21	November. Although, I have low hopes, (laughter)
22	given

```
CHAIR JENKINS: No worries.
 1
 2
                MR. COLARULLI: Given that --
 3
                CHAIR JENKINS: You'll still go first.
                MR. COLARULLI: Given selection here. I
 4
 5
       -- but I --
 6
                 CHAIR JENKINS: (Inaudible) go first.
 7
                MR. COLARULLI: -- appreciate I got that
 8
      voucher, so.
 9
                 SPEAKER: (Inaudible) before the
10
      election, right?
11
                MR. COLARULLI: When is the next PPAC
12
      meeting? Is it --
13
                 SPEAKER: Before, before.
14
                      (Inaudible)
                 MR. COLARULLI: It's before the
15
16
      election. Even more exciting. (Inaudible) I'll
17
      still try to be brief and I had the opportunity to
18
      meet with the Executive Committee yesterday and
19
      brought in some of these updates already. I'll go
20
      through legislative activity on some of our
      operational priorities. The PPAC asked that I
21
22
      highlight some of the patent-related activity,
```

legislative activity, and then there's been quite a interest in some small business issues, both on hearings and in legislation that's generally supportive of the work we do here at PTO. So, with that overview, we'll go through a couple slides.

Tony had already touched a little bit on 7 8 our funding. We are funded at slightly below our 9 request due to a CBO score, both bills were reported out of their respective Committees in 10 11 May. Tony also highlighted that the report also 12 had some very positive words about our IP attachés 13 program. I know Shira mentioned that, as well. We always like to see that. Unclear how they'll 14 15 all move forward together when Congress comes back. The House right now is out of town for its 16 17 annual August recess. They come back right after 18 Labor Day. The Senate is in pro forma session. 19 They'll continue to be in pro forma session right 20 now until about August 13th, where they come back. 21 At least for the Senate, particularly 22 the Judiciary Committee, which we spend a lot of

time with, they have a very active September coming up. Supreme Court nominee hearings among other issues will be taking a lot of the Senate Judiciary Committee's bandwidth. But expect the Senate to be around pro forma session for much of August, but then they'll be back before the House returns right after Labor Day.

8 They'll take up the appropriations 9 bills, hopefully take some action before the end 10 of the fiscal year, the end of September. If not, enter into a CR. Unclear what will happen, at 11 12 this point. Likely, I think, as has happened in 13 past years, we expect Congress to pass the CR and pass it onto the President. The length of which 14 15 is unclear. But at least for PTO, commitment that we access all of our fees continues in the 16 17 appropriations bills and we're happy to see that. 18 I'll mention two things. The first 19 thing, fee setting authority, as I'm sure Tony 20 also mentioned, expires September 16, 2018. We've been in many conversations with the Congress with 21 22 hopes that they will move forward to extend our

1 authority and we've gotten a very positive 2 feedback from the Judiciary Chairman in both the 3 House and the Senate that they will do so. It is just a matter of time. And as I mentioned, lots 4 5 of other competing issues in both Houses. There -- but likely, the Chairman will certainly move 6 forward. We've also seen some other legislation, 7 8 the Senator side from Senator Coons and Hatch, on 9 the House side a companion bill with Chairman 10 Chabot and Ranking Member Johnson. So, we're 11 positive that this will move forward. 12 I'll also mention, there has been other 13 legislation we've seen that reintroduces this idea of transitioning the PTO funding to a revolving 14 fund and essentially takes PTO out of the 15 16 appropriations process. This was a proposal that 17 we saw in the leadup to the AIA. Compromise permission was adopted in the AIA, which generally 18 19 has worked, generally has allowed PTO to access

20 all the fees it collects. If we collect above 21 what were appropriated, those fees go into the 22 Patent and Trademark Fee Reserve Fund, which we

can access in the subsequent fiscal year. But
 interesting to see those provisions resurface in
 legislation.

4 On this slide, I'll also mention, the 5 agency had been looking for a three-year extension of its TEAP authority. This is the Telework Act 6 7 of 2010 to allow us to run a pilot program, to 8 allow employees to waive their right to 9 reimbursement for federal travel when we ask them 10 to come back. And in turn, they allow -- they -we allow them to change their duty station to 11 12 wherever they'd like in the country. It's been extremely successful for the USPTO, as we've said, 13 14 loved by the employees. Yesterday, the Senate passed the National Defense Authorization Act, 15 16 which included a provision to extend that 17 authority to December 31, 2020. We're very happy 18 to see that move forward. It's on its way to the 19 President and we expect him to sign it shortly. But that's good news for the agency. 20 So, recent patent bills that have been 21 22 introduced, they have been a small flurry of

1 activity. The -- in addition to the STRONGER Act, 2 which was introduced earlier, at the end of last 3 year. Two new bills, one by Representative Massie, another by Representative Rohrabacher just 4 5 last week, and those two bills add to the discussion of what reforms may be needed to the 6 patent system. It adds to discussion in terms of 7 8 adding to what the STRONGER Act had already talked 9 about. Now, as we've discussed at this meeting, 10 many of the things in the STRONGER I think we could move forward with, with authority under --11 12 the USPTO already has and, in fact, the agency is 13 looking at doing that and has moved forward in 14 some of those things. These two bills introduce a series of 15 16 other suggested provisions, notably, two things 17 that the American Invents Act had done. One, transition the U.S. from a first- to-invent to a 18 19 first-inventor-to-file system. Both of these 20 bills would revert the U.S. back to a first-to-invent system. Both bills also would 21 22 repeal the provisions that established the Patent

Trial and Appeal Board and abolish those 1 2 proceedings IPR and PGR. So, those are two very 3 dominant provisions in these bills. I already mentioned the resurfacing of the revolving fund, 4 5 proposal of that in both of these bills, as well. Now, significantly, the bills differ 6 7 slightly in a couple aspects. The Massie bill 8 would overturn eBay. That was a Supreme Court 9 case identifying when an injunction is proper. 10 The Massie bill also addresses other Supreme Court 11 cases, including the Lexmark case on patent 12 exhaustion, and has a number of other features, 13 many of which I've listed here, so I won't go into 14 detail there. 15 The Inventor Protection Act, which was 16 the Rohrabacher bill, again, has some provisions 17 that are different. It would create a category of applicant and owner inventor-owned patents and 18 19 subject them to special venue rules and judicial 20 procedures in the courts and subject them to the special rules in front of the PTO, as well. So, 21

we're still looking at those provisions to see

22

what the impact would be, but that's the focus 1 2 there, creating a special category of patent 3 applicant or patent owner and subjecting them to special rules. 4 5 In addition, that bill addresses issues 6 of willfulness and introduces a loser pays provision, again, targeted at trying to -- from 7 8 some of the statements made about the bills 9 leveled the playing field between smaller entities 10 in the system and larger entities. So, a series 11 of two bills adding to the public discussion about 12 potential reforms in the system. 13 I did want to highlight one bill of 14 general significance for both patents and trademarks and the PTO generally and that's the 15 Small Business Innovation Protection Act. 16 This bill has moved forward both in the House and in 17 the Senate. Each body has sent to the other House 18 for action an identical bill. It's unclear which 19

19 for action an identical bill. It's unclear which 20 one will move forward. Regardless, the identical 21 language is supportive of much of the work that

PTO does and particularly focuses on ensuring that

22

we're working with the Small Business 1 2 Administration to provide clear and high-quality 3 training particularly to small businesses. 4 So, if you take my comments on the 5 previous two bills on patents as targeting this community, trying to level a playing field, I 6 7 think this is also a helpful bill that ensures 8 that SPA and PTO are working together to also 9 provide assistance, guidance to this community to 10 make sure that they can navigate effectively the 11 patent system. Again, unclear when it might move 12 forward. I think perhaps later this year, I think 13 we'll see some legislative activity probably after 14 the election. 15 Three hearings I wanted to highlight. 16 One, oversight hearing of the PTO and Director Iancu had his second opportunity to engage members

17 Iancu had his second opportunity to engage members 18 of the Congress. First time it was on the Senate 19 side, now on the House side. Many of the same 20 topics were discussed at this hearing. I would 21 mention that the Director was asked about IP 22 attachés, as well as much of our international

1 work that you've heard about today.

2 There was a focus on increasing filings 3 from China on the trademark side and other enforcement issues in China and as well as many 4 5 things that the Director has made his priorities certainly clarifying a lot around 101 and 6 potential changes to PTAB. So, a very 7 8 comprehensive hearing addressing a lot of the 9 issues that their Director's had the opportunity 10 to talk about publicly, also came in front of the House Judiciary Committee. 11 12 And then very quickly, two other 13 hearings, both in front of the Small Business -the House Small Business Committee. The --14 interestingly enough, the Chairman of the House 15 16 Small Business Committee has publicly said he 17 would very much like to be Chairman of the 18 (inaudible) at the next Congress. As a result, I 19 think he's showed an increasing interest in many 20 of our issues. I think that's a good thing. 21 The two -- series of two hearings that 22 they've held did focus on issues that small

1 businesses have in navigating the patent system, 2 both this hearing back in May and then more 3 recently in July, featuring many of the stakeholders that we work with. Each of these --4 5 well, I'll say many of the witnesses highlighted that there is lots of resources at the PTO to help 6 7 navigate the system and did focus on some of the 8 unique challenges that they have. So, again, I 9 think good -- a good focus.

10 We've subsequently gone up on the staff level and briefed the Staff of the House Small 11 12 Business Committee on the work of the Office of 13 Innovation Development, the Office of the Global 14 Intellectual Property Academy, highlighted in particular some of the China road shows that we've 15 done around the country. We've done a number this 16 year already, have a couple more coming up in New 17 18 York and other -- and Chicago in the balance of 19 this year. Very interested in all of those 20 activities, again, reflecting well on PTO. With that, Marylee, I'm going to end and 21 22 find some new things to report on first on the

agenda the next PPAC meeting. (Laughter) Thanks. 1 2 CHAIR JENKINS: Going to hold you to 3 that. (Laughter) Any questions? 4 MR. WALKER: Well, let me correct the 5 record that our next meeting is after the elections. 6 CHAIR JENKINS: After the election. Ah, 7 8 noted. Noted for the record. Any questions for 9 Dana? No? 10 MR. GOODSON: Yeah, I had one. And I know it doesn't make any difference to if one of 11 12 these bills pass, but they're all forward-looking 13 bills; they're not retroactive, are they? Like, first-to-file versus invent -- first-to- invent. 14 MR. COLARULLI: The provision there, 15 16 yes, I think it's forward-looking. It wouldn't 17 have retroactive -- it'd be very difficult to unravel that, if that was the case. 18 19 MR. GOODSON: Okay. 20 MR. COLARULLI: But yeah, that's right. CHAIR JENKINS: Great. On behalf of the 21 22 Committee, I just want to say what a great

meeting. I also was very reflective on the time this afternoon and we have so many great topics that the PTO is addressing and working on. And I will make sure these folks come back and give us some more details and maybe give us some examples of what specifically they're working on, because I know people like to see examples.

8 The Director has joined us again and 9 which I -- (laughter) welcome back again. And I 10 just, again, want to support and share and applaud 11 your leadership today. You actually haven't been 12 here that long, so -- but you have them all moving 13 in all sorts of directions. So, I think as a 14 stakeholder, I think that's a very good thing for the office and for the user community and for the 15 16 IP system, so.

UNDERSECRETARY IANCU: Well, thank you and thank you for your leadership of this Committee and this meeting and the various meetings that you hold. I very much appreciate everything that you do, Marylee, and also Mike, same for -- goes for you and to all the members of


the PPAC. And I think our Commissioner for 1 2 Patents, Drew Hirshfeld, had something to say. 3 MR. HIRSHFELD: Well, I was only going to say thank you to everybody. A lot of work goes 4 5 into this day, both on the USPTO side and the PPAC side and so thank you to all the USPTO people and 6 7 the PPAC folks for all of their great work. We 8 started a day that -- where I believe Andrei said 9 in the beginning that we measure our time by the 10 number of PPACs. 11 This is the first time that we actually -- Marylee, I have to give you lots of credit that 12 13 you ended early or at least close to -- close. 14 We're always struggling. For those of you that couldn't see Marylee on camera, when she was --15 16 when we were behind, she was giving the (laughter) 17 hustle signal. So, she does a great job to keep us on line. 18 Another theme that I'd just like to 19

20 point out is, somebody said earlier -- and I 21 apologize for not remembering who -- that PTO is 22 listening. Certainly, we are listening. The

1 gentleman to my left who has been great to work 2 with over the last six months, I know he's humble 3 and wants to add, but I know he's been meeting with many stakeholders. I'm in a number of those 4 5 meetings. I believe those have reached probably about 60 or so different stakeholder meetings. 6 So, we are listening. We're listening that way 7 8 and in a variety of other ways. And I'd also like 9 to add that PPAC is listening. As you notice 10 today, there were a number of emails that were 11 being read out from either members of PPAC who are 12 not here or members of the public who are sending 13 their comments in, and that is not something that 14 has always been done in the past and I think that's good. So, if we can continue this 15 16 dialogue, the better. 17 The last thing I will say is, I recognize the same faces through all the PPACs 18 19 that have been to -- and I'm not talking about the

20 PTO or PPAC staff. I'm talking about others who 21 engage. And I believe that's because people who 22 do engage in this meeting recognize its true

1	value. So, let me ask everyone who's involved to
2	do one favor for all of us and that's spread the
3	word about these meetings because I do think
4	there's a lot of great discussion that takes place
5	and the more people that engage, the better we all
6	are. So, thank you to everybody and I don't know
7	if Marylee, if you'd like to just officially
8	close us.
9	CHAIR JENKINS: All right. I'm going to
10	officially close and I thank both of you. And I
11	think I was the one that said we do that you
12	are listening and we listen, too. So, on that
13	note, remind everyone that our next meeting for
14	PPAC is September 6, Thursday; that's going to be
15	the fee setting hearing. Mark your calendars.
16	And you all know I usually ask, I like to move to
17	close the meeting and do I have a second?
18	MR. GOODSON: Second.
19	CHAIR JENKINS: Second. Thanks, Mike.
20	So, meeting closed. Thank you.
21	MR. GOODSON: Thank you.
22	(Whereupon, at 2:59 p.m., the



1 CERTIFICATE OF NOTARY PUBLIC 2 I, Carleton J. Anderson, III do hereby 3 certify that the forgoing electronic file when originally transmitted was reduced to text at my 4 5 direction; that said transcript is a true record of the proceedings therein referenced; that I am 6 7 neither counsel for, related to, nor employed by 8 any of the parties to the action in which these 9 proceedings were taken; and, furthermore, that I 10 am neither a relative or employee of any attorney or counsel employed by the parties hereto, nor 11 12 financially or otherwise interested in the outcome 13 of this action. 14 15 Carleton J. Anderson, III 16 17 (Signature and Seal on File) 18 Notary Public in and for the Commonwealth of 19 20 Virginia Commission No. 351998 21 22 Expires: November 30, 2020